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This work is mainly focused in the development of new synthetic 
methodologies. A new method for the preparation of optically active aziridines 
was developed, as well as their transformation into influenza antiviral drugs 
oseltamivir (Tamiflu) and tamiphosphor. Other important chemical 
transformations useful for organic synthesis were also studied. 
 In the first part of this work a new method for the asymmetric synthesis 
of cyclic 4-hydroxy-acylazyridines is described. It is based on a very efficient 
enzymic resolution procedure using novozym 435 (solid-supported Candida 
Antarctica Lipase B). The optically active aziridines were obtained in high yields 
(up to 50%) and enantiomeric excesses (up to 99%).  These very important chiral 
building blocks were used as substrates in the syntheses described in this work. 
 Approaches to the synthesis of terpestacin, a bioactive natural product, 
are also described. The three designed strategies failed, however interesting 
chemistry was discovered and new molecules were prepared that may be used 
in the synthesis of other products. In one of these molecules it was possible to 
observe by NMR aziridine invertomers, a special type of conformers. To our 
knowledge alkyl aziridine invertomers have not been previously observed at 
room temperature and this equilibrium was studied by DFT calculations. 
Novel formal syntheses of the antiviral drugs oseltamivir and 
tamiphosphor were also developed. Using the enzymatic resolution procedure, 
an almost enantiomerically pure aziridine was prepared and used as starting 
material for subsequent conversion to oseltamivir and tamiphosphor diethyl 
ester in 10 or 12 additional steps and 22% or 19% overall yield, respectively, is 
described. The preparation of a new sulfur analogue of oseltamivir was also 
Abstract 
 
xxxii 
 
attempted. Although it was not successful, two reactions were discovered and 
the study of their scope is described in the last two chapters. 
An efficient method for the α-chlorination of ketones under basic 
conditions is described using methyl chlorosulfate. It is a very clean reaction and 
the products are obtained in quantitative yield. Its use in the α-chlorination of 
carbonyl group of other functional groups was also studied, and was equally 
useful for the preparation of α-chloroesters or amides and 4-chloro dicarbonyl 
compounds. Methyl chlorosulfate is described for the first time as an 
electrophilic chlorine source. Some aldol and Claisen condensation reactions that 
also occur during the chlorination of some substrates were also studied. 
 Lastly, a method for the transformation of 2-oxo S-carbonyl or 
thiocarbonyl into 2-oxo (thio)carbonyl compounds, by a base promoted sulfur 
abstraction rearrangement is described. It is a very clean reaction and products 
are obtained in good yield (close to 90%) in just 30 minutes. This method is 
particularly efficient for the introduction of thiocarbonyl containing groups 
whereas for the introduction of acid derivatives it is less efficient. This constitutes 
an alternative synthetic strategy for the generation of a new carbon-carbon bond 
and the preparation of β-dicarbonyl compounds. 
 
Keywords: organic synthesis; asymmetric synthesis; aziridines; oseltamivir; 
tamiphoshphor; terpestacin; aziridine invertomers; chlorination; sulfur 
abstraction.
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O principal objetivo deste trabalho foi o desenvolvimento de novas 
metodologias de síntese orgânica. Foi desenvolvido um novo método para a 
preparação de aziridinas opticamente ativas, assim como a sua conversão em 
oseltamivir e tamiphosphor, dois antivirais da gripe. Também foram estudadas 
outras transformações químicas com igual importância e interesse para a síntese 
orgânica.  
 Inicialmente, foi desenvolvido um novo método para a síntese assimétrica 
de 4-hidroxi-acilaziridinas cíclicas. Este método tem por base um procedimento 
de resolução enzimática, usando novozym 435 (lípase B de Candida Antarctica 
em suporte sólido). As aziridinas opticamente ativas foram produzidas com 
elevado rendimento (até 50%) e excesso enantiomérico (até 99%). Estes 
importantes building blocks foram usados como substratos nas sínteses 
desenvolvidas neste trabalho.   
 Estão descritas tentativas de síntese de terpestacin, um produto natural 
com atividade biológica. As três estratégias concebidas não tiveram sucesso, 
contudo foram preparadas moléculas com interesse que podem ser usadas na 
síntese de outros produtos. Numa destas moléculas, foi possível observar por 
RMN invertómeros da aziridina, um tipo especial de confórmeros. Dentro do 
nosso conhecimento, invertómeros de alquilaziridinas nunca foram observados 
à temperatura ambiente. Este equilíbrio foi estudado usando ferramentas de 
química computacional. 
 Uma nova síntese dos antivirais oseltamivir e tamiphosphor foi 
desenvolvida. Utilizando o novo método de resolução enzimática, uma aziridina 
foi preparada praticamente enantiomericamente pura e usada como material de 
Resumo 
 
xxxvi 
 
partida. A sua conversão em oseltamivir e éster dietílico de tamiphosphor foi 
conseguida em 10 ou 12 passos e 22% ou 19% de rendimento, respetivamente. 
Também foram feitas tentativas de usar esta metodologia na preparação de um 
análogo de oseltamivir com enxofre. Apesar de não se o ter conseguido com 
sucesso, duas reações foram descobertas e o estudo do seu escopo está descrito 
nos dois últimos capítulos.    
 Está também descrito um novo método para a α-cloração de cetonas em 
meio básico usando clorosulfato de metilo.  É uma reação bastante limpa, em 
que os produtos são obtidos praticamente puros e com rendimento quantitativo. 
O seu uso na cloração de outros grupos funcionais foi também explorado e é 
igualmente útil na preparação de α-cloroésteres ou amidas e compostos 4-
clorodicarbonílicos. O clorosulfato de metilo é pela primeira vez descrito como 
uma fonte eletrofílica de cloro. Foram também estudadas reações de aldol e 
condensação de Claisen que ocorrem durante a cloração de alguns substratos. 
 Por último, está descrito um método para a transformação de compostos 
2-oxo-S-carbonílicos ou tiocarbonílicos em 2-oxo(tio)carbonílicos, através de um 
rearranjo com extrusão de enxofre em meio básico. É uma reação 
consideravelmente limpa e os produtos são obtidos com bom rendimento (cerca 
de 90%) em apenas 30 minutos. Este método é particularmente eficiente na 
introdução de um tiocarbonilo, ao passo que a introdução de derivados de ácido 
não é tão eficiente. É também uma estratégia sintética alternativa para a criação 
de uma nova ligação carbono-carbono e preparação de compostos β-
dicarbonílicos. 
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xxxvii 
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Organic synthesis 
 Organic compounds are needed in different fields of Science (biology, 
materials, pharmacy, etc.) as well as in our daily lives (drugs, food additives, dyes, 
polymers and other materials, etc.). Hence organic synthesis plays a central role 
in the development of Science and in the improvement of our quality of life, 
providing not only new molecules with potential social applications but also 
environmental implications such as more economical or clean processes.   
  The focus of the research of a synthetic chemist can vary. It can be 
focused on the product, when a new compound that has not been previously 
synthetized is the target. Although the new compound may have a purpose, 
structure elucidation, particularly the stereochemistry, of new isolated natural 
products is also an important topic. In this case, the main goal of the work is to 
provide the desired compound in a reasonably amount in the shortest possible 
time, regardless of the method used. Alternatively, the objective may be the 
development of an improved method for the preparation of an already known 
molecule for large scale production. Contrary to the first case, the development 
of a new method should consider several factors: global yield, number of steps, 
time economy, safety, costs, available raw materials, impact on the environment, 
etc… 
 The development of a new synthetic methodology implies the design of a 
synthetic transformation and its execution in the laboratory. The successful 
design of a new synthetic methodology relies on a good knowledge of chemistry: 
chemical transformations, functional group reactivities, reaction mechanisms, 
stereochemistry, protecting groups, etc… On the other hand, its execution 
requires also practical skills such as the design and setting up of experiments; 
Chapter 1 
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execution of unit operations; purification and drying of reagents, solvents and 
products and characterization and structure determination of products. It can be 
hard to find or train someone to have both the knowledge and the required skills. 
 Recently, Nature published1 a comment on chemical synthesis and its 
importance. A point discussed was the fact that students with skills in chemical 
synthesis can find jobs in the pharmaceutical industry more easily. However, 
synthetic methods developed in the laboratory are often impracticable in 
industry, therefore the specific synthetic skills are not per se the most valued. 
Pharmaceutical industry is more interested in other skills developed by these 
students such as the capacity to solve problems rapidly, cope with disappointing 
results, perseverance and a broad knowledge of chemistry. In conclusion, 
students engaged in chemical synthesis (including organic synthesis) seem to be 
more prepared for the job market. 
 In general, synthetic strategies comprise several steps to transform the 
starting material into the final product. In each step, a different reaction or 
transformation occurs. The development of new and improved reactions is 
essential for the improvement of organic synthesis. The reactions described in 
the literature are the tools available for a chemist to shape the molecules into 
the desired structure. The more tools available, the greater the number of 
molecules it is possible to prepare. Although some groups are focused exclusively 
on either developing new reactions or new synthetic strategies, both are 
intrinsically connected. During the development of a new reaction, its application 
in a complex synthesis demonstrates its scope or perhaps its limitations. On the 
other hand, while developing a new synthesis sometimes a chemist must develop 
a new method for a specific transformation. 
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Figure 1. 
 
Strategies for optically active molecules synthesis 
   Most molecules have an asymmetric structure in a way that their mirror 
image is not superposable, this property is called chirality and these two different 
structures are called enantiomers. Most organic compounds in nature occur as 
only one enantiomer, for example aminoacids, nucleic acids and sugars. 
Therefore, different enantiomers of the same molecule interact in a different 
way with biomolecules and hence may produce different effects when 
administrated. Most chiral drugs are commercialized as a single enantiomer and 
for reasons of efficiency need to be produced selectively that way. The synthesis 
of just one enantiomer of a molecule constitutes a challenge for synthetic 
chemists. 
Organic 
synthesis
New 
reactions
New 
syntheses
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Figure 2 - Comparison of the structures of the two enantiomers (R and S) of 2-phenylethanol. 
 For the synthesis of a optically active compound different strategies may 
be followed. One strategy is to use a chiral enantiomerically pure starting 
material. Some compounds are commercially available as single enantiomers at 
an affordable cost. In general, they are extracted from an abundant natural 
source or produced by fermentation, some examples are simple acids (e.g. 
tartaric acid), the amino acids or sugars. This set of chiral available molecules is 
called the chiral pool. Some of the compounds produced by the other strategies 
that will be presented but are commercially available may be considered as being 
part of the chiral pool too. 
 
Figure 3 - Examples of chiral molecules from the chirality pool. 
When the starting material used is not optically active, selective 
formation or isolation of one enantiomer is always dependent on the formation 
of a diastereomeric species, at least transiently. Diastereomers are a different 
type of stereoisomers and unlike enantiomers have different physical properties.  
Other strategy is the use of an enantioselective reaction. In some 
reactions, a symmetric molecule is transformed into an asymmetric one, typical 
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conditions lead to the formation of two enantiomers in the same amount 
(racemate). However, if a chiral reagent or catalyst is used, one enantiomer may 
be produced in a selective way. Chiral catalysts containing a metal are commonly 
used, but more recently a new field emerged, the organocatalysis, using non-
metal catalyst. Enzymes are also used as they are extremely selective and, in 
some cases, whole cells or microorganisms are used (e.g. pig liver cells or baker’s 
yeast). These reagents normally are dependent upon the formation of a loose 
chiral intermediate that then reacts in a diastereoselective way. The catalyst then 
leaves to transform another molecule and the optically enriched product 
remains. 
 
Scheme 1 - Example of a symmetric and asymmetric reaction2 catalyzed by an enzyme. 
 The use of chiral auxiliaries is also a possible strategy. It consists in the use 
of a chiral-non-racemic reagent that will be covalently connected to a symmetric 
molecule transforming it into an asymmetric one. Further diastereoselective 
reaction(s) and removal of the chiral auxiliary render predominantly one 
enantiomer, the unaffected chiral auxiliary may be recovered and reused. 
 The last strategy that can be used is the resolution of a racemate, it 
consists in the separation of two enantiomers present in a mixture. Enantiomers 
cannot be separated by common purification techniques as both have the same 
physical properties, however some approaches can be used. One is the 
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derivatization of the racemate with a chiral reagent transforming the 
enantiomers into diastereomers and their further separation, it is commonly 
called diastereomeric resolution. As in the case of chiral auxiliaries the 
derivatization reagents may be recovered and reused. Other approach is a 
reaction with a chiral reagent or catalyst (kinetic resolution) and one enantiomer 
will react faster than the other. Is possible to stop the reaction at a point where 
one enantiomer has almost reacted completely and the other not, the product 
can then be separated from the unreacted enantiomer. The most used catalysts 
are the same for asymmetric reactions. One common approach also used is the 
formation of a salt with a chiral acid or base. This way is possible to recrystallize 
selectively one diastereomer and then convert the salt into the required acid or 
base. 
 
Scheme 2 - Example of a kinetic resolution3. 
 When the asymmetric strategy used is a resolution procedure, it should 
be considered that half of the material is lost. There is the idea that a resolution 
should be done as soon as possible in the synthesis, otherwise an impurity (the 
undesired enantiomer) will be carried through the synthesis. This will lead to an 
unnecessary use of solvents, reagents and other resources. On the other hand, a 
resolution carried earlier in a synthesis will result in more costs than one carried 
later, because a larger amount of chiral reagent or catalyst needs to be used. It 
should be noted that in many cases the asymmetric step in the synthesis is the 
one that requires more costs.  In conclusion, the cost of the other steps and of 
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the resolution should be balanced, and probably a very early resolution will be as 
bad option as a very late one. 
 The first impression can be that a resolution is a bad option when 
compared with the other strategies, since it implies a decrease in 50% of the final 
yield of the product. It is a fair argument but not that straightforward, since each 
strategy has its pros and cons. For example, a compound from the chiral pool 
may be expensive or unavailable in large amounts when compared to a simpler 
raw material, that other strategies may constitute a better alternative. 
Alternatively, the cost or efficiency of an asymmetric reaction may be so bad that 
a resolution may be a better alternative. Several aspects need to be considered 
in order to choose the best alternative for the purposes of the synthetic chemist. 
While in some cases time efficiency may be more important than costs, in others, 
raw material availability may be an essential feature. 
Aziridines 
Aziridines are an important class of organic compounds, basically they are 
a fully saturated three-member ring containing one nitrogen and two carbon 
atoms. This moiety is present in natural products, molecules having biological 
activity and even in products of industrial interest. Figure 4 illustrates some 
examples of natural bioactive molecules baring an aziridine ring.  They play an 
important role in organic synthesis and methods for their preparation4 and new 
application are still being developed5.  
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Figure 4 - Examples of bioactive natural products containing aziridines.  
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Aziridines are very versatile regarding its synthesis and reactions, 
therefore they are frequently used as a strategy to introduce a nitrogen atom 
into a molecule. Since the aziridine ring is very rigid, they often play an important 
role as intermediates orienting the stereochemical outcome of subsequent ring 
opening reactions. The following schemes illustrate examples of recent syntheses 
using aziridines: fasicularin6, crambescin A7, α-C-galactosylceramide8 and SGRM 
modulators9. 
 
 
Scheme 3 - Synthesis of fasicularin. 
 
 
Scheme 4 - Synthesis of crambescin A. 
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Scheme 5 - Synthesis of α-C-galactosylceramide. 
Scheme 6 - Synthesis of SGRM modulators. 
Cyclic acylaziridines (azabicyclo[x.1.0]alkane-2-ones) 
 In our group a Grabriel-Cromwell10 like method for the synthesis of 
acylaziridines has been studied11. It consists of the reaction of iodoenones with a 
primary amine under basic conditions (Scheme 7). It is particularly useful with 
cyclic substrates leading to the formation of the bicyclic compounds 
azabicyclo[x.1.0]alkane-2-ones. Since this discovery, its synthetic potential has 
been exploited and new applications for this reaction have been developed. 
Scheme 8 illustrates some applications for these compounds. As in the case of 
acyl epoxides they are particularly rich, since reactions can occur both at the 
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aziridine or ketone carbonyl. One particularly interesting transformation is the 
reaction with hydrazine to form an allylic amine, which we called the aza-
Wharton reaction after the discoverer of the epoxide analogue and was recently 
published12. 
 
Scheme 7 - Aziridination of cyclic iodoenones. 
 
Scheme 8 - Synthetic applications of cyclic acylaziridines. 
This aziridination method was used in the synthesis of two natural 
products: bromoxone13 and LL-C10037α14 (Scheme 9). In the case of bromoxone 
an enantiomerically pure iodoenone prepared from quinic acid was used. In the 
case of LL-C10037α a racemic iodoenone was resolved with a chiral amine, 
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demonstrating the usefulness of this reaction as a possible strategy for 
resolution. In both cases, it should be noted the stereoselectivity of both the 
aziridination and the epoxidation, in which the aziridine orientates the formation 
of the epoxide. 
Scheme 9 - Synthesis of bromoxone and LL-C10037α. 
Objectives 
 Cyclic acyl aziridines are particularly useful for the design of synthetic 
strategies as demonstrated. In the presented syntheses, besides the 
stereoselectivity of the aziridination, the aziridine is used as protecting, orienting 
and diastereomeric resolving group. We have previously described12,14 the 
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stereoselective aziridination of cyclic 4-hydroxyiodohexenones and respective 
TBS derivatives (Scheme 10). The trans aziridine would be the expected product, 
by Michael addition occurring at the least hindered side of the enone double 
bond. However, using alkyl amines, the cis aziridine is formed instead. We believe 
this is due to hydrogen bonding between the amine and the oxygen atom 
(Scheme 11) and a similar selectivity has previously been observed in the 1,4-
additions of thiols to similar systems15. In the case of tosylamide the proton 
attached to the nitrogen atom is much more acidic therefore a nitrogen anion 
may be formed by reaction with cesium carbonate, hence in the absence of 
hydrogen bonding the expected trans aziridine is formed. 
 
 
Scheme 10 - Stereoselective aziridination of cyclic 4-hydroxyiodohexenones. 
 
Scheme 11 - Proposed mechanism for the formation of cis 5-hydroxyazabicyclo[4.1.0]heptane-
2-ones. 
Taking advantage of the synthetic potential of these compounds, the 
objective of this work was to develop new strategies for the asymmetric synthesis 
of bioactive compounds: terpestacin, oseltamivir and analogues. 
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Figure 5 – Proposed synthesis of oseltamivir and terpestacin. 
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Abstract 
A method for the preparation of optically active cyclic 4-hydroxy-
acylazyridines ((x+1)-hydroxyazabicyclo[x.1.0]alkane-2-ones) is described. It is 
based on the stereoselective aziridination of protected racemic 4-
hydroxycycloenones followed by enzymic resolution with Novozym 435 (CAL-B). 
The described method is simple, reproducible, scalable and chiral 
hydroxyaziridines are obtained in good yield (up to 50%) and enantiomeric excess 
(up to 99%). A stereoselective nucleophilic substitution of the acetyl group of an 
acetylated five-membered ring substrate (4‐oxo‐6‐azabicyclo[3.1.0]hexan‐2‐yl 
acetate)  is also described. 
Introduction 
  For the development of new asymmetric syntheses of bioactive molecules 
and their analogues, the first task to be undertaken should be the synthesis of 
the optically active cyclic 4-hydroxyacylaziridines. The previous approaches used 
quinic acid as starting material from the chiral pool or an optically active amine 
during aziridination for the purpose of resolution (Scheme 12).14 The first 
approach is very time consuming since 8 steps are needed to convert quinic acid 
into (R)-4-hydoxy-cyclohexenone and 4 steps into (S)-4-hydoxy-cyclohexenone.16 
The second approach involves the separation of two diastereomers by 
chromatography, although practicable it needs very good chromatographic skills 
and some work in order to find the right conditions, since the difference in Rf of 
the two diastereomers is normally small. Alternative published methods15,17 for 
the preparation of optically active 4-hydroxycycloenones are time consuming, 
expensive or involve derivatization prior to resolution. In contrast, the 
preparation15,18,19 of racemic enones is expedient and inexpensive (Scheme 13). 
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In addition, 4-hydroxycycloenones are volatile and unstable, therefore a method 
for the resolution of cyclic 4-hydroxyacylaziridines ((x+1)-
hydroxyazabicyclo[x.1.0]alkane-2-ones) would be a good alternative for an 
asymmetric route for these compounds. 
Scheme 12 - Previous synthetic strategies for the preparation of optically active cyclic 4-
hydroxyacylaziridines. 
 
Scheme 13 - Asymmetric routes to 4-hydroxycycloenones. 
 In a method reported for the enantioselective synthesis of 4-
hydroxycycloenones, a procedure for the enzymic resolution of 3-thiobenzyl-4-
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hydroxy cyclic enones was used (Scheme 14). This procedure is very efficient, 
having high yields (>43%) and enantiomeric excesses (>99%). The enzyme used 
Novozym 435 is the lipase CAL-B on a solid support and has the advantages of 
being commercially available, affordable, easy to handle and compatible with 
organic solvents. Due to structure similarity, the procedure was expected to work 
as well in cyclic 4-hydroxyacylaziridines and appeared to constitute a good option 
for their resolution. 
 
 
Scheme 14 - Enzymic resolution of 3-thiobenzyl-4-hydroxy cycloketones. 
Preparation of racemic cyclic 4-hydroxyacylaziridines 
  Stereoselective aziridinations of TBS-protected 4-hydroxy-
cycloiodoenones 1 (scheme 3) have been discussed in the previous chapter. Cis 
aziridines 2a-c have been prepared using benzylamine as well as trans tosyl 
aziridine 2d. In the case of 1c (n=3) no selectivity was observed using tosylamide 
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and for 1b (n=1) aziridination is not possible, as the only product formed is 4. 
Product 4 is probably formed by basic rearrangement of aziridine 3 (Scheme 16). 
 
 
 
Scheme 15 - Stereoselective aziridination of 4-((tert-butyldimethylsilyl)oxy)-2-iodocycloenones. 
Reaction conditions: a) BnNH2, Cs2CO3, 1,10-Phenanthroline, Toluene; b) TsNH2, Cs2CO3, 
Toluene. 
 
 
 
Scheme 16 - Proposed mechanism for the formation of product 4. 
 
Hydroxyaziridines 5a-c were obtained by TBS group removal of 2a-c with 
TBAF in excellent yields (Scheme 17). Deprotection of tosylaziridine 2d with TBAF 
resulted in the formation of 6. Since fluoride is also a base it may have promoted 
the same rearrangement as in Scheme 16. Deprotection was possible with the 
less basic reagent triethylamine trihydrofluoride. 
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Scheme 17 - TBS deprotection of aziridines 2. 
Enzymic resolution 
Aziridine 5a was used to optimize a resolution protocol, the same 
conditions15 were applied and products analyzed by chiral HPLC. The method 
worked very well and (-)-5a was obtained in good yield (48%) and enantiomeric 
excess (>99%). In the other hand acetate (+)-7a was obtained with only 83% of 
enantiomeric excess and shorter conversions were not leading to a higher 
enantiomeric excess as expected. In addition, HPLC analyses were not 
reproducible and very dependent on the analyte concentration. The acetate 
group of (+)-7a was removed with potassium carbonate in methanol leading to 
the formation of (+)-5a in quantitative yield. The HPLC analysis of (+)-5a afforded 
a reproducibly higher enantiomeric excess. Graphic 1 shows the chromatograms 
of a sample before and after the acetate hydrolysis. Although we do not have an 
explanation for this, the HPLC analysis of acetate (+)-7a was leading to inaccurate 
values of enantiomeric excess. Another interesting feature of this protocol is that 
4, 8 or 16 hours of reaction time leads to the same conversion and enantiomeric 
excess. The lipase reaches a point where it stops catalyzing the acetylation and 
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this might be explained by a very high-energy transition state for the acylation of 
the unreacted enantiomer. 
 
Graphic 1 - Chiral HPLC analysis of resolved acetoxyaziridine (+)-7a and hydroxyaziridine (+)-5a 
after acetate hydrolysis.  
Elution conditions: AD-H column; 95:5 hexane:isopropanol; 1.0ml.min-1; 237nm. 
 The results of the lipase-catalyzed resolution of aziridines 5a-d are 
summarized in Table 1, all the acetates were analyzed after methanolysis. It is 
interesting to notice that lipase substrate selectivity was only dependent on the 
stereochemistry of the hydroxyl group and not on the aziridine. While 5a was an 
oil, 5b and 5d were solids only partially soluble in the solvent, diisopropyl ether, 
and probably for this reason the conversions of these compounds using the 
conditions applied to racemic 5a were lower (35%). This problem was solved by 
using a larger amount of solvent while maintaining the proportion of diisopropyl 
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ether/vinyl acetate and resulted in higher conversions (Table 1). In the case of 
substrates 5c and 5d at the point where the reaction stopped the conversions 
were only about 40%. Increasing the amount of enzyme used lead to higher 
conversions. We also found that the addition of all of the enzyme in one portion 
at the beginning or in several smaller portions during the esterification, did not 
affect the final outcome.  
Table 1 - Enzymatic resolution of cyclic 4-hydroxy-acylazyridines. 
 
Reaction conditions: a) Novozym 435 (25 mg), vinyl acetate (5 eq.), Diisopropyl ether (1 mL); b) 
K2CO3, MeOH. a All yields refer to isolated products starting from 50 mg of aziridine. b All 
enantiomeric excesses were determined by chiral HPLC. c 10 eq. of vinyl acetate and 2mL of DIPE 
were used. d 75 mg of lipase was used. e 50 mg of lipase was used. 
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 Methanolysis of acetate 7b was not possible under the same basic 
conditions, to form the corresponding alcohol, instead the methyl ether 8 was 
formed. The presence of a methyl group at 3.35 ppm on the 1H NMR spectrum 
(Figure 6) is indicative that the structure of compound 8 contains a methoxy 
group. The NMR signal of H-4 of cis aziridines 2b, 5b and 7b is a triplet of doublets 
while for aziridine 8 is a doublet, therefore it is possible to conclude formation of 
8 occurred with inversion of configuration. 
Figure 6 - Partial 1H NMR spectrum of aziridine 8. 
A plausible explanation for the formation of 8 involves elimination of 
acetate followed by stereoselective methanol addition (Scheme 18). The high 
stereoselectivity of the reaction is noteworthy, methanol addition occurred 
exclusively at the side of the enone system at the opposite face to the aziridine 
nitrogen atom. This result is most certainly due to steric hindrance of the aziridine 
ring. 
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Scheme 18 - Acetate elimination and methanol addition of 7b. 
Conclusion 
 The described enzymic resolution method allows the preparation of chiral 
cyclic 4-hydroxy-acylaziridines, useful molecules for organic chemistry as they 
can be transformed into functionalized cycloalkane products. It is an affordable, 
reproducible and scalable method, therefore having the potential to be used in 
multistep syntheses, as it will be demonstrated in the next two chapters.  
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Abstract 
 Three strategies for the synthesis of natural product terpestacin were 
designed. Although those strategies failed, interesting molecules were prepared 
that may be useful as intermediates in other syntheses. Aziridine invertomers 
were observed by NMR in one of these molecules and this equilibrium was 
studied by DFT calculations.  
Introduction 
 Terpestacin is a fungal secondary metabolite. It is a sesterterpene that 
was first isolated from Arthrinium sp. in 1993 and described as an inhibitor of the 
formation of syncytia by HIV-infected T cells.20 After its initial discovery, it was 
also isolated from other species of fungi21 and reported to have other biological 
activities such as the inhibition of angiogenesis22 and syncytia formation in other 
viruses23. Therefore, it is a promising lead for the development of new anticancer 
and antiviral drugs. 
 
Figure 7 - Terpestacin structure. 
 Due to its importance as a lead for drug development and its structural 
complexity, terpestacin has been a target for synthetic chemists and several 
syntheses have been developed24. All reported syntheses can be divided into two 
different parts, a) the synthesis of the cyclopentadione ring and b) of the 
macrocycle ring. Even though both tasks are very challenging, the construction 
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of the cyclopentadione ring requires the most stereocontrol. One of the more 
expedient routes was developed by Trost and coworkers24f,24g and is illustrated 
in Scheme 19. 
Scheme 19 - Trost synthesis of terpestacin. 
 Based on the Trost synthesis, a synthetic strategy for a key intermediate 
was designed (Scheme 20). The starting material is one of the 4-
hydroxyacylaziridines described in the previous chapter. In this strategy, the 
aziridine ring orients the introduction of the several groups in the 
cyclopentanone ring.  The described allyl group Michael addition is expected to 
form trans product due to aziridine steric hindrance. This allyl group would orient 
the ketone alkylation and the second substituted allyl group would be formed 
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trans to first one. Although the presented strategy is based on the 
macrocyclization approach developed by Trost, other described strategies or a 
new one could be used depending on the groups introduced. This strategy would 
constitute a new asymmetric approach for terpestacin. 
terpestacin is a considerable complex structure and its synthesis involves 
several steps, and like other complex natural products efficient processes are 
needed for its production to be viable. Probably, terpestacin won’t be a good 
candidate for a new commercial drug, however its structure can be used as a lead 
for the design of new drugs. For the design of new analogues efficient synthetic 
tools are needed, therefore development of new and efficient synthetic 
strategies for terpestacin are still useful. In this part of the work, the objective 
was to develop a new synthetic strategy for terpestacin and eventually other 
analogues. 
 
Scheme 20 - Proposed synthetic strategy for Trost intermediate.  
1st attempt 
 Aziridine 7b underwent beta elimination and stereoselective methanol 
1,4-addition as described in the previous chapter. The addition of other C and N 
nucleophiles was also tested (Scheme 21) and the trans products 10-12 were 
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exclusively obtained, albeit in moderate yield. Again, the aziridine ring seems to 
orientate very efficiently the addition of nucleophiles in this system. 
 
Scheme 21 - Aziridine 7b elimination of acetate and addition of different nucleophiles.  
Aziridine 11 was one of the intermediates of the proposed synthetic route 
(Scheme 20), its complete synthesis is described in Scheme 22. We opted to start 
with racemic 7b for an initial development of the methodology, however it can 
be obtained in optically enriched form by resolution as described in the previous 
chapter. The starting material, furfuryl alcohol 13 is inexpensive and 
commercially available, its transformation into 4-hydroxycyclopent-2-enone has 
been described15. Stereoselective aziridination and the preparation of 2b has 
already been discussed in the previous chapter. α,β-Unsaturated ketone 9 can be 
obtained by treating 7b with a base, however it is a very reactive species that 
quickly degrades upon isolation. Nevertheless, it was possible to identify its 
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structure by 1H NMR (Figure 8). The two signals at 7.6 and 5.9 ppm are consistent 
with the presence of a enone system, while the ones at 3.0 and 2.7 are produced 
by the unreacted aziridine moiety.   
 
 
Scheme 22 - Synthesis of 11.  
Reaction conditions: a) KH2PO4, H2O, reflux, 48h, 40%; b) TBSCl, DIPEA, DMAP (cat.), DCM, r.t., 
16h, 92%; c) I2, DMAP (cat.), Et2O:Py 1:1, r.t., 1h, 99%; d) BnNH2, Cs2CO3, 1,10-Phenanthroline, 
Toluene, r.t., 4h, 83%; e) TBAF, THF, r.t., 30 min, 98%; f) Ac2O, Et3N, DCM, r.t., 5h, 93%; g) DBU, 
THF, -20°C, 30 min; h) AllylMgBr, CuI, LiBr, THF, -78°C, 30min, 54%. 
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Figure 8 - Partial 1H NMR spectrum of compound 9. 
The enolate of 11 was formed with LDA and reacted with methyl iodide. 
Unfortunately, even at room temperature no reaction occurred and only initial 
compound 11 was recovered. Probably 11 is too crowded and methylation is not 
possible. Hence this was a dead end to this route. 
 
Scheme 23 - Unsuccessful reaction of lithium enolate of 11 with methyl iodide. 
2nd attempt 
 An alternative strategy for the synthesis of compound 13 (17 R=Bn) was 
planned, where the methyl group was already in the cyclopentanone ring before 
aziridination and allyl group addition (Scheme 24). As before, trans product 17 
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was expected to be formed and the alkylation of its enolate was considered to 
be possible using a more reactive allylic electrophile. 
 
Scheme 24 - Strategy for the synthesis of 17. 
5-Methyl-4-hydroxy-cyclopentenone 19 (Scheme 25) was prepared 
starting from methylfurylketone 18.25 Ketone 18 was reduced to the respective 
alcohol that underwent a Piancatelli rearrangement26 to form the enone 19. 
Steric hindrance of a methyl trans to the protected hydroxyl group should favor 
the cis-selectivity of 21 aziridination. Indeed, 22 was exclusively obtained and 
further elaboration produced the desired compound 24. 
 
Scheme 25 - Synthesis of 24.  
Reaction conditions: a) NaBH4, EtOH, r.t., 1h, 98%; b) ZnCl2, HCl, Dioxane/H2O, reflux, 24h, 90%; 
c) TBSCl, DIPEA, DMAP (cat.), DCM, r.t., 16h, 66%; d) I2, DMAP (cat.), Et2O:Py 1:1, r.t., 30 min, 56%; 
e) BnNH2, Cs2CO3, 1,10-Phenanthroline, Toluene, r.t., 3h, 70%; f) TBAF, THF, r.t., 30 min, 93%; g) 
Ac2O, Et3N, DCM, r.t., 3h, 73%. 
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Treatment of 24 with a base generated the expected α,β-unsaturated 
ketone 25 (Scheme 26), it was much more stable than 9 and could be isolated. 
The addition of the allyl group occurred, however, the expected product 17 was 
not formed, instead 26 was obtained. A possible mechanism for this 
transformation is proposed in Scheme 27, where Michael addition of the allyl 
group takes place but the enolate formed collapses opening both rings to form 
the unsaturated linear enaminone 26. 
 
Scheme 26 - Formation of 26.  
Reaction conditions: a) DBU, THF, -20°C, 30 min; b) AllylMgBr, CuI, LiBr, THF, -78°C, 30min, 20%. 
 
Scheme 27 - Proposed mechanism for the formation of 26. 
The 1H spectrum of 26 (Figure 9) contains several signals at low field (5-7 
ppm), consistent with a structure containing multiple unsaturations. There is also 
a signal at very low field (10.3 ppm) that corresponds to the NH of the enamine 
group. 2D experiments (COSY, HMQC and HMBC) were essential for the 
determination of the presented structure and attribution of signals. The 
stereochemistry of the double bond between carbon 4 and 5 was determined by 
a NOESY experiment, in which it was possible to observe a correlation signal 
between the methyl group and proton 6, as well as between protons 5 and 2.   
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Figure 9 - Partial 1H NMR of compound 26. 
For the formation of 26 was used an organometallic reagent 
(allylcuprate). Suspecting that the organocuprate was responsible for this 
reaction we decided to use a different nucleophile to check if the same 
rearrangement still occurred. Indeed, using diethyl malonate and an organic base 
(DBU) a similar product 27 was also obtained (Scheme 28). Treatment of 24 with 
a base in methanol resulted in the formation of enone 25 and the addition of 
methanol was not observed. It seems to be a very crowded system and probably 
the preparation of a compound with structure 17 would not be possible, so this 
was a dead end for this strategy. Although the rearrangement that produces 26 
and 27 is interesting, it has few synthetic applications since all the chiral 
information of the starting material was lost. 
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Scheme 28 - Formation of 27. 
3rd attempt 
 A new synthetic strategy for Trost intermediate 33 was designed, starting 
from a substrate with a methyl group in a different position (Scheme 29). While 
the simple allyl group would still be introduced by Michael addition, the 
substituted allyl group would be introduced by Claisen rearrangement and not 
by alkylation as initially planned. 
 
Scheme 29 - synthetic strategy for Trost intermediate 33. 
 Preparation of 3-methyl-4-hydroxy-cyclopentenone 35 has been 
described27 starting from 2,5-dimethylfuran 34 (Scheme 30). The aziridination of 
36 was less stereoselective when compared with previous substrates, a mixture 
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of 3:1 cis:trans was obtained whereas only one diastereoisomer is normally 
observed. However, a mixture of dichloromethane and toluene was used 
because the reaction was very slow in just toluene. We had previously observed 
with other substrates that, although the reaction is faster in dichloromethane, it 
is more selective in toluene. Further investigation of the right conditions for the 
aziridination of 36 for optimization of yield and selectivity is required. Further 
elaboration produced the desired compound 39. 
 
Scheme 30 - Synthesis of 39. 
Reaction conditions: a) m-CPBA, DCM, r.t., 30 min, 94%, b) Na2CO3, H2O, reflux, 2h, 70%; c) TBSCl, 
DIPEA, DMAP (cat.), DCM, r.t., 16h, 55%; d) I2, DMAP (cat.), Et2O:Py 1:1, r.t., 16h, 80%; e) BnNH2, 
Cs2CO3, 1,10-Phenanthroline, Toluene/DCM, r.t., 24h, 61% (28% trans); f) TBAF, THF, r.t., 30 min, 
100%; g) Ac2O, Et3N, DCM, r.t., 16h, 91%.  
Treating 39 with a base generates α,β-unsaturated ketone 40 and further 
Michael addition of allylcuprate produced the expected product 41 (Scheme 31). 
However, no selectivity was observed and 41 was obtained as a 1:1 mixture of 
diastereomers in only 30% yield. The diastereomer of 41 obtained is not 
important for the planned strategy, as the aziridine chiral information is lost in 
its opening, but a good selectivity is essential. Table 2 summarizes other 
conditions tried for the Michael addition. Maintaining the allylcuprate as reagent 
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but using isolated 40 leads to a little improvement on the selectivity (6:4) but the 
yield was still low (34%). The use of other nucleophiles resulted in a much better 
selectivity (42 and 43). We tried to substitute lithium bromide with 
hexamethylphosphoramide (HMPA), but the allylcuprate was not formed and, 
instead of 1,4-addition, 1,2-addition occurred and 44 was formed (Scheme 32). 
We also tried to use allyltrimethylsilane instead of an organometallic reagent but 
the desired product 41 was not obtained. 
 
Scheme 31 - Formation of 41.  
Reaction conditions: a) DBU, THF, -20°C, 30 min; b) allylMgBr, CuI, LiBr, THF, -78°C, 30 min, 30% 
(d.r.=1:1 RMN). 
Table 2 - Several Michael addition conditions. 
initial conditions product 
40 
allylMgBr, CuI, LiBr, THF, -
78°C 
41 34% (d.r.=6:4, a:b) 
39 K2CO3, MeOH, r.t. 
 
39 
diethyl malonate, DBU, 
DCM, r.t. 
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39 
1) DBU, THF 
2) allylMgBr, CuI, HMPA, 
THF, -78°C 
 
39 
1) DBU, THF 
2) allylTMS, MgBr2.Et2O, -
78°C 
 
39 
DBU, CsF, allylTMS, THF, 
r.t. 
40 
39 
1) DBU, THF 
2) allylTMS, TiCl4 
Complex mixture 
 
 
 
 
 
Scheme 32 - Proposed mechanism for the formation of 44. 
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Figure 10 - Partial 1H NMR spectrum of compound 44. 
 
From the 1H NMR (Figure 10) it is possible to conclude that compound 44 
contains unsaturations other than the allyl group. Signals at 6.2 and 6.1 ppm are 
consistent with the cyclopentene double bond. Also, signals at 5.0 and 4.8 
indicate the presence of a methylene group, as by HMQC is possible to conclude 
both protons are bonded to the same carbon. Carbon 4 generates a signal at 155 
ppm in the 13C NMR spectrum and was possible to conclude by HMBC it is 
connected to the methylene group and carbons 3 and 5. A second quaternary 
carbon is also present at 80 ppm, which corresponds to carbon 1. By HMBC was 
possible to conclude it is connected to carbons 1’, 2 and 5.  By FTIR spectroscopy 
the absence of a carbonyl groups in this molecule is also evident, supporting the 
presented structure. 
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Figure 11 - Partial 1H spectrum of compound 45. 
 
From the 1H and 13C NMR spectra of compound 45 (Figure 11) it is possible 
to understand it is the result of some type of dimerization of 40, as it contains 
two signals of each moiety of the structure (e.g. Bn and Me). Analyzing COSY and 
HMQC experiments it was possible to conclude carbons 2’ and 3 were bonded to 
each other. From the chemical shifts, we have hypothesized carbons 3’ and 4’ 
were connected to a bromine atom, what was consistent with chemical shift, but 
further mass spectrometry analysis is needed for confirmation. 
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The use of a bulkier group in the aziridine could be a strategy to improve 
the selectivity of the Michael addition. The aziridination was carried using 
methylbenzylamine and cyclohexylamine, however the expected aziridines were 
not observed. Instead, a disproportionation seems to take place, and 46 and 47 
were isolated (Scheme 33). 
 
Scheme 33 - Attempted aziridination of iodoenone 36. 
Figure 12 - Partial 1H spectrum of compound 47. 
 1H spectrum of compound 47 (Figure 12) contains a signal at low field 
(10.2 ppm), which corresponds to an aldehyde group. The rest of the 
Terpestacin synthesis preliminary attempts 
 
47 
 
spectroscopic data is consistent with the proposed structure and signals were 
assigned with the help of 2D NMR experiments. 
Three of the steps of this route were not very efficient: TBS-protection, 
aziridination and Michael addition of the allyl group. Hence, this route was 
abandoned, as it was becoming much less efficient when compared to other 
described syntheses. 
Aziridine invertomers 
 An interesting feature about aziridine 40 is that two species can be 
observed in both 1H and 13C NMR spectra, having the same type of signals but 
with different chemical shifts (Figure 13). It is unexpected as its structure cannot 
have diastereomers, therefore they must be conformers of the same molecule. 
The only part of the molecule flexible enough to have different conformations is 
the aziridine ring (Figure 14). Although invertomers of aziridines have already 
been described28, we had never observed them for other compounds, not even 
for the very similar aziridines 25 and 9. We decided to investigate deeper this 
effect by DFT calculations. 
 
Chapter 3 
 
48 
 
 
Figure 13 - Partial 1H NMR spectrum of aziridine 40. 
 
Figure 14 - Invertomers (conformers) endo and exo of aziridine 40. 
The structures of both invertomers of 40 (Figure 15) and of the transition 
state between them were calculated along with their respective energies, using 
Gaussian 9. For the optimization of the structures the method/basis set used was 
PBE1PBE/6-311g** and to calculate the energy of the optimized structure 
MP2/6-311g**.  For two species in equilibrium to be observed by NMR, the 
energy barrier between them should be in the range of 8-14 Kcal/mol. Hence, the 
calculated value of 18,4 Kcal/mol (Graphic 2) indicates that the observed species 
may be the invertomers. The calculated difference in energy 1,4 Kcal/mol 
corresponds to a ratio endo to exo of 9:1. The proportion, determined by 
integration of the 1H NMR, of 7:3 is not very far from the predicted value. 
Unexpectedly the more stable structure was the endo-invertomer. Empirically, 
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due to steric effects, the expected more stable structure would be the exo, also 
in previous12 X-ray structures of similar aziridines the exo structure was always 
obtained. 
 
 
 
Figure 15 - Optimized structures of exo-40 (left) and endo-40 (right) (PBE1PBE/6-311g**). 
 
Graphic 2 - Calculated Gibbs energies of the aziridines endo- and exo-40 and the transition state 
(MP2/6-311g**). 
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 These calculations are in accordance with the assumption that the species 
observed in the NMR spectra of 25 are invertomers, however, it appears that this 
effect has never been observed in similar compounds. To get a deeper 
understanding, the same calculations were also performed for different 
substrates (Figure 16), and the results are summarized in Table 3. The first 
interesting observation is that for compounds that do not contain the double 
bond or the methyl group (9, 48 and 50) the exo structure is the more stable and 
not the endo, but not for the compound without the carbonyl group at position 
2 (49). This indicates that the methyl group and the double bond was facilitating 
this effect, while the carbonyl seems to be irrelevant. Compared with 9, the 
aziridine 40 nitrogen atom is pushed closer to the double bond by the methyl 
group. Due to this proximity, the repulsion between the lone pair of electrons of 
the nitrogen atom and the π electrons of the double bond is higher (Figure 17). 
Therefore, the exo structure of 40 is destabilized. The calculations were also 
carried out with other compounds (51-53) and it was possible to predict that the 
alkyl group at the nitrogen (51) and at position 5 (52) do not significantly change 
the difference in energy of exo and endo, but a second alkyl group at position 1 
(53) greatly increases this difference.  
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Figure 16 - Structures of the compounds 9 and 48-53. 
 
Table 3 - Calculated values of ΔG‡ and ΔG(exo - endo) for compounds 9, 40 and 48-53. 
compound 
ΔG‡  
(Kcal/mol) 
ΔG(exo - endo) 
(Kcal/mol) 
40 18.4 1.4 
9 20.2 -0.8 
48 17.2 -1.7 
49 18.4 2.2 
50 18.7 -4.1 
51 17.2 1.8 
52 18.1 1.8 
53 17.3 4.0 
 
 
Figure 17 - Illustration of the repulsion between the lone pair of electrons of the nitrogen and 
the π electrons of the double bond in exo-40. 
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 From these results, we deduced that in similar aziridines previously 
prepared the endo- invertomer was much less stable than the exo- and thus had 
never been observed. In the case of aziridine 40, the endo invertomer is 
destabilized by electronic repulsion forces and the exo could be observed by 
NMR. 
Conclusion 
 The initial goal of developing a new synthetic route for terpestacin was 
not achieved, as the three designed strategies were not successful. However, 
several aziridines were prepared, which may be interesting intermediates for the 
synthesis of other products of interest. It is also interesting to observe how little 
changes in a molecule, such as the introduction of a methyl group, can change its 
reactivity completely. Finally, for the first time we have observed aziridine 
invertomers and their equilibrium was studied by DFT calculation 
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Abstract 
A new method for the synthesis of the influenza antiviral drugs 
oseltamivir and tamiphosphor was developed. A chiral aziridine produced by the 
enzymic method described in the chapter 1 was used as starting material. Its 
conversion to oseltamivir and tamiphosphor diethyl ester in 10 or 12 additional 
steps and 22% or 19% yield, respectively, is described. An attempt to synthesize 
a sulfonate analogue is also described. 
Introduction 
Influenza is still a considerable threat to human health. New strains of the 
virus continue to appear, in some cases turning into deadly global pandemics 
(e.g. H1N1 2009). The most common treatment for these infections is 
oseltamivir29 administration. This drug is commercialized by Roche under the 
name Tamiflu®, as a phosphate salt. It is a prodrug hydrolyzed in vivo to the 
corresponding acid (Scheme 34). This species is a potent inhibitor of influenza 
neuraminidase (NA), because it is structurally similar to NA natural substrate, a 
sialic acid (Scheme 35). During infection, influenza virus recognizes sialic acid 
present on glycoproteins on host cell surface and after removing it infects the 
cell. When administrated, oseltamivir acts by preventing new cells of an infected 
patient from being infected.  
 
Scheme 34 – Oseltamivir in vivo hydrolysis. 
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Scheme 35 – Influenza Neuraminidase (NA) activity. 
After its discovery, oseltamivir became an important target for synthetic 
chemists and a great number of syntheses have been developed by Roche and 
others30. In 2009, during the H1N1 pandemic, Tamiflu was the only effective 
treatment against the virus. This event turned even more the attention of 
chemists toward oseltamivir and new syntheses continued to be reported31. An 
important factor in any synthesis is control of the relative stereochemistry of the 
required product. More recently an efficient oseltamivir synthetic methodology 
comprising an asymmetric Michael addition32, based on the Hayashi31a route has 
been reported. Notably Hayashi and co-workers have reported a time-efficient 
one-pot methodology for the production of oseltamivir.33 
 Fang et al.30k developed a strategy to produce a new phosphorus 
analogue he called tamiphosphor. Tamiphosphor has a phosphonate group 
instead of the carboxylate and it has been shown to be more potent than 
oseltamivir. Further studies34 demonstrated that tamiphosphor was active 
against oseltamivir resistant strains of influenza virus, however poor 
bioavailability was a problem. In a recent paper35, in which Fang describes an 
improvement on the first synthesis, the importance of tamiphosphor was 
highlighted. Besides this synthetic route there is only one reported alternative36, 
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also described by Fang, and a method31j to convert oseltamivir into 
tamiphosphor. 
 
 
Figure 18 - Tamiphosphor structure. 
 
Previously we had developed a synthesis of an oseltamivir analogue 
(Scheme 36) based on the aza-Wharton reaction.37 This synthesis was a model 
for the development of a new synthetic route to oseltamivir, however it failed 
with a more substituted substrate (Scheme 37). During aza-Wharton reaction a 
double bond migration occurred forming an undesired α,β-unsaturated ester. 
The 5-OTBS analogue seems to significantly change reactivity of the molecule and 
the outcome of the reactions, probably by imposing different conformational 
strains on the cyclohexane ring.  Thus, we decided to design a new strategy, this 
time using the required hydroxylated starting material and not a simpler model. 
 
 
 
 
Chapter 4 
 
58 
 
Scheme 36 – Synthesis of an oseltamivir analogue based upon an aza-Wharton reaction. 
Reaction conditions: a) LDA, EtOCOCN, THF, -78ºC 1h (77%); b) N2H4.H2O; AcOH, MeOH, r.t. 15h 
(61%); c) CF3CO2H, CF3CO3H, CH2Cl2, r.t. 30 min (87%); d) H2, Pd(C), THF, AcOH, 4h; Ac2O, Py, r.t. 
30 min (61%); e) K2CO3, EtOH, r.t. 4h (100%); f) DIAD, PPh3, p-nitrobenzoic acid, THF, 0ºC 20 min; 
K2CO3, EtOH, r.t. 30 min. (87%); g) CCl3C(NH)OCHEt2, TfOH, CH2Cl2, r.t. 24h (20%). 
 
 
Scheme 37 - Aza-Wharton reaction/double bond migration. 
 
 A considerable number of the recorded synthetic routes to oseltamivir 
use an aziridine as intermediate that can be opened with 3-pentanol producing 
a trans-α-hydroxyamine (Scheme 38). For this work, we designed a synthetic plan 
to produce this intermediate aziridine from one of the 4-hydroxyacylaziridines 
described in the chapter 2. Thus, we expected to develop a new versatile and 
concise synthesis to oseltamivir, tamiphosphor and other analogues. 
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Scheme 38 - Plan for the synthesis of oseltamivir and tamiphosphor. 
 
Oseltamivir synthesis 
 Optically active aziridine 55 was prepared using the methodology 
described in chapter 2 (Scheme 39). We opted to change the alkyl group in the 
aziridine from benzyl to allyl, because removal of benzyl group by hydrogenolysis 
could be a problem in the presence of the double bond. In chapter 2 all 
resolutions were carried on a small scale (50 mg), 1.4 grams of aziridine 56 were 
resolved maintaining the excellent yields and e.e., thus demonstrating the scope 
of this methodology and its ability to be scaled-up. A TBS group had to be 
introduced using DBU as base, because the reaction of 56 using DIPEA and DMAP 
as base resulted only in the recovery of starting material. The use of more 
reactive reagents such as imidazole and/or TBSOTf, resulted in degradation of 
the aziridine 56. 
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Scheme 39 - Synthesis of aziridine (+)-55.  
Reagents and conditions: a) Allylamine, Cs2CO3, 1,10-Phenantroline, Toluene, r.t., 4h, 88%; b) 
TBAF, THF, r.t., 30 min, 100%; c). Novozym 435, vinyl acetate, DIPE, r.t., 4h, 49%, e.e.>99%; d) 
K2CO3 (cat.), MeOH, r.t., 99%; e) TBSCl, DBU, DCM, r.t., 1h, 95%. 
  
The ethoxycarbonyl group was introduced successfully by acylation of the 
lithium enolate of 55 affording β-ketoester 58 (80% yield) as a mixture of two 
diastereoisomers in equilibrium with the respective enol (Scheme 40). 
Subsequent one-pot reduction, mesylation and elimination produced 59 
([∝]𝐷
20℃= -70 (c= 0.7; DCM)), however the yield (50%) was not good but 
represents a three-step transformation. In the first step, the reduction of the 
ketone carbonyl, four different diastereoisomers were formed. Although all of 
these diastereoisomers converge to the same final product each of them seems 
to have a different reactivity with methanesulfonyl chloride and the resulting 
methanesulfonates also having different rates of elimination. 
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Scheme 40 - Synthesis of oseltamivir. 
Reagents and conditions: a) EtOCOCN, LDA, THF, -78oC, 1h, 80%; b) 1. NaBH4, EtOH, 0oC, 1h; 2. 
MsCl, Py, r.t, 1h; 3. K2CO3, EtOH, r.t., 1h, 50% (3 steps); c) TBAF, THF, r.t., 1h, 100%; d) BF3.Et2O, 
3-pentanol, 70oC, 30 min, 90%; e) 1. thiosalicylic acid, Pd(dba)2/DPPB (cat.), THF, 60oC, 30 min; 2. 
Ac2O, Py, r.t., 15 min, 83%. 
 Opening of the aziridine 60 with 3-pentanol was accomplished by Lewis 
acid catalysis (90% yield). A palladium catalyst in the presence of thiosalicylic acid 
was used for the removal of the allyl group 6138 followed by acetylation of the 
product without isolation of the intermediate amine afforded 62 ([∝]𝐷
20℃= -100 
(c=1.7; AcOEt); lit39: [∝]𝐷
25℃= -104 (c=3.0; AcOEt)) in a good yield (83%). Its 
transformation into oseltamivir has already been described.31f 
Tamiphosphor synthesis 
A similar strategy was used for the synthesis of the diethyl ester of 
tamiphosphor 70 (Scheme 41). The enol phosphate 63 (87% yield, [∝]𝐷
20℃= +45 
(c=1.1; DCM)), was obtained by reacting the enolate of ketone 55 with diethyl 
cyanophosphonate and the required phosphonate 64 was generated (91% yield) 
by subsequent treatment with a strong base.40 As in the case of ketoester 58, 
phosphonate 64 was present in three forms and phosphorous coupling with 
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adjacent protons and carbon atoms was evident in the respective NMR spectra 
(Figure 19).  
Scheme 41 - Synthesis of tamiphosphor diethyl phosphonate 70. 
Reagents and conditions: a) (EtO)2POCN, LDA, THF, -78oC, 1h, 87%; b) LDA, THF, -78oC, 30 min, 
91%; c) 1. NaBH4, EtOH, -78oC, 1h; 2. MsCl, Et3N, DCM, r.t, 3h; 3. DBU, DCM, r.t., 1h 47%; d) TBAF, 
THF, r.t., 1h, 100%; e) BF3.Et2O, 3-pentanol, 70oC, 30 min, 100%;  f) 1. 1,3-dimethylbarbituric acid, 
Pd(dba)2/DPPB (cat.), THF, 60oC, 30 min; 2. Ac2O, Et3N, r.t., 1 h; 3. K2CO3, EtOH, 70%; g) MsCl, 
Et3N, DCM, r.t., 1h, 99%. 
By lowering the temperature of the borohydride reduction of 64 from 0°C 
to -78°C the global yield of 65 increased from 28 to 47%. In our opinion, the yield 
increased due to a higher selectivity during the reduction. As before, four 
diastereoisomers were formed in this step, each one having a different reactivity. 
Hence the global yield could be higher if the diastereoisomer or diastereoisomers 
more suitable for mesylation/elimination are formed in a larger quantity. The use 
of K-selectride, a more hindered reducing agent, was tested, however only 
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ketophosphonate 64 was recovered. For the elimination step 1,8-
Diazabicyclo[5.4.0]undec-7-ene (DBU), a stronger homogeneous base had to be 
used instead of potassium carbonate. This was expected since the proton α to a 
phosphonate ester is less acidic than that α to a carboxylate ester. 
Figure 19 - Partial 13C and 31P spectrum of compound 64. 
Some alterations were made in the deprotection/acetylation of 
allylamine 67 to form acetamide 68 (77% yield). 1,3-Dimethylbarbituric acid was 
used instead of thiosalicylic acid because during chromatographic purification 
the latter co-eluted with product 68. Also, selective acetylation of the amine was 
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not possible, so an additional hydrolysis of the acetate ester, also formed, had to 
be carried out. The conversion of mesylate 69 ([∝]𝐷
20℃= -110 (c=1.2; AcOEt); lit35: 
[∝]𝐷
22℃= -102.5 (c=0.4; AcOEt)) into tamiphosphor diethyl ester 70 and 
subsequent conversion into tamiphosphor has already been described35. 
Tamisulfur 
 As in the case of tamiphosphor, where the substitution of the carboxylate 
group by a phosphonate group rendered a more potent analogue, a sulfonate 
group could also act as a bioisoster. The new target became the sulfonate 
analogue of oseltamivir, which we called tamisulfur (Scheme 42). 
 
 
Scheme 42 - Synthetic plan to tamisulfor. 
 
 Initial plans involved the direct inclusion of a sulfonate group by reacting 
the lithium enolate of aziridine 55 with methyl chlorosulfate. However, the 
product of this reaction was the chloroketone 71 in quantitative yield (Scheme 
43). This type of chlorination had already been described using tosyl chloride.41 
This was a very efficient alfa-chlorination method and was thus further studied, 
the results are presented in the next chapter.  
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Scheme 43 - Reaction of lithium enolate of 55 with methyl chlorosulfate. 
 Since the direct introduction of the sulfonate group did not occur, an 
alternative strategy could involve the substitution of the chlorine atom by a thio 
group, which could then be further oxidized. To develop this approach, we used 
4-(tert-butyl)-2-chlorocyclohexanone 72 as a model. Chloride displacement with 
potassium ethyl xanthate (KEX) produced 73 in 74% yield (Scheme 44). Basic 
hydrolysis of 73, using potassium carbonate in methanol did not generate the 
respective thiol, instead thionoester 74 was formed in 93% yield. This type of 
sulfur abstraction process is known42 and was also further studied and the results 
are presented in the next chapters. Thioacetate 75 was prepared also by chloride 
displacement (Scheme 45). Further hydrolysis produced a complex mixture, 
although the thiol may have been formed, it is probably very reactive and formed 
other products. 
 
Scheme 44 - Xanthate 73 preparation and conversion into thionoester 74.  
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Scheme 45 - Thioacetate 75 preparation and hydrolysis. 
  
Since thiol preparation seemed to be a difficult task, we decided to oxidize 
thioacetate 75 directly (Scheme 46). We opted to use tertbutylhypochlorite43 as 
oxidizing reagent, but surprisingly the chloroketone 72 was obtained. To check if 
the carbonyl has any influence, cyclohexyl thioacetate 76 was also oxidized under 
the same conditions (Scheme 47). The oxidation occurred and methyl sulfonate 
78 (51%) and benzyl sulfonamide 79 (78%) were obtained without isolating 
chlorosulfonate 77. Indeed the carbonyl group has an influence, 2-
oxocycloakanesulfunyl chlorides 80 are known to rearrange spontaneously to 
form the respective chlorides 81 (Scheme 48).44 
 
 
Scheme 46 - oxidation of thioacetate 75. 
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Scheme 47 - Oxidation of cyclohexyl thioacetate 76. 
 
Scheme 48 - Spontaneous conversion of 2-oxocycloalkanesulfonylchlorides into 2-
chlorocycloalkanones. 
 Unable to develop a strategy to introduce the sulfonate group in aziridine 
55, the synthesis of tamisulfor was abandoned. Nevertheless, the α-chlorination 
of ketones and the sulfur abstraction of α-xanthyl ketones appeared to be 
interesting subjects for further study and the results of this are presented in the 
next chapters. 
Conclusion 
A new versatile synthesis of the anti-influenza drugs oseltamivir and 
tamiphosphor was developed. The early formation of an aziridine moiety is a key 
step, not used in previous syntheses. Also, the resolution of intermediate 55 
constitutes an efficient asymmetric approach, with almost quantitative yield and 
very high enantiomeric excess. Its conversion into oseltamivir was achieved in 10 
steps and 22% yield and into tamiphosphor diethyl phosphonate in 12 steps and 
19% yield. Work to find the optimum conditions for the reduction/mesylation/ 
elimination step is required to improve the global yield of the synthesis. To this 
end some studies were carried out in an attempt to increase the selectivity of the 
reduction. An expedient asymmetric route for the synthesis of the key 
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intermediate (R)-4-hydroxyxyclohexenone would also render a more efficient 
process. Nevertheless, the development of a notable strategy for the asymmetric 
synthesis of two small but highly functionalized molecules of some economic 
importance was achieved. 
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Abstract 
Methyl chlorosulfate is described for the first time as an electrophilic 
chlorine source. An efficient method for the α-chlorination of ketones under 
basic conditions using methyl chlorosulfate is described. Its applicability for the 
chlorination of other functional groups have been studied and is equally useful 
for the synthesis of α-chloroesters and amides. Aldol and Claisen condensation 
reactions that occur during the chlorination of some substrates were also 
studied. 
Introduction 
Halogenation of the alpha position of carbonyl containing compounds is 
a classical method for the introduction of several functional groups in organic 
chemistry. It is widely used in synthesis both in academia and in industry, and is 
particularly useful in heterocycle generation.45 New methods for the 
halogenation of carbonylic compounds are still being developed46, as the search 
for more efficient, selective, economical or greener solutions that are essential 
for improved industrial processes. While the use of acid catalyzed methods has 
been extensively explored, basic methods have been less studied since 
polyhalogenation can be difficult to avoid. 
 Brummond and Gesenberg41 described the chlorination of the lithium 
enolates of ketones using chlorosulfonates as chlorinating reagents (Scheme 49). 
It constitutes a good alternative for the chlorination of acid sensitive molecules 
and/or selective chlorination at the more acidic carbon atom. This strategy has 
been used with tosyl, benzenesulfonyl, mesyl and triflyl chlorides.47 It is a very 
useful method but there is still space for reaction yield improvement since one 
of the problems involves the purification of the product having reagent-derived 
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contaminants. In our experience, the chromatographic purification of this type 
of compound leads to the loss of product as they degrade by several processes. 
Hence the development of cleaner methods without the need for purification 
would lead to improved yields. 
 
Scheme 49 - Chlorination of a ketone lithium enolate with alkyl and arylsulfonyl chlorides. 
 In this chapter, we report the use of methyl chlorosulfate as an improved 
chlorinating reagent for ketones under basic conditions. Its use in the 
chlorination of other functional groups was also studied. To our knowledge this 
is the first report of the use of an alkyl chlorosulfate for chlorination. 
Preparation of α-chloroketones  
 Methyl chlorosulfate can be readily prepared48 by reacting methanol with 
sulfuryl chloride and has been used as a sulfating49 and methylating50 reagent. Its 
reaction with camphor is described51 as producing methyl camphor-3-sulfonate 
under neutral conditions. Consequently, it would be expected that the reaction 
of ketones with methyl chlorosulfate under basic conditions would form the 
respective methyl α-sulfonates, however we found that the α-chloroketones are 
formed instead (Scheme 50), as reported in the previous chapter. This 
transformation was not completely predictable because, unlike chlorosulfonates, 
alkyl chlorosulfates have never been described as an electrophilic chlorine 
source. 
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Scheme 50 - Reaction of ketones with methyl chlorosulfate under basic conditions and possible 
sulfated and methylated products. 
 A range of ketones was submitted to the chlorination conditions (Scheme 
51), and the products were always obtained in quantitative yields with exception 
of some small volatile molecules (83a, 83b and 83f). It is a relatively clean 
reaction and there was normally no need for further purification after work-up. 
Preparation of 83f had already been described by Brummond and Gesenberg41 
with tosyl chloride, it is the only reported route to these compounds, since other 
chlorination methods resulted in the chlorination of carbon 2 instead of 6. The 
reaction worked very well with a tertiary ketone and 83g was formed in 
quantitative yield, containing a quaternary carbon. Chlorination of 1-
methylcyclohexanone was regioselective, as expected, and only the product (83i) 
from reaction of the kinetic enolate was obtained. The chlorination of the highly 
functionalized ketone 82l (55) has already been reported in the previous chapter 
and this result shows the versatility of this method for molecules having reactive 
functional groups. The aziridine ring is very sensitive to acidic conditions and it 
would probably be difficult to perform this transformation using classical 
methods. The stereoselectivity obtained for 83l is also interesting, as it was 
obtained as a single diastereomer while other asymmetric substrates (83i-k and 
83m) were obtained as mixtures. Contrary to previous reports for neutral 
conditions51, reaction with camphor resulted in the chlorination products 83m.  
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Scheme 51 - Results of α-chlorination of ketones. 
a Diastereomeric ratio calculated by 1H NMR. b yield after chromatographic purification. 
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 The method was applied to acetophenone and 83n was obtained as the 
major product. Initially chlorination of acetophenone occurs but then addition of 
acetophenone lithium enolate to the formed 2-chloroacetophenone apparently 
occurs faster than the chlorination (Scheme 52). Methyl ketones seems to be a 
substrate limitation of this method. This limitation was observed by Brummond 
and Gesenberg41 but only decomposition of the starting material was reported. 
The chlorine atom seems to have an important role in the aldol reaction as it 
occurs only in poor yield with acetophenone (Table 7). This is predictable since 
the carbonyl of the chloroacetophenone is more electrophilic and the alkoxide of 
83n more stable. 83n chloride intramolecular substitution with subsequent 
formation of an epoxide would be expected, however it has not been observed 
under the reaction conditions. 
 
Scheme 52 - Formation of 83n by addition of acetophenone lithium enolate with 2-
chloroacetophenone. 
Chlorination of substrates containing different functional groups  
Other substrates have been subjected to the same conditions (Table 4). 
Aldehyde 84a and nitro compound 84m apparently didn’t react and all the 
starting material was recovered. Some esters have also been tested (84b-d), in 
the case of esters 84b and 84d the reaction took place but it was not complete 
and some starting material was recovered. More equivalents of base and reagent 
were used in an attempt to increase the conversion of 84b but no difference was 
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observed. This limitation is probably due to the higher acidity of chloroester 85b 
compared to the respective ester 85b, the proton exchange being faster than the 
chlorination. For the less hindered ester 84c Claisen condensation products were 
formed, as in the case of methyl ketone 82n. Amides were also tested (84d-f) and 
chloroamides 85e and 85g were produced in good yield. In the case of less 
hindered amide 84f Claisen condensation product 86k was the main product 
obtained. The chlorination of 1,3-dicarbonyl compounds (84h-k) resulted in low 
conversions (14-66%) and in the case of ethyl acetoacetate 84i no reaction 
occurred at all. 
 Applying the same conditions to benzylnitrile (phenylacetonitrile) 84l, 
product 85l and starting material were obtained as major products. Using two 
equivalents of base and methyl chlorosulfate lead to complete conversion of 84l 
and a higher yield of 85l. By 1H and 13C NMR is only possible to detect a phenyl 
group and a quaternary carbon, however the signals have different chemical 
shifts than the ones described for dichlorobenzylnitrile, the expected product. By 
mass spectrometry (EI-B) was not possible to detect the molecular ion, only a 
fragment with half of the mass (m/z=150.0114). We believe 85l has the 
presented structure because the chemical shift of the quaternary carbon (68.2 
ppm) is that expected and its formation had already been reported during 
chlorination of 84l using thionyl chloride under acid conditions.52 It is interesting 
to note that formation of 85l was stereoselective and only one diastereomer was 
obtained.  
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Table 4 - Chlorination of different functional groups. 
substrate product substrate product 
 
No reaction (only 
SM recovered). 
  
 
 
 
 
 
 
 
No reaction (only 
SM recovered). 
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No reaction (only 
SM recovered). 
a Yield after purification by chromatography. b Two equivalents of LDA and MeOSO2Cl were 
used. 
 The lithium dianion of 3-keto esters and amide 84i-k was generated and 
further chlorinated (Table 5). In all cases 4-chlorination occurred and products 
86i-k were obtained in good yield. 
Table 5 - 4-chlorination of 1,3-dicarbonyl compounds. 
 
substrate product 
  
  
  
Alpha-chlorination of carbonyls under basic conditions using methyl chlorosulfate 
 
79 
 
Chlorination of mixtures of compounds 
 Given that chlorination of less hindered substrates (82n, 84c and 84f) 
resulted in aldol reactions, we decided to investigate the chlorination of mixtures 
containing those compounds (Table 6). The objective was to understand the 
synthetic usefulness of this reaction for the preparation of different γ-chloro-
carbonyl derivatives such as 83n, 85c’ and 86k. In mixtures containing the same 
functional groups (entry 1-2) cross reaction products were not observed, only the 
same products obtained using single compounds. Using a mixture of 
acetophenone 82n with ester 84c and dimethyl acetamide 84f (entry 3-4) aldol 
reaction occurred and products 87 and 88 were isolated. The respective 
chlorination products (chloroacetophenone, 85c and 85f) were also detected by 
NMR. Surprisingly, products 87 and 88 do not contain chlorine, they are the result 
of a simple aldol reaction of the substrates. We propose that initial chlorination 
occurs but acetophenone is reprotonated and reacts with the ester or amide 
lithium enolate (Scheme 53). To support this mechanism, we have reacted the 
lithium enolate of 84c and 84f with acetophenone (Table 7). While in the case of 
84f product 88 was formed, for 84c only starting materials were recovered in the 
presence of 85c’’ and product 87 was not observed. In light of this result, we 
reacted the lithium enolates of 82n and 84c together with chloroester 85c and 
surprisingly product 87 was produced. It is very interesting and unexpected how 
direct aldol reaction of 82n and 84c doesn’t occur in the conditions used, 
however producing both enolates and reacting with a chloroester led to the aldol 
reaction to take place (Scheme 54). This reaction can be an alternative to the 
Reformatsky reaction for the synthesis of tertiary 3-hydroxyesters like 87.  
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The reaction with the mixture of 84c and 84f (entry 5) produced two cross 
reaction products 89 and 90. Contrary to the results obtained with other two 
mixtures, chlorine was present in these products, obtained in low yields. The 
presence of the amide 3c and 3f seems to enhance a mutual chlorination, since 
products 4c and 4f were obtained in a better yield compared to the reaction with 
the single compounds.  
Table 6 - Chlorination of equimolar mixtures of different substrates. 
Entry Substrates Products 
1 
  
Cross reaction products 
not observed 
2 
  
Cross reaction products 
not observed 
3 
 
 
 
4 
 
  
5 
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Scheme 53 - Proposed mechanism for the formation of 87 and 88 (87 is used as example). 
 
 
Scheme 54 - Reaction of lithium enolate of 84c with acetophenone and of both enolates with 
chloroester 85c. 
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Table 7 - Additional aldol experiments results. 
reagents products 
 
 
 
 
 
 
 
 
  
All reactions were carried in THF at -78°C for 30 min. a Yield after purification by 
chromatography. 
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Conclusion 
 A method for the basic α-chlorination of ketones and other functional 
groups is described. It is useful for acid sensitive substrates or selective 
chlorination of the less substituted carbon, since most of the methods available 
are acid catalyzed. To our knowledge, this is the first time an alkyl chlorosulfate 
has been described as a chlorinating reagent. Methyl chlorosulfate is an 
inexpensive and easily preparable reagent and found to have a better 
performance when compared to alkyl and aryl chlorosulfonates. Also, the 
reaction is very clean and affords quantitative yields and for all these reasons it 
is a very practical procedure. It works particularly well with ketones but can also 
be applied to esters and amides. It is useful in the preparation 4-chloro-1,3-
dicarbonyl compounds via chlorination of the lithium dianion. Finally, the aldol 
and Claisen condensation of different molecules was also studied. Applying these 
conditions to less hindered ketones, esters and amides results in a one-pot 
chlorination and aldol or Claisen condensation process. On the other hand, using 
a mixture of a ketone with an ester or amide results in a simple aldol reaction. 
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Abstract 
A method for the transformation of 2-oxo S-carbonyl or thiocarbonyl into 
2-oxo (thio)carbonyl compounds by a base promoted sulfur abstraction 
rearrangement is described. It is a very clean reaction and products are obtained 
in good yield (around 90%) in just 30 minutes. This method is particularly efficient 
for the introduction of thiocarbonyl containing groups, whereas for the 
introduction of acid derivatives it is less efficient. This method constitutes an 
alternative synthetic strategy for the generation of a new carbon-carbon bond 
and preparation of β-dicarbonyl compounds. 
Introduction 
Rearrangement reactions, although in some cases unpredictable, are 
important transformations in organic chemistry and particularly useful in 
synthesis when a new carbon-carbon bond is formed. The sulfur abstraction 
reaction of β-oxo thioacyl compounds is one example, where two carbons 
connected by a sulfur atom become directly connected.  
 This rearrangement (Scheme 55) was first reported by Lightner and 
Djerassi53 in 1963 with the conversion of a steroid β-oxo xanthate into a β-oxo 
thionoester under basic conditions, the mechanism is illustrated in Scheme 56. 
Later, Eshenmoser54 described the use of a tertiary phosphine as an alternative 
reagent, acting as a thiophile. This method has been extensively used with β-oxo 
thioimidates and is known as Eschenmoser sulfide contraction.55 Besides the 
Eschenmoser reaction this rearrangement has been little used despite its 
synthetic potential, examples described in the literature42,56 are summarized in 
Scheme 55. 
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Scheme 55 - Examples of sulfur abstraction reactions. 
 
Scheme 56 - Mechanism of sulfur abstraction of a α-dithiocarbonate (or xanthate) ketone. 
In this chapter, we explored the potential of this reaction for the 
introduction of different groups via sulfur abstraction. We opted to use a base 
promoted method since the use of phosphines normally produces a great mass 
of byproducts. This rearrangement constitutes a clean and green method for the 
introduction of different carbonyl and thiocarbonyl containing groups. 
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Reaction with β-oxo xanthates 
 β-oxo xanthates or α-xanthyl ketones can be readily prepared by reacting 
the α-halo ketones with the respective xanthate salt. With the commercially 
available ethyl potassium xanthate a series of cyclic β-oxo ethyl xanthates was 
prepared and reacted with sodium hydride to promote the rearrangement (Table 
8). It is a very clean and fast reaction; however, it is sensitive to the quality of 
sodium hydride used and a degraded sodium hydride (probably containing 
NaOH) leads to complex mixtures of products. Two simple substrates, S-(2-
oxocyclohexyl) and S-(2-oxocyclopentyl) O-ethyl xanthates (91a and 91b), were 
used and the respective β-oxo thionoesters 92a and 92c were obtained in 
moderate yields. Other substituted cyclohexanones were also used and the 
respective thionoesters 92c-f were always obtained with good yields. A possible 
explanation for the lower yield of 92b could be its higher volatility and loss during 
solvent evaporation since it has a low molecular weight. A highly functionalized 
optically active thionoester 92g was also prepared in good yield, demonstrating 
the compatibility of this transformation with different functional groups. 
 Although the thionoesters (92a-g) were mainly present in the enol form, 
in the 1H and 13C NMR spectra (Figure 20) it was possible to detect also the keto- 
form. The enol produced a characteristic signal in the 1H NMR spectrum at low 
field (13-15 ppm). In the 13C NMR spectrum a signal at low field (>205 ppm) was 
characteristic of thiocarbonyl groups. 
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Table 8 - Cyclic β-oxo thionoesters synthesis via sulfur abstraction of the respective β-oxo 
xanthates. 
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Figure 20 - Partial 13C APT NMR spectrum of compound 92a. 
S-(2-oxocyclohex-3-en-1-yl) O-ethyl xanthate 91h was prepared starting 
from 6-chloro-2-cyclohexenone, although Michael addition of the xanthate 
occurs we found that chloride substitution is also possible using two equivalents 
of xanthate. Using a sodium bicarbonate solution in the work-up instead of 
water, the xanthate group added to the enone eliminates and 91h is obtained. In 
the rearrangement of 91h the expected product 92h is obtained, however a 
secondary product 92h’ is also produced. The product 92h’, containing two 
cyclohexane rings fused by a cyclobutane, is produced by a tandem Michael-
Dieckmann reaction (Scheme 57). During an attempt to avoid 92h’ formation, the 
reaction was carried at a lower temperature (-20°C), however the opposite effect 
was observed and the yield of 92h’ increased to 40%. Although it was not 
investigated, carrying out the reaction at an even lower temperature could lead 
to the exclusive formation of 92h’. 
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Scheme 57 - Proposed mechanism for the formation of compound 92h’. 
In the 1H and 13C NMR spectrum of compound 92h’ (Figure 21) it was 
possible to observe two different ethyl groups, which indicated that it was the 
result of the dimerization of 91h. Two different signals (224 and 207 ppm) for 
thiocarbonyl groups were also present in the 13C spectrum. These differences in 
chemical shift and the presence of the enol group in the 1H spectrum were an 
indication that one of the groups was the expected 2-oxo-thionoester, while the 
other one seemed to be a xanthate. It was also possible to observe a double 
bond, however the chemical shifts (5.9 and 5.6 ppm for 1H; 129 and 128 ppm for 
13C) are not consistent with conjugation with a carbonyl as expected. With the 
help of 2D experiments the presented structure have been determined; however 
it was not possible to determine the relative stereochemistry of the cyclobutane 
ring, further X-Ray structure determination is required.    
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Figure 21 - Partial 1H spectrum of compound 92h’. 
Reaction with β-oxo thioacetates 
As for β-oxo xanthates, β-oxo thioacetates are easily prepared by halogen 
substitution using commercially available potassium thioacetate. A series of β-
oxo thioacetates was also prepared and submitted to the same conditions (Table 
9). Two linear substrates were tested and the respective β-diketones 92i and 92j 
were obtained in good yield. 3-acetylthio-4-tertbutylcyclohexanone 91l was 
tested for comparison with the structurally similar ethyl xanthate 91d, 92l was 
obtained almost in the same yield as 92d. Thioacetate 91k was prepared in the 
same way as 91h. Upon reaction with sodium hydride 92k was obtained in good 
yield and the Michael addition that produced 92h’ was not observed. 2-
acetylthiocyclooctanone 91m and cyclododecanone 91n were prepared by 
chlorine substitution, however the reaction had to be carried at 70°C for 70 
hours. For these 2-chloro substituted cycloketones containing a larger cycle, 
chlorine displacement seems to be more difficult and their substitution with ethyl 
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xanthate was not possible (Scheme 58). The respective β-diketones (92m and 
92n) were however obtained in good yields. 
Table 9 - β-diketones synthesis via sulfur abstraction of the respective β-oxo thioacetates. 
 
As presented in Scheme 58, reaction of chloroketone 83c with potassium 
ethyl xanthate resulted in thioether 93. The expected 2-oxo xanthate was 
probably formed but was hydrolyzed to the corresponding thiol and reacted with 
the chloroketone 83c. By NMR it was possible to conclude that compound 93 was 
an alpha substituted cylcooctanone and a molecular ion (m/z: 283) was 
consistent with the presented structure. By NMR it was possible to observe the 
two diastereoisomers of 93 in a 6:4 ratio. 
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Scheme 58 - Reaction of 2-chlorocyclooctanone 83c with potassium ethyl xanthate.  
Reaction with different functional groups 
 Tetralone was used as a model to study the reaction with different 
carbonyl and thiocarbonyl containing groups at the sulfur atom (Table 10). 
Compounds 91o and 91p were prepared by halogen substitution using the right 
salt. Reaction of dithiocarbamate 91o produced thioamide 92o in good yield, 
however the reaction had to be carried at 60°C and therefore solvent was 
changed to DMF. The sodium enolate of 91o is formed at lower temperatures, as 
can be observed by hydrogen releasing, however the sulfur abstraction only 
occurred when the temperature was raised to 60°C. Dithioester 92p was also 
obtained in good yield. 
Compounds 91q-t were obtained by thiocarbonyl oxidation of 
compounds 91f, 91o and 91p (Scheme 59). Reaction of monothiocarbonate 91q 
afforded ester 92q in a moderate yield and a secondary product 92q’ was also 
formed. The trithiolane 92q’ was probably formed by reaction of thioketone 94 
with sulfur released from the rearrangement (Scheme 60).57 Two diastereomers 
of 92q’ are possible but only one was observed. In the 13C NMR of compound 
92q’ a quaternary carbon was observed at 83.9 ppm, which corresponds to the 
carbon alpha to the carbonyl group. Mass spectrometry ([M+Na]+ C20H16NaO2S3 
m/z: 407.0199) was essential for the determination of the proposed structure, 
having a trithiolane ring since it contained 3 sulfur atoms and 2 tetralone rings. 
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Table 10 - Basic rearrangement of different 2-S-carbonyl and thiocarbonyl tetralone derivatives. 
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a Reaction was carried in DMF at 60°C. b Reaction was carried in DMF at 80°C. c After 30 min, MeI was added. 
 
 
 
Scheme 59 - Oxidation of compounds 91f, 91o and 91p.  
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Scheme 60 - Proposed mechanism for the formation of trithiolane 92q’. 
 
 
Basic rearrangement of monothiocarbamate 91r resulted in a 
quantitative yield of 92r, as for dithiocarbamate 91o any reaction only occurs at 
a higher temperature (80°C). Instead of sulfur abstraction the carbamate group 
migrated from the sulfur to the oxygen atom, further dimerization resulted in 
92r. In the 13C NMR spectrum is possible to observe four quaternary unsaturated 
carbons and the absence of a ketone carbonyl group, leading to the conclusion 
that 92r was an enol derivative of tetralone. A signal at 1721 cm-1 in the FTIR 
spectrum was consistent with the presence of a carbamate carbonyl, which could 
also be observed in the 13C NMR spectrum. Once again mass spectrometry was 
essential for the determination of the proposed structure. 
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Figure 22 - Partial 13C NMR spectrum of compound 92r. 
 Oxidation of trithiocarbonate 91p using permanganate resulted in 
dithiocarbonate 91s while using m-CPBA, sulfine 91t was obtained (Scheme 59). 
Spectroscopic data for these two compounds was very similar, only by mass 
spectroscopy could they be distinguished. Although reaction of 91s produced the 
expected product 92s, a secondary product was also formed. The formation of 
92s’ could be due to sulfur and CO elimination or direct elimination of carbonyl 
sulfide, further aromatization is possible in the presence of sulfur. During the 
rearrangement of 91t both sulfur abstraction and oxygen migration occurred 
resulting in the formation of 92t as well as aromatic secondary product 92t’.  
Compounds 91q-s seem to be less suitable for the rearrangement when 
compared to the respective thiocarbonyl analogues 91f, 91o and 91p. Their basic 
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rearrangement resulted in the formation of secondary products (92s’ and 92q’) 
or sulfur abstraction didn’t occur at all in the case of 91t. According to the 
proposed mechanism (Scheme 56) an episulfide intermediate needs to be 
formed for the sulfur abstraction to occur, in the case of carbonyl derivatives an 
alkoxide is formed instead of a thiolate. Thus, this episulfide intermediate is 
probably less stable for carbonyl derivatives explaining the lower efficiency of the 
sulfur abstraction.   
 Considering the good results of thioacetates 91i-n rearrangement, 
monothiobenzoate 91u and dithioesters 92v and 92w were prepared by 
substitution of 2-bromotetralone with the right salt and submitted to the same 
conditions. Reaction of 91u resulted in the expected product 92u in quantitative 
yield. Rearrangement of dithioesters 91v and 91w produced the expected 
thioketones, however these products were very unstable and degradation was 
observed upon air exposure or chromatographic purification. For an easy 
isolation of the products they were methylated with iodomethane in a one-pot 
procedure and 91v and 91w were obtained as a mixture of two diastereoisomers. 
Other methylation (O and C) products were observed in the NMR of the crude, 
what may explain the lower yields of 91v and 91w. 
 A dithiophosphate derivative 91x (Scheme 61) was also prepared and 
submitted to basic conditions to understand if the sulfur abstraction was also 
possible in a phosphorous analogue. However only migration of the 
thiophosphate from the sulfur to the oxygen occurred and 92x was obtained. As 
in the case of 92r, by 13C NMR was possible to conclude 92x is an enol derivative 
of tetralone. A thiol proton could also be observed in the 1H NMR spectrum at 
3.62 ppm. 
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Scheme 61 - Basic rearrangement of 2-diethyldithiophosphate tetralone 91x. 
Conclusion 
 The basic sulfur abstraction of 2-oxo (thio)carbonyl compounds is a useful 
synthetic strategy for the preparation of β-dicarbonyl compounds that comprises 
the generation of a new carbon-carbon bond. Although synthetic applications 
described in the literature are almost all restricted to the Eschenmoser method, 
a broader range of substrates has here been demonstrated. It is a very clean 
reaction and the products are obtained in good yields. It is particularly useful for 
the introduction of a thiocarbonyl containing group: thioketone, thionoester, 
thioamide and dithioester. In addition to its potential for new synthetic routes 
design, the β-dicarbonyl compounds produced are useful as ligands in metal 
complexes especially when containing a thiocarbonyl group. Although the 
generation of acid derivative group (ester, amide and thioester) seem to be a 
limitation of this method, products and by products obtained have been isolated 
and identified. 
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The aim of this work was to develop new synthetic applications for cyclic 
acyl aziridines (azabicyclo[x.1.0]alkane-2-ones), particularly in the preparation of 
oseltamivir, terpestacin and analogues. While for oseltamivir a new synthesis is 
described, for terpestacin all the synthetic strategies designed failed. As part of 
this project, a new asymmetric synthesis of the studied cyclic acyl aziridines 
based on an enzymic resolution methodology was also developed. Other 
transformations with great synthetic potential were also studied. 
 The described preparation of optically active cyclic 4-
hydroxyacylaziridines is very efficient. Both enantiomers can be produced in high 
yield and enantiomeric excess. It is easily scalable maintaining the efficiency, as 
demonstrated in the oseltamivir synthesis. The main disadvantage of this 
strategy is the need to introduce the TBS group for the aziridination that is 
subsequently removed for the resolution process. The direct halogenation of the 
cyclic 4-hydroxyenones would render a more efficient process. Further work may 
be done for the development of a new halogenation methodology, since the 
conditions used are not compatible with the unprotected hydroxyl group. 
Nevertheless, a very efficient process for the preparation of useful building 
blocks for organic chemistry is described. These small chiral molecules were used 
as starting materials in the synthetic strategies developed. 
  The synthetic strategies designed for terpestacin did not work out as 
planned and its synthesis was not achieved as initially proposed. Nevertheless, 
some interesting molecules were prepared and may be used in the synthesis of 
other products. It is interesting to observe how small changes in the structure of 
a molecule, such as the introduction of a methyl group, can change completely 
the outcome of a reaction. Although the initial idea was that the aziridine ring 
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could orient the introduction of the functional groups, it seems to impose such a 
steric hindrance that render it a very unstable system. The observation of 
aziridine invertomers was also interesting and to our knowledge they have never 
been detected at room temperature in alkyl aziridines. Computational chemistry 
tools were essential for the study of this effect. 
 The new synthesis of oseltamivir was achieved as initially proposed. Many 
syntheses are described in the literature, for example the recent one-pot method 
of Hayashi33. The early formation of the aziridine and the enzymic resolution are 
the most distinguishable features of the developed synthesis. The process could 
still be improved, especially the reduction/mesylation/elimination. Contrary to 
other described syntheses of oseltamivir, the one reported in this thesis 
employed simple and reproducible reactions and also relatively inexpensive and 
readily available reagents. For those reasons, it is a methodology easy to 
reproduce and scale up, even by less experienced synthetic chemists. Probably, 
this synthesis is not the most viable for industrial production of oseltamivir, 
however it is very versatile and can be used for the synthesis of different 
analogues. The synthesis of tamiphosphor illustrates this potential and similarly 
other molecules containing different acid bioisosters could be produced. The α-
chloroketone prepared could also be useful in this task, as different groups could 
be introduced by chlorine displacement. Resuming, this methodology has a great 
potential to be used in the medicinal chemistry of antiviral drugs. 
 The last two chapters of this work were focused on the study of two 
reactions that are particularly useful for organic synthesis. The first one, the basic 
chlorination of ketones with methyl chlorosulfate was not easily predicted, since 
α-sulfonates were the expected products under the reaction conditions. It is a 
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very clean and efficient reaction, and the reagent used was easily prepared and 
inexpensive. Although this type of reaction has been described using alkyl 
sulfonyl chlorides (chlorosulfonates), the use of methyl chlorosulfate rendered a 
much more efficient reaction. Moreover, this was the first time a chlorosulfate 
has been described as an electrophilic chlorine source to our knowledge. The α-
halogenation of carbonyl containing compounds is a classical strategy for the 
functionalization of organic molecules. The methodology herein described is one 
of the few examples described for this transformation under basic conditions, 
hence being compatible with a variety of functional groups and very useful. 
 The second reaction was the basic sulfur abstraction of 2-oxocarbonyl and 
thiocarbonyl compounds and is also a very efficient and clean reaction. In this 
reaction, a new carbon-carbon bond is formed, one of the most important tasks 
in organic chemistry. Therefore, this transformation has great synthetic 
potential. The products obtained, 1,3-dicarbonyl compounds, are very useful as 
metal ligands. The reported methodology can be used for the design of new 
metal complexes, that have different applications (e.g. catalysis). The work 
presented in this two last chapters deviated a little from what was initially 
proposed. Although the two reactions studied have great potential, reports of 
their use in organic synthesis are scarce, therefore we decided to investigate 
them deeper to understand their scope and limitations. 
 With this work, we hope to have contributed to our organic chemistry 
knowledge with new synthetic methodologies. The developed synthesis of 
oseltamivir and tamiphosphor may provide a contribution to medicinal 
chemistry, making available new routes for different molecules with potential 
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antiviral activity. All the described transformations and strategies are tools 
available to synthetic chemists for the preparation of compounds of interest. 
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General 
All chemicals used were of reagent grade. All solvents were dried where 
necessary by established methods.58 Flash chromatography was performed on 
Kieselgel 60, particle size 0.032–0.063 mm. Preparative TLC employed silica gel 
Merck 60 GF254. Analytical TLC: Aluminum-backed silica gel Merck 60 F254. 
Infrared (IR) spectra were obtained using a commercial ATR-FTIR 
spectrophotometer and are in cm−1. Specific rotations were measured using an 
automatic polarimeter and are reported as follows: [∝]𝐷
𝑇  (c= g/100mL; solvent). 
Melting points were determined with a capillary apparatus and are uncorrected. 
HRMS was recorded on a commercial apparatus (ESI Source). NMR spectra were 
obtained at commercial instrument 400 MHz (1H NMR), 101 MHz (13C NMR) and 
162 MHz (31P NMR) using CDCl3 as solvent. Chemical shifts are reported in parts 
per million relative to TMS (1H and 13C) or phosphoric acid (31P) and coupling 
constants in hertz. The chemical shift assignments of all compounds were carried 
out with the help of 2D NMR experiments as COSY, HMQC and HMBC. Chiral HPLC 
analysis was carried out by using a Chiralpak® AD-H or IB (250 x 4.6 mm) column 
in a Waters system: 515 pump and 2485 dual λ absorbance detector. All 
calculations were performed with Gaussian 09w, the vibrational frequencies 
were computed to check whether each optimized structure is an energy 
minimum or a transition state and to calculate thermal corrections at 298 K. 
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4‐[(tert‐Butyldimethylsilyl)oxy]‐2‐
iodocyclohept‐2‐en‐1‐one 1c 
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(±)-(1S,5S,6R)‐7‐Benzyl‐5‐[(tert‐
butyldimethylsilyl)oxy]‐7-
azabicyclo[4.1.0]heptan‐2‐one 2a 
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(±)-(1S,4S,5R)‐6‐Benzyl‐4‐[(tert‐
butyldimethylsilyl)oxy]‐6‐
azabicyclo[3.1.0]hexan‐2‐one 2b 
131 
 
(±)-(1S,6S,7R)‐8‐Benzyl‐6‐[(tert‐
butyldimethylsilyl)oxy]‐8‐
azabicyclo[5.1.0]octan‐2‐one 2c 
131 
 
(±)-(1R,5S,6S)-5-[(tert-
Butyldimethylsilyl)oxy]-7-[(4-
methylphenyl)sulfonyl]-7-
azabicyclo[4.1.0]heptan-2-one 2d 
132 
 
(-)-(1S,5S,6R)‐7‐benzyl‐5‐hydroxy‐7‐
azabicyclo[4.1.0]heptan‐2‐one 5a 
133, 
134 
 
(-)-(1S,4S,5R)‐6‐Benzyl‐4‐hydroxy‐6‐
azabicyclo[3.1.0]hexan‐2‐one 5b 
133, 
134 
Experimental 
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(-)-(1S,6S,7R)‐8‐Benzyl‐6‐hydroxy‐8‐
azabicyclo[5.1.0]octan‐2‐one 5c 
133, 
135 
 
(+)-(1R,5S,6S)‐5‐Hydroxy‐7‐(4‐
methylbenzenesulfonyl)‐7‐
azabicyclo[4.1.0]heptan‐2‐one 5d 
133, 
136 
 
(+)-(1S,2R,6R)‐7‐Benzyl‐5‐oxo‐7‐
azabicyclo[4.1.0]heptan‐2‐yl acetate 7a 
134 
 
(+)-(1S,2R,5R)‐6‐Benzyl‐4‐oxo‐6‐
azabicyclo[3.1.0]hexan‐2‐yl acetate 7b 
135 
 
(+)-(1S,2R,7R)‐8‐Benzyl‐6‐oxo‐8‐
azabicyclo[5.1.0]octan‐2‐yl acetate 7c 
136 
 
(-)-(1R,2R,6S)‐7‐(4‐
Methylbenzenesulfonyl)‐5‐oxo‐7‐
azabicyclo[4.1.0]heptan‐2‐yl acetate 7d 
137 
 
(+)-(1R,4S,5S)‐6‐Benzyl‐4‐methoxy‐6‐
azabicyclo[3.1.0]hexan‐2‐one 8 
138 
Experimental 
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(±)-1,3‐Diethyl 2‐[(1R,2R,5R)‐6‐benzyl‐4‐
oxo‐6‐azabicyclo[3.1.0]hexan‐2‐
yl]propanedioate 10 
138 
 
(±)-(1R,4S,5R)‐6‐Benzyl‐4‐(prop‐2‐en‐1‐yl)‐
6‐azabicyclo[3.1.0]hexan‐2‐one 11 
139 
 
(±)-(1R,4S,5R)‐6‐Benzyl‐4‐(benzylamino)‐6‐
azabicyclo[3.1.0]hexan‐2‐one 12 
140 
 
(±)-(4R,5S)‐4‐[(tert‐
Butyldimethylsilyl)oxy]‐5‐
methylcyclopent‐2‐en‐1‐one 2059 
140 
 
(±)-(4S,5S)‐4‐[(tert‐Butyldimethylsilyl)oxy]‐
2‐iodo‐5‐methylcyclopent‐2‐en‐1‐one 21 
141 
 
(±)-(1S,3S,4S,5R)‐6‐Benzyl‐4‐[(tert‐
butyldimethylsilyl)oxy]‐3‐methyl‐6-
azabicyclo[3.1.0]hexan‐2‐one 22 
142 
 
(±)-(1S,3S,4S,5R)‐6‐Benzyl‐4‐hydroxy‐3‐
methyl‐6‐azabicyclo[3.1.0]hexan‐2‐one 23 
142 
 
(±)-(1R,2S,3S,5S)‐6‐Benzyl‐3‐methyl‐4‐oxo‐
6‐azabicyclo[3.1.0]hexan‐2‐yl acetate 24 
143 
 
6‐Benzyl‐3‐methyl‐6‐azabicyclo[3.1.0]hex‐
3‐en‐2‐one 25 
144 
Experimental 
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(4E)‐1‐(Benzylamino)‐4‐methylocta‐1,4,7‐
trien‐3‐one 26 
144 
 
1,3‐Diethyl 2‐[(1E)‐5‐(benzylamino)‐2‐
methyl‐3‐oxopenta‐1,4‐dien‐1‐
yl]propanedioate 27 
145 
 
4‐[(tert‐Butyldimethylsilyl)oxy]‐3‐
methylcyclopent‐2‐en‐1‐one60 
146 
 
4‐[(tert‐Butyldimethylsilyl)oxy]‐2‐iodo‐3‐
methylcyclopent‐2‐en‐1‐one 3660 
146 
 
(±)-(1S,4S,5R)‐6‐Benzyl‐4‐[(tert‐
butyldimethylsilyl)oxy]‐5‐methyl‐6‐
azabicyclo[3.1.0]hexan‐2‐one 37 
146 
 
(±)-(1R,4S,5S)‐6‐Benzyl‐4‐[(tert‐
butyldimethylsilyl)oxy]‐5‐methyl‐6‐
azabicyclo[3.1.0]hexan‐2‐one 37’ 
147 
 
(±)-(1S,4S,5R)‐6‐Benzyl‐4‐hydroxy‐5‐
methyl‐6‐azabicyclo[3.1.0]hexan‐2‐one 38 
147 
 
(±)-(1R,2S,5S)‐6‐Benzyl‐1‐methyl‐4‐oxo‐6‐
azabicyclo[3.1.0]hexan‐2‐yl acetate 39 
148 
 
6‐Benzyl‐5‐methyl‐6‐azabicyclo[3.1.0]hex‐
3‐en‐2‐one 40 
149 
Experimental 
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(±)-(1S,4S,5S)‐6‐Benzyl‐5‐methyl‐4‐(prop‐
2‐en‐1‐yl)‐6‐azabicyclo[3.1.0]hexan‐2‐one 
41a 
150 
 
(±)-(1S,4R,5S)‐6‐Benzyl‐5‐methyl‐4‐(prop‐
2‐en‐1‐yl)‐6‐azabicyclo[3.1.0]hexan‐2‐one 
41b 
150 
 
(±)-(1S,4R,5R)‐6‐Benzyl‐4‐methoxy‐5‐
methyl‐6‐azabicyclo[3.1.0]hexan‐2‐one 42 
151 
 
1,3‐Diethyl 2‐[(1S,2S,5S)‐6‐benzyl‐1‐
methyl‐4‐oxo‐6‐azabicyclo[3.1.0]hexan‐2‐
yl]propanedioate 43a 
152 
 
1,3‐Diethyl 2‐[(1S,2R,5S)‐6‐benzyl‐1‐
methyl‐4‐oxo‐6‐azabicyclo[3.1.0]hexan‐2‐
yl]propanedioate 43a 
152 
 
6‐Benzyl‐4‐methylidene‐1‐(prop‐2‐en‐1‐
yl)‐6‐azabicyclo[3.1.0]hex‐2‐ene 44 
152 
 
6‐Benzyl‐3‐{6‐benzyl‐3‐bromo‐1‐methyl‐4‐
oxo‐6‐azabicyclo[3.1.0]hexan‐2‐yl}‐4‐
bromo‐5‐methyl‐6‐azabicyclo[3.1.0]hexan‐
2‐one 45 
153 
 
5‐[(tert‐Butyldimethylsilyl)oxy]‐3‐
oxocyclopent‐1‐ene‐1‐carbaldehyde 47 
154 
Experimental 
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(+)-(1R,5R,6S)‐5‐[(tert‐
Butyldimethylsilyl)oxy]‐7‐(prop‐2‐en‐1‐yl)‐
7‐azabicyclo[4.1.0]heptan‐2‐one 55 
155, 
157 
 
(+)-(1R,5R,6S)‐5‐Hydroxy‐7‐(prop‐2‐en‐1‐
yl)‐7‐azabicyclo[4.1.0]heptan‐2‐one 56 
155, 
156 
 
(+)-(1S,2R,6R)‐5‐Oxo‐7‐(prop‐2‐en‐1‐yl)‐7‐
azabicyclo[4.1.0]heptan‐2‐yl acetate 57 
156 
 
Ethyl (-)-(1R,5R,6S)‐5‐[(tert‐
butyldimethylsilyl)oxy]‐2‐hydroxy‐7‐(prop‐
2‐en‐1‐yl)‐7‐azabicyclo[4.1.0]hept‐2‐ene‐
3‐carboxylate 58 
158 
 
Ethyl (-)-(1S,5R,6S)‐5‐[(tert‐
butyldimethylsilyl)oxy]‐7‐(prop‐2‐en‐1‐yl)‐
7-azabicyclo[4.1.0]hept‐2‐ene‐3‐
carboxylate 59 
159 
 
Ethyl (-)-(1S,5R,6S)‐5‐hydroxy‐7‐(prop‐2‐
en‐1‐yl)‐7‐azabicyclo[4.1.0]hept‐2‐ene‐3‐
carboxylate 60 
160 
 
Ethyl (-)-(3R,4R,5R)‐5‐hydroxy‐3‐(pentan‐
3‐yloxy)‐4‐[(prop‐2‐en‐1‐
yl)amino]cyclohex‐1‐ene‐1‐carboxylate 61 
161 
 
Ethyl (-)-(3R,4R,5R)‐4‐acetamido‐5‐
hydroxy‐3‐(pentan‐3‐yloxy)cyclohex‐1‐
ene‐1‐carboxylate 62 
162 
Experimental 
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(+)-(1R,5R,6S)‐5‐[(tert‐
Butyldimethylsilyl)oxy]‐7‐(prop‐2‐en‐1‐yl)‐
7‐azabicyclo[4.1.0]hept‐2‐en‐2‐yl diethyl 
phosphate 63 
163 
 
Diethyl (+)-[(1R,5R,6S)‐5‐[(tert‐
butyldimethylsilyl)oxy]‐2‐oxo‐7‐(prop‐2‐
en‐1‐yl)‐7-azabicyclo[4.1.0]heptan‐3‐
yl]phosphonate 64 
164 
 
Diethyl (-)-[(1S,5R,6S)‐5‐[(tert‐
butyldimethylsilyl)oxy]‐7‐(prop‐2‐en‐1‐yl)‐
7‐azabicyclo[4.1.0]hept‐2‐en‐3‐
yl]phosphonate 65 
166 
 
Diethyl (-)-[(1S,5R,6S)‐5‐hydroxy‐7‐(prop‐
2‐en‐1‐yl)‐7‐azabicyclo[4.1.0]hept‐2‐en‐3‐
yl]phosphonate 66 
167 
 
Diethyl (-)-[(3R,4R,5R)‐5‐hydroxy‐3‐
(pentan‐3‐yloxy)‐4‐[(prop‐2‐en‐1‐
yl)amino]cyclohex‐1‐en‐1‐yl]phosphonate 
67 
168 
 
Diethyl (-)-[(3R,4R,5R)‐4‐acetamido‐5‐
hydroxy‐3‐(pentan‐3‐yloxy)cyclohex‐1‐en‐
1‐yl]phosphonate 68 
169 
 
(-)-(1R,5R,6S)‐3‐(Diethoxyphosphoryl)‐6‐
acetamido‐5‐(pentan‐3‐yloxy)cyclohex‐3‐
en‐1‐yl methanesulfonate 69 
170 
Experimental 
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1-(Cyclohexylsulfanyl)ethan-1-one 7661 171 
 
Methyl cyclohexanesulfonate 78 171 
 
N-Benzylcyclohexanesulfonamide 79 172 
 
Methyl chloranesulfonate48 172 
 
2‐Chlorocyclohexan‐1‐one 83a63 173 
 
2‐Chlorocyclopentan‐1‐one 83b44 173 
 
2‐Chlorocyclooctan‐1‐one 83c41 173 
 
2‐Chlorocyclododecan‐1‐one 83d41 173 
 
2‐Chloro‐1,2,3,4‐tetrahydronaphthalen‐1‐
one 83e63 
174 
 
6‐Chlorocyclohex‐2‐en‐1‐one 83f64 174 
 
2‐Chloro‐2‐methyl‐1,2,3,4‐
tetrahydronaphthalen‐1‐one 83g65 
174 
Experimental 
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2‐Chloro‐1‐phenylpropan‐1‐one 83h46h 174 
 
2‐Chloro‐6‐methylcyclohexan‐1‐one 83i66 174 
 
4‐tert‐Butyl‐2‐chlorocyclohexan‐1‐one 
83j47h 
174 
 
2‐Chloro‐4‐phenylcyclohexan‐1‐one 83k63 174 
 
(1S,3S,5S,6R)‐5‐[(tert‐
Butyldimethylsilyl)oxy]‐3‐chloro‐7‐(prop‐
2‐en‐1‐yl)‐7-azabicyclo[4.1.0]heptan‐2‐one 
83l 
175 
 
3‐Chloro‐1,7,7‐
trimethylbicyclo[2.2.1]heptan‐2‐one 
83m67 
175 
 
4‐Chloro‐3‐hydroxy‐1,3‐diphenylbutan‐1‐
one 83n68 
175 
 
Ethyl 2‐chloro‐2‐phenylacetate 85b 176 
Experimental 
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methyl 2‐chloro‐3‐phenylpropanoate 85c 176 
 
Methyl 2‐benzyl‐4‐chloro‐3‐oxo‐5‐
phenylpentanoate 85c’ 
176 
 
methyl 2‐benzyl‐3‐oxo‐5‐
phenylpentanoate 85c’’ 
176 
 
3‐chlorooxolan‐2‐one 85d 177 
 
2‐Chloro‐N,N‐diethylpropanamide 85e 177 
 
2‐chloro‐N,N‐dimethylacetamide 85f 
177, 
182 
 
3‐chloro‐1‐methylpyrrolidin‐2‐one 85g 177 
 
1,3‐diethyl 2‐chloropropanedioate 85h 178 
 
Ethyl 1‐chloro‐2‐oxocycloHex‐1‐
carboxylate 85j 
178 
 
2‐chloro‐N,N‐dimethyl‐3‐oxobutanamide 
85k 
178 
 
2,3‐Dichloro‐2,3‐diphenylbutanedinitrile 
85l 
178 
Experimental 
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Ethyl 4‐chloro‐3‐oxobutanoate 86i77 179 
 
Ethyl 3‐chloro‐2‐oxocycloHex‐1‐
carboxylate 86j 
179 
 
4‐Chloro‐N,N‐dimethyl‐3‐oxobutanamide 
86k 
180 
 
2‐Benzyl‐3‐hydroxy‐3‐phenylbutanoate 87 180 
 
3‐hydroxy‐N,N‐dimethyl‐3‐
phenylbutanamide 88 
181 
 
4‐Chloro‐N,N‐dimethyl‐3‐oxo‐5‐
phenylpentanamide 89 
182 
 
2‐Chloro‐N,N‐dimethyl‐3‐oxo‐5‐
phenylpentanamidethe 90 
182 
 
Ethyl [(2-
oxocyclopentyl)sulfanyl]methanethioate 
91b 
183 
 
Ethyl [(3-methyl-2-
oxocyclohexyl)sulfanyl]methanethioate 
91c 
183 
 
Ethyl [(5‐tert‐butyl‐2‐
oxocyclohexyl)sulfanyl]methanethioate 
91d 
184 
Experimental 
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Ethyl [(2‐oxo‐5‐
phenylcyclohexyl)sulfanyl]methanethioate 
91e 
184 
 
Ethyl {[(1S,5S,6R)-5-[(tert-
butyldimethylsilyl)oxy]-2-oxo-7-(prop-2-
en-1-yl)-7-azabicyclo[4.1.0]heptan-3-
yl]sulfanyl}methanethioate 91g 
185 
 
Ethyl [(2-oxocyclohex-3-en-1-
yl)sulfanyl]methanethioate 91h 
186 
 
2-(Acetylsulfanyl)-1-phenylpropan-1-one 
91i80 
186 
 
2-(Acetylsulfanyl)-1-phenylethan-1-one 
91j80-81 
186 
 
6-(Acetylsulfanyl)cyclohex-2-en-1-one 91k 187 
 
2-(Acetylsulfanyl)-4-tert-butylcyclohexan-
1-one 91l 
187 
Experimental 
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2-(Acetylsulfanyl)cyclooctan-1-one 91m 188 
 
2-(Acetylsulfanyl)cyclododecan-1-one 91n 188 
 
N,N-Dimethyl-1-[(1-oxo-1,2,3,4-
tetrahydronaphthalen-2-
yl)sulfanyl]methanethioamide 91o 
189 
 
2-{[(tert-
Butylsulfanyl)methanethioyl]sulfanyl}-
1,2,3,4-tetrahydronaphthalen-1-one 91p 
189 
 
Ethyl [(1-oxo-1,2,3,4-
tetrahydronaphthalen-2-
yl)sulfanyl]formate 91q 
190 
 
N,N-Dimethyl-1-[(1-oxo-1,2,3,4-
tetrahydronaphthalen-2-
yl)sulfanyl]formamide 91r 
190 
 
2-{[(tert-Butylsulfanyl)carbonyl]sulfanyl}-
1,2,3,4-tetrahydronaphthalen-1-one 91s 
191 
 
2‐{[(tert‐Butylsulfanyl)(oxo‐lambda4‐
sulfanylidene)methyl]sulfanyl}‐1,2,3,4-
tetrahydronaphthalen‐1‐one 91t 
192 
 
2-(Benzoylsulfanyl)-1,2,3,4-
tetrahydronaphthalen-1-one 91u 
193 
Experimental 
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1‐Oxo‐1,2,3,4‐tetrahydronaphthalen‐2‐yl 
benzenecarbodithioate 91v 
193 
 
1‐Oxo‐1,2,3,4‐tetrahydronaphthalen‐2‐yl 
pentanedithioate 91w 
194 
 
O,O‐Diethyl [(1‐oxo‐1,2,3,4‐
tetrahydronaphthalen‐2‐
yl)sulfanyl]phosphonothioate 91x 
195 
 
Ethyl 2‐hydroxy‐5‐phenylcyclohex‐1‐ene‐
1‐carbothioate 92a 
196 
 
Ethyl 2‐hydroxycyclopent‐1‐ene‐1‐
carbothioate 92b86 
196 
 
Ethyl 2‐hydroxy‐3‐methylcyclohex‐1‐ene‐
1‐carbothioate 92c 
197 
 
Ethyl 5‐tert‐butyl‐2‐hydroxycyclohex‐1‐
ene‐1‐carbothioate 92d 
197 
 
Ethyl 2‐hydroxy‐5‐phenylcyclohex‐1‐ene‐
1‐carbothioate 92e 
198 
 
Ethyl 1‐hydroxy‐3,4‐dihydronaphthalene‐
2‐carbothioate 92f85 
198 
Experimental 
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Ethyl (1S,5S,6R)‐5‐[(tert‐
butyldimethylsilyl)oxy]‐2‐hydroxy‐7‐(prop‐
2‐en‐1‐yl)‐7‐azabicyclo[4.1.0]hept‐2‐ene‐
3‐carbothioate 92g 
199 
 
Ethyl 2‐oxocyclohex‐3‐ene‐1‐carbothioate 
92h 
200 
 
Ethyl 4b‐[(ethoxymethanethioyl)sulfanyl]‐
1,8a‐dihydroxy‐3,4,4a,4b,5,6,8a,8b‐
octahydrobiphenylene‐2‐carbothioate 
92h’ 
200 
 
2‐methyl‐1‐phenylbutane‐1,3‐dione 92i 201 
 
3‐hydroxy‐1‐phenylbut‐2‐en‐1‐one 92j 201 
 
6‐Acetylcyclohex‐2‐en‐1‐one 92k 201 
 
1‐(5‐tert‐butyl‐2‐hydroxycyclohex‐1‐en‐1‐
yl)ethan‐1‐one 92l 
202 
 
1‐(2‐hydroxycyclooct‐1‐en‐1‐yl)ethan‐1‐
one 92m 
202 
Experimental 
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2‐Acetylcyclododecan‐1‐one 92n92 202 
 
N,N‐Dimethyl‐1‐oxo‐1,2,3,4‐
tetrahydronaphthalene‐2‐carbothioamide 
92o 
203 
 
2-(tert-Butylsulfanylcarbothioyl)-1,2,3,4-
tetrahydronaphthalen-1-one 92p 
203 
 
Ethyl 1-hydroxy-3,4-dihydronaphthalene-
2-carboxylate 92q 
204 
 
3,3'',4,4''-Tetrahydro-1H,1''H-
dispiro[naphthalene-2,2'-
[1,3,5]trithiolane-4',2''-naphthalene]-1,1''-
dione 92q’ 
204 
 
2‐({1‐[(Dimethylcarbamoyl)oxy]‐3,4‐
dihydronaphthalen‐2‐yl}disulfanyl)‐3,4-
dihydronaphthalen‐1‐yl N,N‐
dimethylcarbamate 92r 
205 
 
(tert-Butylsulfanyl)(1-hydroxy-3,4-
dihydronaphthalen-2-yl)methanone 92s 
205 
 
2‐(tert‐Butylsulfanyl)naphthalen‐1‐ol 92s’ 206 
 
2-(tert-Butylsulfanylcarbothioyl)-2-
hydroxy-1,2,3,4-tetrahydronaphthalen-1-
one 92t 
207 
Experimental 
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2-(tert-
Butylsulfanylcarbothioyl)naphthalen-1-ol 
92t’ 
207 
 
2-benzoyl-3,4-dihydronaphthalen-1-ol 92u 207 
 
2-[(Methylsulfanyl)(phenyl)methylidene]-
1,2,3,4-tetrahydronaphthalen-1-one 92v 
208 
 
2-[1-(Methylsulfanyl)pentylidene]-1,2,3,4-
tetrahydronaphthalen-1-one 92w 
208 
 
Ethyl 2-sulfanyl-3,4-dihydronaphthalen-1-
yl ethoxy(sulfanylidene)phosphonite 92x 
209 
 
2‐[(2‐Oxocyclooctyl)sulfanyl]cyclooctan‐1‐
one 93 
210 
 
Synthesis experiments 
4‐[(tert‐Butyldimethylsilyl)oxy]cyclohept‐2‐en‐1‐one 
To a stirred solution of 4-hydroxycyclohept-2-en-1-one19 (1.0 g, 7.9 mmol) 
in dry DCM (16 mL) under argon was added diisopropylamine (2.8 mL, 2.5 eq.), 
tert-butyldimethylsilylchloride (2.4 g, 2 eq.) and DMAP (cat.) at 0oC. After 16 
hours of stirring at room temperature the reaction was quenched with water 
(20mL) and the mixture was extracted with DCM (3x 10mL). The combined 
organic phases were dried with magnesium sulfate and evaporated to dryness. 
Experimental 
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Purification by flash column chromatography, eluted with Hex:AcOEt (95:5), 
afforded 1.6 g (84%) of the pure title compound as colorless oil. 
1H NMR δ: 6.50 (1H, ddd, J3,2=12.5, J3,4=3.2, J3,5=1.0, H-3); 5.91 (1H, ddd, J2,3=12.5, 
J2,4=2.0, J2,7=0.8, H-2); 4.56-4.51 (1H, m, H-4); 2.65-2.58 (1H, m, H-7); 2.56-2.49 
(1H, m, H-7); 2.12-2.04 (1H, m, H-5); 1.89-1.78 (3H, m, H-5, H-6), 0.91 (9H, s, tBu 
TBS); 0.11 (3H, s, Me TBS); 0.10 (3H, s, Me TBS). 13C NMR δ: 203.5 (C-1); 150.6 (C-
3); 129.4 (C-2); 71.0 (C-4); 43.0 (C-7); 35.4 (C-5); 25.8 (3xMe tBu); 18.3 (C-6); 18.1 
(Cq tBu); -4.6 (Me TBS); -4.7 (Me TBS). FTIR(Neat): 1674 (C=O st). HRMS (ESI-TOF) 
m/z: [M+H]+ Calcd for C13H25O2Si 241.1618; Found 241.1612. 
4‐[(tert‐Butyldimethylsilyl)oxy]‐2‐iodocyclohept‐2‐en‐1‐one 1c 
To a stirred solution of 4‐[(tert‐butyldimethylsilyl)oxy]cyclohept‐2‐en‐1‐
one (1.0 g, 4.2 mmol) in a 1:1 THF:water mixture (17 mL) was added K2CO3 (1.15 
g, 2 eq.), iodine (2.1 g, 2 eq.) and DMAP (100 mg, 20 mol%). After 24 hours of 
stirring at 60°C the reaction was diluted with ethyl ether (20mL) and washed with 
a sodium thiosulfate solution 20%(w/V) (20mL) and water (20mL). The combined 
organic phases were dried with magnesium sulfate and evaporated to dryness, 
affording 699 mg (46%) of the pure compound 1c as colorless oil. 
1H NMR δ: 7.48 (1H, d, J3,4=3.7, H-3); 4.51 (1H, dt, J4,5=8.5, J4,3=J4,5=4.1, H-4); 2.81 
(1H, dt, 2J=15.2, J7,6=5.1, H-7); 2.57 (1H, ddd, 2J=15.0, J7,6=10.1, J7,6=4.8, H-7); 
2.05-1.95 (1H, m, H-5); 1.87-1.76 (3H, m, H-5, H-6), 0.90 (9H, s, tBu TBS); 0.10 (3H, 
s, Me TBS); 0.09 (3H, s, Me TBS). 13C NMR δ: 197.9 (C-1); 159.4 (C-3); 103.3 (C-2); 
72.0 (C-4); 39.7 (C-7); 34.0 (C-5); 25.7 (3xMe tBu); 18.09 (C-6); 18.06 (Cq tBu); -
4.79 (Me TBS); -4.83 (Me TBS). FTIR(Neat): 1682 (C=O st). HRMS (ESI-TOF) m/z: 
[M-TBS+H]+ Calcd for C7H10IO2 252.9720; Found 252.9714. 
Experimental 
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General procedure for the preparation of TBS-protected cis-
hydroxybenzylaziridines (±)-2 
 In a flask under argon a mixture of iodoenone (1.35 mmol), anhydrous 
cesium carbonate (480 mg, 1.1eq.), 1,10-phenanthroline (240 mg, 1.0 eq.), 
benzylamine (220 µL, 1.5 eq.) and dry toluene (10 mL) was stirred at room 
temperature. After complete reaction (TLC, around 4 hours), the reaction 
mixture was diluted with DCM (10 mL) and washed with water (10 mL). The 
organic layer was dried with magnesium sulfate and evaporated to dryness. 
Purification by chromatography (flash column eluted with Hex:AcOEt 9:1) 
afforded the pure aziridine 2. 
(±)-(1S,5S,6R)‐7‐Benzyl‐5‐[(tert‐butyldimethylsilyl)oxy]‐7-azabicyclo[4.1.0]heptan‐
2‐one 2a 
Using the general procedure 700 mg of compound 2a were obtained as 
colorless oil in 82% yield. 
1H NMR δ: 7.41 (2H, d, 3J=7.6, Ar(o)), 7.31 (2H, t, 3J=7.4, Ar(m)), 7.25 (2H, t, 3J =8.0 
Hz, Ar(p)), 4.12 (1H, ddd, J5,4=10.4, J5,4=5.2, J5,6=1.8, H-5), 3.91 (1H, d, 2J=14.0, CH2 
Bn), 3.35 (1H, d, 2J=14.0, CH2 Bn), 2.45 (1H, ddd, 2J=18.4, J3,4=5.6, J3,4=2.0, H-3), 
2.32 (1H, br d, J6,1=6.4,H-6), 2.29-2.21 (1H, m, H-4), 2.19 (1H, d, J1,6=6.0, H-1), 2.08 
(1H, ddd, 2J=18.8, J3,4=12.4, J3,4=6.4, H-3), 1.67-1.60 (1H, m, H-4), 0.87 (9H, s, tBu 
TBS), 0.08 (3H, s, Me TBS), 0.05 (3H, s, Me TBS). 13C NMR δ: 205.7 (C-2), 138.1 (Ar 
Cq), 128.3 (Ar(m)), 127.5 (Ar(o)), 127.1 (Ar(p)), 67.9 (C-5), 62.8 (CH2 Bn), 48.2 (C-
6), 46.9 (C-1), 35.3 (C-3), 25.9 (C-4), 25.7 (3xMe tBu), 18.1 (Cq tBu), -4.66 (Me TBS), 
-4.72 (Me TBS). FTIR (Neat): 1711 (C=O st). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C19H30NO2Si 332.2040; Found 332.2038. 
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(±)-(1S,4S,5R)‐6‐Benzyl‐4‐[(tert‐butyldimethylsilyl)oxy]‐6‐azabicyclo[3.1.0]hexan‐2‐
one 2b 
Using the general procedure 780 mg of compound 2b were obtained as 
colorless oil in 83% yield. 
1H NMR δ: 7.46 (2H, d, 3J=7.2, Ar(o)), 7.32 (2H, t, 3J=7.3, Ar(m)), 7.26 (2H, t, 3J =7.3 
Hz, Ar(p)), 4.39 (1H, td, J4,3=8.0, J4,5=3.1, H-4), 3.95 (1H, d, 2J=14.2, CH2 Bn), 3.26 
(1H, d, 2J=14.2, CH2 Bn), 2.76 (1H, t, J5,4= J5,1=3.7, H-5), 2.49 (1H, dd, 2J=16.8, 
J3,4=8.0, H-3), 2.37 (1H, d, J1,5=4.2, H-1), 2.22 (1H, ddd, 2J=16.8, J3,4=8.0, H-3), 0.90 
(9H, s, tBu TBS), 0.07 (3H, s, Me TBS), 0.06 (3H, s, Me TBS). 13C NMR δ: 205.7 (C-
2), 137.9 (Ar Cq), 128.4 (Ar(m)), 127.3 (Ar(o)), 127.1 (Ar(p)), 68.3 (C-4), 60.8 (CH2 
Bn), 50.3 (C-5), 48.6 (C-1), 41.6 (C-3), 25.8 (3xMe tBu), 18.1 (Cq tBu), -4.7 (Me TBS), 
-4.8 (Me TBS). FTIR (Neat): 1741 (C=O st). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C18H28NO2Si 318.1884; Found 318.1884. 
 (±)-(1S,6S,7R)‐8‐Benzyl‐6‐[(tert‐butyldimethylsilyl)oxy]‐8‐azabicyclo[5.1.0]octan‐2‐
one 2c 
Using the general procedure 580 mg of compound were obtained as 
colorless oil in 68% yield. 
1H NMR δ: 7.39 (2H, d, 3J=7.4, Ar(o)), 7.31 (2H, t, 3J=7.4, Ar(m)), 7.25 (2H, d, 3J 
=7.2 Hz, Ar(p)), 3.85 (1H, dd, J6,5=10.8, J6,5=3.2, H-6), 3.63 (1H, d, 2J=13.8, CH2 Bn), 
3.55 (1H, d, 2J=13.8, CH2 Bn), 2.83 (1H, ddd, 2J=13.8, J3,4=10.9, J3,4=3.1, H-3), 2.23-
2.04 (4H, m, H-1, H-3, H-5, H-7), 1.85-1.78 (1H, m, H-4), 1.73-1.68 (1H, m, H-5), 
1.17 (1H, q, J=13.7, H-4), 0.86 (9H, s, tBu TBS), 0.06 (3H, s, Me TBS), 0.05 (3H, s, 
Me TBS). 13C NMR δ: 211.7 (C-2), 138.2 (Ar Cq), 128.3 (Ar(m)), 127.8 (Ar(o)), 127.1 
(Ar(p)), 72.6 (C-6), 64.0 (CH2 Bn), 51.2, 48.2 (C-1, C-7), 41.4 (C-3), 34.3 (C-5), 25.7 
(3xMe tBu), 22.9 (C-4); 18.0 (Cq tBu), -4.7 (Me TBS), -4.8 (Me TBS). FTIR (Neat): 
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1696 (C=O st). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C20H32NO2Si 346.2197; 
Found 346.2202. 
(±)-(1R,5S,6S)-5-[(tert-Butyldimethylsilyl)oxy]-7-[(4-methylphenyl)sulfonyl]-7-
azabicyclo[4.1.0]heptan-2-one 2d  
The general procedure was followed except that 1,10-phenanthroline was 
not added and 3 eq. of tosylamide was used instead of the normal 1.5 eq. 386 
mg (85% yield) of the pure product 2d was obtained as a white solid. 
1H NMR δ: 7.80 (2H, d, 2J=8.0, Ar(o)); 7.36 (2H, d, 2J=8.0, Ar(m)); 4.38 (1H, q, 
J5,4=J5,6=3.1, H-5); 3.34 (1H, ddd, J6,1=6.4; J6,5=2.8; J=1.2, H-6); 3.17 (1H, d, J1,6=6.4, 
H-1); 2.45 (3H, s, Me Ts); 2.38 (1H, ddd, 2J=18.2; J3,4=12.2, J3,4=6.2, H-3); 2.20 (1H, 
ddd, 2J=18.4, J3,4=5.2, J3,4=3.2, H-3); 2.07−1.99 (1H, m, H-4); 1.71−1.63 (1H, m, H-
4); 0.89 (9H, s, tBu TBS); 0.13 (3H, s, Me TBS); 0.09 (3H, s, Me TBS). 13C NMR 
δ:200.8 (C-2); 145.2 (Ar C−SO2 Ts); 134.0 (Ar(p)); 129.9 (Ar(m)); 127.9 (Ar(o)); 63.6 
(C-5); 43.7 (C-1); 43.5 (C-6); 31.9 (C-3); 25.6 (3 × Me tBu); 35.4 (C-4); 21.6 (Me Ts); 
17.9 (Cq tBu); −4.8 (Me TBS); −4.9 (Me TBS). FTIR (Neat): 1722 (C=O st); 1163 (SO2 
st). M.p. = 98.5−99 °C. Anal. Calcd for C19H29NO4SSi: C 57.69; H 7.39; N 3.54; S 
8.11. Found: C 57.90; H 7.54; N 3.58; S 7.90. 
General procedure for the preparation of cis-hydroxybenzylaziridines 5 
To a stirred solution of TBS-protected aziridine 2 (1.26 mmol) in dry 
tetrahydrofuran (5mL) under argon was added tetrabutylammonium fluoride 
(2.3 mL, 1 M in THF, 1.8 eq.). After 30 minutes, the reaction mixture was diluted 
with DCM (5 mL) and washed with water (5 mL). The organic layer was dried with 
magnesium sulfate and evaporated to dryness. Purification by chromatography 
(flash column eluted with Hex:AcOEt 1:1) afforded the pure aziridine 5 with a 
yield greater than 98%. 
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(±)-(1S,5S,6R)‐7‐Benzyl‐5‐hydroxy‐7‐azabicyclo[4.1.0]heptan‐2‐one 5a 
Using the general procedure 430 mg of compound 5a were obtained as 
colorless oil in quantitative yield. 
(±)-(1S,4S,5R)‐6‐Benzyl‐4‐hydroxy‐6‐azabicyclo[3.1.0]hexan‐2‐one 5b 
Using the general procedure 380 mg of compound 5b were obtained as 
white solid (m.p.=90-91°C) in 98% yield. 
(±)-(1S,6S,7R)‐8‐Benzyl‐6‐hydroxy‐8‐azabicyclo[5.1.0]octan‐2‐one 5c 
Using the general procedure 360 mg of compound 5c were obtained as 
colorless oil in 99% yield. 
(±)-(1R,5S,6S)‐5‐Hydroxy‐7‐(4‐methylbenzenesulfonyl)‐7‐azabicyclo[4.1.0]heptan‐
2‐one 5d 
A procedure similar to the general was used, but 10 eq. of triethylamine 
trihydrofluoride were used instead of 1.8 eq. of tetrabutylammonium fluoride 
and the reaction took 16h to be complete. 180 mg of compound 5d were 
obtained as a white solid (m.p. = 121-122°C) in quantitative yield. 
General procedure for the resolution 
A mixture of racemic hydroxyaziridine 5 (50 mg), vinyl acetate (5 eq.), 
novozym 435 and diisopropyl ether (1mL) was agitated (700 r.p.m.) in a closed 
tube at 24°C. After the resolution was completed the solid-supported enzyme 
was removed by decantation and the organic solution was evaporated to 
dryness. Purification by flash column chromatography, eluted with Hex/AcOEt 
(1:1), afforded (-)-hydroxyaziridine 5 and (+)-acetoxyaziridine 7. 
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(-)-(1S,5S,6R)‐7‐benzyl‐5‐hydroxy‐7‐azabicyclo[4.1.0]heptan‐2‐one 5a 
 Using the general procedure, with 25 mg of novozym 435 and the 
resolution took 4h to be complete, 24 mg (48%) of (-)-5a (>99% e.e, HPLC) as a 
white solid and 28 mg (47%) of (+)-7a (97% e.e., HPLC) as an oil. HPLC conditions: 
AD-H; 95:5 Hex:isopropanol; 1.0ml.min-1; 237nm. 
1H NMR δ: 7.37-7.27 (5H, m, Ar), 4.11-4.05 (1H, m, H-5), 3.77 (1H, d, 2J=13.2, CH2 
Bn), 3.40 (1H, d, 2J=13.2, CH2 Bn), 2.57-2.46 (2H, m, H-3, H-6), 2.31 (1H, br t, J=8.6, 
OH), 2.07-1.94 (2H, m, H-3, H-4), 1.85-1.73 (1H, m, H-4). 13C NMR δ: 206.0 (C-2), 
137.8 (Ar Cq), 128.7 (Ar(m)), 128.0 (Ar(o)), 127.7 (Ar(p)), 64.8 (C-5), 63.3 (CH2 Bn), 
48.0, 47.7 (C-1, C-6), 34.9 (C-3), 29.2 (C-4). [∝]𝐷
20𝑜𝐶= -81 (c=1.1; CH2Cl2). M.p. = 
78-79°C. HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C13H16NO2 218.1176; Found 
218.1171. 
(+)-(1S,2R,6R)‐7‐Benzyl‐5‐oxo‐7‐azabicyclo[4.1.0]heptan‐2‐yl acetate 7a 
1H NMR δ: 7.34-7.25 (5H, m, Ar), 5.08 (1H, ddd, J2,3=10.1, J2,3=5.2, J2,1=2.3, H-2), 
3.96 (1H, d, 2J=13.2, CH2 Bn), 3.21 (1H, d, 2J=13.4, CH2 Bn), 2.56 (1H, dm, J1,6=6.0, 
H-1), 2.52 (1H, ddd, 2J=17.3, J4,3=4.3, J4,3=3.3, H-4), 2.29 (1H, d, J6,1=6.1, H-6), 2.26-
2.04 (2H, m, H-3, H-4), 1.88 (3H, s, CH3 Ac), 1.82-1.75 (1H, m, H-3). 13C NMR δ: 
206.0 (C-5), 170.7 (C=O Ac), 137.7 (Ar Cq), 128.3 (Ar(m)), 128.0 (Ar(o)), 127.3 
(Ar(p)), 69.0 (C-2), 62.9 (CH2 Bn), 46.9 (C-6), 43.7 (C-1), 34.8 (C-4), 22.8 (C-3), 20.8 
(CH3 Ac). [∝]𝐷
20𝑜𝐶= -185 (c=1.0; CH2Cl2). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C15H18NO3 260.1281; Found 260.1279. 
(-)-(1S,4S,5R)‐6‐Benzyl‐4‐hydroxy‐6‐azabicyclo[3.1.0]hexan‐2‐one 5b 
 Using the general procedure, with 25 mg of novozym 435, the quantity of 
diisopropyl ether and vinyl acetate used was 2 mL and 10 eq., respectively, and 
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the resolution took 16h to be complete, 24 mg (48%) (-)-5b  (99% e.e, HPLC) as a 
white solid and 30 mg (50%) (+)-7b (95% e.e., HPLC) as an oil. HPLC conditions: 
AD-H; 95:5 Hex:isopropanol; 1.0ml.min-1; 237nm. 
1H NMR δ: 7.37-7.27 (5H, m, Ar), 4.33 (1H, td, J4,3=8.1, J4,5=3.3, H-4), 3.65 (1H, d, 
2J=13.4, CH2 Bn), 3.47 (1H, d, 2J=13.4, CH2 Bn), 2.95 (1H, t, J5,1=J5,4=3.8, H-5), 2.47 
(1H, d, J1,5=4.2, H-1), 2.45-2.30(1H, br s, OH), 2.38 (1H, dd, 2J=17.8, J3,4=8.4, H-3), 
2.22 (1H, dd, 2J=17.8, J3,4=7.0, H-3). 13C NMR δ: 206.8 (C-2), 137.6 (Ar Cq), 128.7 
(Ar(m)), 127.9 (Ar(o)), 127.8 (Ar(p)), 67.5 (C-4), 61.3 (CH2 Bn), 50.1, 49.6 (C-1, C-
5), 42.2 (C-3). FTIR (Neat): 3260 (OH st), 1731 (C=O st). [∝]𝐷
20𝑜𝐶= -36 (c=1.0; 
CH2Cl2). M.p. = 115.5-117.5°C (decomp.). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C12H14NO2 204.1019; Found 204.1020. 
(+)-(1S,2R,5R)‐6‐Benzyl‐4‐oxo‐6‐azabicyclo[3.1.0]hexan‐2‐yl acetate 7b 
1H NMR δ: 7.37-7.26 (5H, m, Ar), 5.15 (1H, td, J2,3=8.1, J2,1=3.2, H-2), 3.84 (1H, d, 
2J=13.5, CH2 Bn), 3.31 (1H, d, 2J=13.6, CH2 Bn), 3.08 (1H, t, J1,2=J1,5=3.7, H-1), 2.49 
(1H, dd, 2J=17.5, J3,2=7.8, H-3), 2.48 (1H, d, J5,1=4.0, H-5), 2.40 (1H, dd, 2J=17.6, 
J3,2=6.8, H-3), 1.97 (3H, s, CH3 Ac). 13C NMR δ: 205.4 (C-2), 170.8 (C=O Ac), 137.6 
(Ar Cq), 128.5 (Ar(m)), 127.8 (Ar(o)), 127.5 (Ar(p)), 69.4 (C-2), 60.9 (CH2 Bn), 48.7 
(C-5), 46.5 (C-1), 38.2 (C-3), 20.7 (CH3 Ac). FTIR (Neat): 1732 (C=O st). [∝]𝐷
20𝑜𝐶= 
+120 (c=0.7; CH2Cl2). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C14H16NO3 246.1125; 
Found 246.1123. 
 (-)-(1S,6S,7R)‐8‐Benzyl‐6‐hydroxy‐8‐azabicyclo[5.1.0]octan‐2‐one 5c 
 Using the general procedure, with 75 mg of novozym 435 and the 
resolution took 24h to be complete, 24 mg (48%) (-)-5c as an oil and 30 mg (50%) 
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(+)-7c (93% e.e., HPLC) as an oil. HPLC conditions: IB; 98:2 Hex:isopropanol (0.1% 
diethylamine); 2.0ml.min-1; 237nm. 
1H NMR δ: 7.36-7.26 (5H, m, Ar), 3.83 (1H, dd, J6,5=10.7, J6,5=2.4, H-6), 3.71 (1H, 
d, 2J=13.3, CH2 Bn), 3.43 (1H, d, 2J=13.3, CH2 Bn), 2.80 (1H, ddd, 2J=13.9, J3,4=10.9, 
J3,4=3.0, H-3), 2.33 (1H, br d, J1,7=7.3, H-1); 2.29 (1H, br d, J7,1=7.6, H-7); 2.24-2.19 
(1H, m, H-3), 1.98-1.78 (4H, m, H-4, H-5, OH), 1.24-1.13 (1H, m, H-4). 13C NMR δ: 
210.8 (C-2), 138.3 (Ar Cq), 128.6 (Ar(m)), 128.0 (Ar(o)), 127.6 (Ar(p)), 71.6 (C-6), 
64.1 (CH2 Bn), 49.6, 49.2 (C-1, C-7), 41.5 (C-3), 34.2 (C-5), 22.3 (C-4). FTIR (Neat): 
3420 (O-H st); 1687 (C=O st). [∝]𝐷
20𝑜𝐶= -110 (c=0.8; CH2Cl2). HRMS (ESI-TOF) m/z: 
[M+H]+ Calcd for C14H18NO2 232.1332; Found 232.1330.  
(+)-(1S,2R,7R)‐8‐Benzyl‐6‐oxo‐8‐azabicyclo[5.1.0]octan‐2‐yl acetate 7c 
1H NMR δ: 7.34-7.26 (5H, m, Ar), 4.96 (1H, dd, J2,3=11.4, J2,3=3.2, H-2), 3.71 (1H, 
d, 2J=13.4, CH2 Bn), 3.44 (1H, d, 2J=13.4, CH2 Bn), 2.81 (1H, ddd, J5,4=13.8, 2J=11.2, 
J5,4=2.9, H-5), 2.32 (1H, d, J7,1=7.4, H-7); 2.27 (1H, d, J1,7=7.7, H-1); 2.24 (1H, dd, 
2J=11.1, J5,4=5.4, H-5), 2.07 (1H, q, 2J=J3,2= J3,4=11.9, H-3), 1.94 (3H, s, CH3 Ac), 
1.89-1.76 (2H, m,H-3, H-4), 1.22 (1H, q, 2J=J4,3=J4,5=13.8, H-4). 13C NMR δ: 210.3 
(C-6), 170.3 (C=O Ac), 137.8 (Ar Cq), 128.4 (Ar(m)), 128.0 (Ar(o)), 127.4 (Ar(p)), 
73.8 (C-2), 63.9 (CH2 Bn), 48.6 (C-7), 46.7 (C-1), 41.3 (C-5), 30.2 (C-3), 21.9 (C-4), 
21.1 (CH3 Ac). FTIR (Neat): 1730, 1693 (C=O st). [∝]𝐷
20𝑜𝐶= +167 (c=0.6; CH2Cl2). 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C16H20NO3 274.1438; Found 274.1436. 
(+)-(1R,5S,6S)‐5‐Hydroxy‐7‐(4‐methylbenzenesulfonyl)‐7‐azabicyclo[4.1.0]heptan‐
2‐one 5d 
 Using the general procedure, with 50 mg of novozym 435, the quantity of 
diisopropyl ether and vinyl acetate used was 2 mL and 10 eq., respectively, and 
the resolution took 24h to be complete, 23 mg (46%) (+)-5d  (91% e.e, HPLC) as 
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a white solid and 28 mg (49%) (-)-7d (96% e.e., HPLC) as an oil. HPLC conditions: 
AD-H; 80:20 Hex:isopropanol; 1.0ml.min-1; 254nm. 
1H NMR δ: 7.81 (2H, d, 3J=8.2, Ar(o)), 7.36 (2H, d, 3J=8.0, Ar(m)), 4.46 (1H, q, 
J5,4=J5,6=2.9, H-5), 3.44 (1H, dm, J6,1=6.4, H-6), 3.19 (1H, d, J1,6=6.4, H-1), 2.46 (3H, 
s, CH3 Ts), 2.41 (1H, ddd, 2J=18.3, J3,4=12.1, J3,4=6.3, H-3), 2.26 (1H, ddd, 2J=18.3, 
J3,4=5.4, J3,4=3.5, H-3), 2.13-2.04 (1H, m, H-4), 1.85 (1H, br s, OH), 1.82-1.75 (1H, 
m, H-4). 13C NMR δ: 201.0 (C-2), 145.5 (Ar C-SO2 Ts), 133.6 (Ar(p)), 130.1 (Ar(m)), 
128.1 (Ar(o)), 62.8 (C-5), 43.6 (C-1), 43.4 (C-6), 31.8 (C-3), 25.2 (C-4), 21,7 (CH3 
Ts). FTIR (Neat): 1701 (C=O st). [∝]𝐷
20𝑜𝐶= +13 (c=1.0; CH2Cl2). M.p. = 114-116°C. 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C13H16NO4S 282.0795; Found 282.0796. 
(-)-(1R,2R,6S)‐7‐(4‐Methylbenzenesulfonyl)‐5‐oxo‐7‐azabicyclo[4.1.0]heptan‐2‐yl 
acetate 7d 
1H NMR δ: 7.82 (2H, d, 3J=8.2, Ar(o)), 7.37 (2H, d, 3J=8.2, Ar(m)), 5.34 (1H, q, 
J2,3=J2,1=3.0, H-2), 3.49 (1H, dm, J1,6=6.3, H-1), 3.25 (1H, d, J6,1=6.3, H-6), 2.46 (3H, 
s, CH3 Ts), 2.34-2.30 (2H, m, H-4), 2.17-2.04 (1H, m, H-3), 2.10 (3H, s, CH3 Ac), 
1.89-1.82 (1H, m, H-3). 13C NMR δ: 199.7 (C-5), 170.0 (C=O Ac), 145.6 (Ar C-SO2 
Ts), 133.7 (Ar(p)), 130.1 (Ar(m)), 128.1 (Ar(o)), 65.3 (C-2), 43.0 (C-6), 41.1 (C-1), 
32.1 (C-4), 22.4 (C-3), 21,7 (CH3 Ts), 20,9 (CH3 Ac). FTIR (Neat): 1743, 1722 (C=O 
st). [∝]𝐷
20𝑜𝐶= -11 (c=0.8; CH2Cl2). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C15H18NO5S 324.0900; Found 324.0897. 
General procedure for the hydrolysis of acetoxyaziridines 
To a stirred solution of acetoxyaziridine (approx. 30 mg, 0.12 mmol) in 
methanol (1 mL) was added potassium carbonate (1.6 mg, 10 mol%). After 1 
hour, ammonium chloride (2 mg) was added. The salts were then filtered and the 
Experimental 
 
138 
 
solution evaporated to dryness affording the hydroxyaziridine 5 in quantitative 
yield. 
(+)-(1R,4S,5S)‐6‐Benzyl‐4‐methoxy‐6‐azabicyclo[3.1.0]hexan‐2‐one 8 
A procedure similar to the general was used, but 2 eq. of potassium 
carbonate were used instead of 10 mol%. 44 mg of compound 8 were obtained 
as colorless oil with quantitative yield. HPLC conditions: AD-H; 95:5 
Hex:isopropanol; 1.0ml.min-1; 237nm.  
1H NMR δ: 7.37-7.26 (5H, m, Ar), 4.07 (1H, J4,5=5.6, d, H-4), 3.65 (1H, d, 2J=13.6, 
CH2 Bn), 3.49 (1H, d, 2J=13.8, CH2 Bn), 3.35 (3H, s, OMe), 2.89 (1H, d, J5,1=3.9, H-
5), 2.41 (1H, dd, 2J=18.2, J3,4=5.6, H-3), 2.36 (1H, d, J1,5=3.9, H-1), 2.03 (1H, d, 
2J=18.2, H-3). 13C NMR δ: 209.4 (C-2), 137.7 (Ar Cq), 128.6 (Ar(m)), 127.7 (Ar(o)), 
127.5 (Ar(p)), 77.4 (C-4), 61.3 (CH2 Bn), 56.5 (OMe), 48.9 (C-5), 46.0 (C-1), 40.3 (C-
3). FTIR (Neat): 1744 (C=O st). [∝]𝐷
20𝑜𝐶= +35 (c=0.6; CH2Cl2). HRMS (ESI-TOF) m/z: 
[M+H]+ Calcd for C13H16NO2 218.1176; Found 218.1176. 
(±)-1,3‐Diethyl 2‐[(1R,2R,5R)‐6‐benzyl‐4‐oxo‐6‐azabicyclo[3.1.0]hexan‐2‐
yl]propanedioate 10 
To a stirred solution of (±)-8 (40 mg, 0.16 mmol) and diethyl malonate 
(50µL, 2eq.) in dry THF (1 mL) under argon was added sodium hydride (8 mg, 
2eq.) at 0°C. After 1 hour of stirring at room temperature, the reaction mixture 
was quenched with a saturated aqueous solution of ammonium chloride and 
extracted with DCM (3x5 mL). The combined organic layers were dried with 
magnesium sulfate and evaporated to dryness. Purification by chromatography 
(preparative TLC eluted with Hex:AcOEt 2:1) afforded 40 mg (71%) of pure 
compound 10 as colorless oil. 
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1H NMR δ: 7.38-7.25 (5H, m, Ar), 4.26-4.13 (4H, m, 2xCH2 Et), 3.63 (1H, d, 2J=13.7, 
CH2 Bn), 3.48 (1H, d, 2J=13.7, CH2 Bn), 3.44 (1H, d, J2,2’=6.9, H-2), 3.11 (1H, ddd, 
J2’,3’=8.3, J2’,2=7.2, J=1.1, H-2’), 2.77 (1H, d, J1’,5’=3.9, H-1’), 2.62 (1H, dd, 2J=18.5, 
J3’,2’=8.7, H-3’), 2.31 (1H, d, J5’,1’=3.9, H-5’), 1.96 (1H, d, 2J=18.5, H-3’), 1.25 (6H, t, 
3J=7.1, 2xCH3 Et). 13C NMR δ: 209.5 (C-4’), 167.84, 167.81 (C-1, C-3), 137.8 (Ar Cq), 
128.5 (Ar(m)), 127.7 (Ar(o)), 127.4 (Ar(p)), 61.9, 61.8 (2xCH2 Et), 61.4 (CH2 Bn), 
54.2 (C-2), 48.3 (C-1’), 47.0 (C-5’), 38.0 (C-3’), 35.9 (C-2’), 14.0 (2xCH3 Et). FTIR 
(Neat): 1743, 1728 (C=O st). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C19H24NO5 
346.1649; Found 346.1649. 
(±)-(1R,4S,5R)‐6‐Benzyl‐4‐(prop‐2‐en‐1‐yl)‐6‐azabicyclo[3.1.0]hexan‐2‐one 11 
To a stirred solution of (±)-8 (60 mg, 0.25 mmol) in dry THF (0.5 mL) under 
argon was added DBU (55 µL, 1.5eq.) at -20°C. After 30 min of stirring at this 
temperature, this solution was added to a mixture of allyl magnesium bromide 
(1M in Et2O, 2.8 eq., 690 µL), CuI (3.2 eq., 150 mg), LiBr (3.2eq., 70 mg) and dry 
THF 1mL at -78°C. After 30 minutes of stirring at this temperature, reaction 
mixture was quenched with a saturated aqueous solution of ammonium chloride 
and extracted with DCM (3x5 mL). The combined organic layers were dried with 
magnesium sulfate and evaporated to dryness. Purification by chromatography 
(preparative TLC eluted with Hex:AcOEt 8:2) afforded 30 mg (54%) of pure 
compound 11 as colorless oil. 
1H NMR δ: 7.40 (2H, d, 3J=7.3,  Ar(o)), 7.32 (2H, t, 3J=7.5,  Ar(m)), 7.25 (1H, d, 
3J=7.2,  Ar(p)), 5.88 (1H, ddt, J2’,3’=18.1, J2’,3’=9.3, J2’,1’=6.9, H-2’), 5.10-5.04 (2H, m, 
H-3’); 3.59 (1H, d, 2J=13.8, CH2 Bn), 3.47 (1H, d, 2J=13.8, CH2 Bn), 2.62 (1H, d, 
J1,5=4.0, H-1), 2.58-2.48 (2H, m, H-3, H-4), 2.24 (1H, d, J5,1=4.0, H-5), 2.16 (1H, dt, 
2J=13.7, J1’,2’=J1’,4=6.8, H-1’), 2.05 (1H, dt, 2J=14.4, J1’,2’=J1’,4=7.1, H-1’), 1.74 (1H, d, 
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2J=16.8, H-3). 13C NMR δ: 211.5 (C-2), 138.3 (Ar Cq), 134.9 (C-2’), 128.5 (Ar(m)), 
127.6 (Ar(o)), 127.3 (Ar(p)), 117.6 (C-3’), 61.5 (CH2 Bn), 50.8 (C-1), 46.6 (C-5), 39.3 
(C-3), 37.6 (C-1’), 35.7 (C-4). FTIR (Neat): 1741 (C=O st). HRMS (ESI-TOF) m/z: 
[M+H]+ Calcd for C15H18NO 228.1383; Found 228.1383. 
(±)-(1R,4S,5R)‐6‐Benzyl‐4‐(benzylamino)‐6‐azabicyclo[3.1.0]hexan‐2‐one 12 
To a stirred solution of (±)-8 (60 mg, 0.25 mmol) and benzylamine (55 µL, 
2 eq.) in dry tert-butanol (1 mL) was added potassium carbonate (70 mg, 2 eq.) 
at room temperature. After 1.5 hours of stirring at this temperature, reaction 
mixture was quenched with water and extracted with AcOEt (3x5 mL). The 
combined organic layers were dried with sodium sulfate and evaporated to 
dryness. Purification by chromatography (preparative TLC eluted with AcOEt) 
afforded 47 mg (52%) of pure compound 12 as fluorescent greenish yellow oil. 
1H NMR δ: 7.36-7.24 (10H, m, Ar), 3.83 (1H, d, 2J=13.1, CH2 Bn amine), 3.79 (1H, 
d, 2J=13.0, CH2 Bn amine), 3.62 (1H, d, 2J=13.8, CH2 Bn aziridine), 3.59 (1H, d, 
J4,3=6.6, H-4), 3.46 (1H, d, 2J=13.7, CH2 Bn aziridine), 2.76 (1H, d, 2J5,1=4.0, H-5), 
2.59 (1H, dd, 2J=18.0, J3,4=6.5, H-3), 2.32 (1H, d, J1,5=3.9, H-1), 1.89 (1H, d, 2J=18.0, 
H-3), 1.50 (1H, S, NH). 13C NMR δ: 210.5 (C-2), 139.6, 137.9 (2xAr Cq), 128.59, 
128.55, 128.2, 127.7, 127.4, 127.3 (6xAr), 61.4 (CH2 Bn aziridine), 55.1 (C-4), 51.4 
(CH2 Bn amine), 50.6 (C-5), 46.2 (C-1), 41.4 (C-3). FTIR (Neat): 1739 (C=O st). 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C19H21N2O 293.1648; Found 293.1646. 
(±)-(4R,5S)‐4‐[(tert‐Butyldimethylsilyl)oxy]‐5‐methylcyclopent‐2‐en‐1‐one 2059 
To a stirred solution of (±)-(4R,5S)‐4‐hydroxy‐5‐methylcyclopent‐2‐en‐1‐
one 1925 (210 mg, 1.9 mmol) in dry DCM (4 mL) under argon was added 
diisopropylamine (810 µL, 2.5 eq.), tert-butyldimethylsilylchloride (560 mg, 2 eq.) 
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and DMAP (cat.) at 0oC. After 16 hours of stirring at room temperature, the 
reaction was quenched with water (5mL) and the mixture was extracted with 
DCM (3x 5mL). The combined organic phases were dried with magnesium sulfate 
and evaporated to dryness. Purification by flash column chromatography, eluted 
with Hex:AcOEt (95:5), afforded 280 mg (66%) of the pure compound as colorless 
oil. 
(±)-(4S,5S)‐4‐[(tert‐Butyldimethylsilyl)oxy]‐2‐iodo‐5‐methylcyclopent‐2‐en‐1‐one 
21 
 To a stirred solution of 20 (270 mg, 1.2 mmol) in Et2O:Py 1:1 (2mL) under 
argon was added iodine (600mg, 2 eq.) at 0 oC. After 30 min of stirring at room 
temperature, the reaction mixture was diluted with Et2O (5mL) and washed with 
a sodium thiosulfate solution 20%(w/V) (5mL), HCl 2M (2x5mL) and water (5mL). 
The combined organic phases were dried with magnesium sulfate and 
evaporated to dryness. Purification by flash column chromatography, eluted with 
Hex:AcOEt (95:5) afforded 235 mg (56%) of the pure compound 21 as colorless 
oil. 
1H NMR δ: 7.74 (1H, d, J3,4=2.3, H-3); 4.48 (1H, t, J4,3=J4,5=2.4, H-4); 2.36 (1H, qd, 
J5,Me=7.4, J5,4=2.4, H-5); 1.28 (3H, d, JMe,5=7.5, Me); 0.92 (9H, s, tBu TBS); 0.15 (3H, 
s, Me TBS); 0.14 (3H, s, Me TBS). 13C NMR δ: 202.1 (C-1); 167.5 (C-3); 103.6 (C-2); 
79.4 (C-4); 48.8 (C-5); 25.7 (3xMe tBu); 18.0 (Cq tBu); 12.9 (Me); -4.63 (Me TBS); -
4.65 (Me TBS). FTIR(NEAT): 1731 (C=O st); 1259 (Si-Me bend); 1105 (Si-O-C st); 
837 (Si-O-C bend); 778 (alkene C-H o.o.p. bend). 
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(±)-(1S,3S,4S,5R)‐6‐Benzyl‐4‐[(tert‐butyldimethylsilyl)oxy]‐3‐methyl‐6-
azabicyclo[3.1.0]hexan‐2‐one 22 
 To a stirred solution of 21 (230 mg, 0.65 mmol) in dry Toluene (3 mL) 
under argon was added anhydrous cesium carbonate (230 mg, 1.1eq.), 1,10-
phenantroline (120 mg, 1.0 eq.) and benzylamine (110 µL, 1.5 eq.) at room 
temperature. After stirring at the same temperature for 3 hours, reaction mixture 
was quenched with water (5mL) and extracted with DCM (3x5 mL). The combined 
organic phases were dried with magnesium sulfate and evaporated to dryness. 
Purification by chromatography (flash column eluted with Hex:AcOEt 95:5) 
afforded 152 mg (70%) of pure compound 22 as colorless oil. 
1H NMR δ: 7.41 (2H, d, 3J=7.2, Ar(o)); 7.32 (2H, t, 3J=7.3, Ar(m)); 7.25 (1H, t, 3J =7.3 
Hz, Ar(p)); 3.86 (1H, d, 2J=13.9, CH2 Bn); 3.82 (1H, dd, J4,5=8.0, J4,3=3.0, H-4); 3.27 
(1H, d, 2J=13.9, CH2 Bn); 2.66 (1H, dd, J5,1=4.3, J5,4=3.2, H-5); 2.54 (1H, p, J3,4= 
J3,Me=7.2, H-3), 2.39 (1H, d, J1,5=4.4, H-1); 1.01 (3H, d, JMe,3=7.1, H-3); 0.89 (9H, s, 
tBu TBS), 0.08 (3H, s, Me TBS), 0.03 (3H, s, Me TBS). 13C NMR δ: 208.7 (C-2); 137.9 
(Ar Cq); 128.4 (Ar(m)); 127.6 (Ar(o)); 127.2 (Ar(p)); 75.9 (C-4); 61.2 (CH2 Bn); 49.1 
(C-5); 48.1 (C-1); 45.5 (C-3); 25.8 (3xMe tBu); 18.1 (Cq tBu); 10.3 (Me); -4.3 (Me 
TBS); -4.7 (Me TBS). FTIR (Neat): 1743 (C=O st); 1107 (Si-O-C st); 837 (Si-O-C 
bend). 
(±)-(1S,3S,4S,5R)‐6‐Benzyl‐4‐hydroxy‐3‐methyl‐6‐azabicyclo[3.1.0]hexan‐2‐one 23 
To a stirred solution of 22 (140 mg, 0.42 mmol) in dry THF (2mL) under 
argon was added TBAF (760 µL, 1 M in THF, 1.8 eq.) at room temperature. After 
15 minutes, the reaction mixture was diluted with DCM (5 mL) and washed with 
water (5 mL). The organic layer was dried with magnesium sulfate and 
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evaporated to dryness. Purification by chromatography (preparative plate eluted 
with Hex:AcOEt 1:2) afforded 85 mg (93%) of pure compound 23 as white solid. 
1H NMR δ: 7.35-7.26 (5H, m, Ar); 3.80-3.76 (1H, m, H-4); 3.63 (1H, d, 2J=13.4, CH2 
Bn); 3.48 (1H, d, 2J=13.4, CH2 Bn); 2.90 (1H, t, J5,1=J5,4=3.3, H-5); 2.50 (1H, d, 
J1,5=4.2, H-1); 2.29 (1H, p, J3,4= J3,Me=7.2, H-3); 2.02 (1H, br s, OH); 1.07 (3H, d, 
JMe,3=7.2, H-3). 13C NMR δ: 208.3 (C-2); 137.7 (Ar Cq); 128.7 (Ar(m)); 127.9 (Ar(o)); 
127.7 (Ar(p)); 75.5 (C-4); 61.4 (CH2 Bn); 49.1 (C-1); 48.4 (C-5); 45.5 (C-3); 10.7 
(Me). FTIR (Neat): 3420 (O-H st); 1737 (C=O st). M.p.=111.5°C. 
(±)-(1R,2S,3S,5S)‐6‐Benzyl‐3‐methyl‐4‐oxo‐6‐azabicyclo[3.1.0]hexan‐2‐yl acetate 
24 
 To a stirred solution of 23 (70 mg, 0.32 mmol) in dry DCM (1mL) under 
argon was added triethylamine (110 µL, 2.5 eq.) and acetic anhydride (60 µL, 2 
eq.) at room temperature. After 3 hours, the reaction mixture was quenched with 
water (5 mL) and extracted with DCM (3x5 mL). The combined organic phases 
were dried with magnesium sulfate and evaporated to dryness. Purification by 
chromatography (preparative plate eluted with Hex:AcOEt 2:1) afforded 61 mg 
(73%) of pure compound 24 as white solid. 
1H NMR δ: 7.37-7.27 (5H, m, Ar); 4.74 (1H, dd, J2,3=8.0, J2,1=3.1, H-2); 3.81 (1H, d, 
2J=13.5, CH2 Bn); 3.28 (1H, d, 2J=13.5, CH2 Bn); 3.05 (1H, t, J1,2=J1,5=3.7, H-1); 2.62 
(1H, p, J3,2=J3,Me=7.4, H-3); 2.51 (1H, d, J5,1=4.4, H-5); 2.00 (3H, s, CH3 Ac); 1.05 
(3H, s, Me). 13C NMR δ: 207.2 (C-4); 171.1 (C=O Ac); 137.7 (Ar Cq); 128.5 (Ar(m)); 
127.7 (Ar(o)); 127.4 (Ar(p)); 76.8 (C-2); 61.0 (CH2 Bn); 48.4 (C-5); 45.3 (C-1); 31.7 
(C-3); 20.8 (CH3 Ac); 10.8 (Me). FTIR (Neat): 1731 (C=O st); 1228 (C-O-C st); 1028 
(C-O-C st). M.p.=37.5-38°C. 
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6‐Benzyl‐3‐methyl‐6‐azabicyclo[3.1.0]hex‐3‐en‐2‐one 25 
 To a stirred solution of 24 (40 mg, 0.15 mmol) in methanol (1mL) was 
added potassium carbonate (42 mg, 2 eq.). After 2 hours, ammonium chloride 
(40 mg) was added. The salts were then filtered and the solution evaporated to 
dryness. Purification by chromatography (preparative plate eluted with 
Hex:AcOEt 1:1) afforded 10 mg (33%) of pure compound 25 as colorless oil. 
1H NMR δ: 7.37-7.28 (5H, m, Ar); 7.24 (1H, p, J4,3= J4,Me=1.6, H-4); 3.64 (1H, d, 
2J=13.6, CH2 Bn); 3.53 (1H, d, 2J=13.6, CH2 Bn); 2.93 (1H, dd, J5,1=4.1, J5,4=2.0, H-
5); 2.65 (1H, d, J1,5=4.1, H-1); 1.70 (3H, d, JMe,4=1.5, H-3). 13C NMR δ: 201.9 (C-2); 
151.3 (C-4); 142.2 (C-3); 137.6 (Ar Cq); 128.6 (Ar(m)); 127.9 (Ar(o)); 127.5 (Ar(p)); 
62.2 (CH2 Bn); 43.9 (C-1); 42.2 (C-5); 10.4 (Me). FTIR (Neat): 1710 (C=O st). 
(4E)‐1‐(Benzylamino)‐4‐methylocta‐1,4,7‐trien‐3‐one 26 
To a stirred solution of 24 (54 mg, 0.21 mmol) in dry THF (0.5 mL) under 
argon was added DBU (37 µL, 1.2eq.) at -20°C. After 30 min of stirring at this 
temperature, this solution was added to a mixture of allyl magnesium bromide 
(1M in Et2O, 2.8 eq., 582 µL), CuI (3.2 eq., 127 mg), LiBr (3.2eq., 58 mg) and dry 
THF (1mL) at -78°C. After 30 minutes of stirring at this temperature, reaction 
mixture was quenched with a saturated aqueous solution of ammonium chloride 
and extracted with DCM (3x5 mL). The combined organic layers were dried with 
magnesium sulfate and evaporated to dryness. Purification by chromatography 
(preparative TLC eluted with Hex:AcOEt 8:2) afforded 10 mg (20%) of pure 
compound 26 as yellow oil. 
1H NMR δ: 10.31 (1H, br s, NH); 7.36-7.25 (5H, m, Ar); 6.84 (1H, dd, J=12.5, 
J1,2=7.7, H-1); 6.40 (1H, t, J5,6=7.7, H-5); 5.83 (1H, ddt, J7,8=16.5, J7,8=10.5, J7,6=6.1, 
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H-7); 5.43 (1H, d, J2,1=7.6, H-2); 5.07 (1H, d, J8,7=17.5, H-8); 5.02 (1H, d, J8,7=10.3, 
H-8); 4.39 (2H, d, J=6.0, CH2 Bn); 2.93 (2H, t, J6,5=J6,7=6.5, H-6); 1.85 (3H, s, Me). 
13C NMR δ: 193.0 (C-3); 153.0 (C-1); 138.0 (C-4, Ar Cq); 132.7 (C-5); 128.8 (Ar(m)); 
127.7 (Ar(p)); 127.2 (Ar(o)); 115.6 (C-8); 90.5 (C-2); 52.6 (CH2 Bn); 32.9 (C-6); 12.2 
(Me). FTIR (Neat): 3300 (N-H st); 1628 (C=O st); 1549 (N-H bend); 1485 (C=C st); 
1278 (C-N st). 
1,3‐Diethyl 2‐[(1E)‐5‐(benzylamino)‐2‐methyl‐3‐oxopenta‐1,4‐dien‐1‐
yl]propanedioate 27 
To a stirred solution of 24 (40 mg, 0.15 mmol) in dry DCM (1 mL) was 
added DBU (25 µL, 1.1eq.) and diethyl malonate (47 µL, 2eq.) at 0°C. After 1 hour 
of stirring at room temperature, reaction mixture was quenched with water (10 
mL) and extracted with DCM (3x5 mL). The combined organic layers were dried 
with magnesium sulfate and evaporated to dryness. Purification by 
chromatography (preparative TLC eluted with DCM:AcOEt 98:2) afforded 7 mg 
(13%) of pure compound 27 as yellow oil. 
1H NMR δ: 10.35 (1H, br s, NH); 7.37-7.25 (5H, m, Ar); 6.90 (1H, dd, J=12.7, 
J5,4=7.6, H-5); 6.56 (1H, d, J1,CH malonate=9.4, H-1); 5.48 (1H, d, J4,5=7.6, H-4); 4.41 
(2H, d, J=6.1, CH2 Bn); 4.35 (1H, d, JCH malonate,1=9.4, CH malonate); 4.21 (4H, q, 
3J=7.1, 2xCH2 Et) 1.91 (3H, s, Me); 1.27 (6H, t, 3J=7.1, 2xCH3 Et). 13C NMR δ: 191.9 
(C-3); 167.6 (C=O malonate); 153.6 (C-5); 141.8 (C-2); 137.8 (Ar Cq); 128.8 (Ar(m)); 
127.8 (Ar(p)); 127.2 (Ar(o)); 125.2 (C-1); 90.7 (C-4); 61.9 (CH2 Et); 52.7 (CH2 Bn); 
52.1 (CH malonate); 14.0 (CH3 Et) 12.9 (Me). FTIR (Neat): 1730 (C=O st); 1628 
(C=O st) 1279, 1217 (C-O-C st, C-N st); 1028 (C-O-C st). 
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4‐[(tert‐Butyldimethylsilyl)oxy]‐3‐methylcyclopent‐2‐en‐1‐one60 
To a stirred solution of 4-Hydroxy-3-methylcyclopent-2-enone 3527 (600 
mg, 5.4 mmol) in dry DCM (20 mL) under argon was added diisopropylamine (2.3 
mL, 2.5 eq.), tert-butyldimethylsilylchloride (1.7 g, 2 eq.) and DMAP (cat.) at 0oC. 
After 16 hours of stirring at room temperature, the reaction was quenched with 
water (20mL) and the mixture was extracted with DCM (3x 10mL). The combined 
organic phases were dried with magnesium sulfate and evaporated to dryness. 
Purification by flash column chromatography, eluted with Hex:AcOEt (9:1), 
afforded 669 mg (66%) of the pure title compound as colorless oil. 
4‐[(tert‐Butyldimethylsilyl)oxy]‐2‐iodo‐3‐methylcyclopent‐2‐en‐1‐one 3660 
To a stirred solution of 4‐[(tert‐butyldimethylsilyl)oxy]‐3‐
methylcyclopent‐2‐en‐1‐one (1g, 4.4 mmol) in Et2O:Py 1:1 (10mL) under argon 
was added iodine (4.5 g, 2 eq.) at 0°C. After 16 hours of stirring at room 
temperature, the reaction mixture was diluted with Et2O (20mL) and washed 
with a sodium thiosulfate solution 20%(w/V) (10mL), HCl 2M (2x10mL) and water 
(10mL). The combined organic phases were dried with magnesium sulfate and 
evaporated to dryness, affording 1.25 g (80%) of the pure compound 36 as 
colorless oil. 
(±)-(1S,4S,5R)‐6‐Benzyl‐4‐[(tert‐butyldimethylsilyl)oxy]‐5‐methyl‐6‐
azabicyclo[3.1.0]hexan‐2‐one 37 
To a stirred solution of 36 (600 mg, 1.7 mmol) in dry Toluene (7 mL) and 
dry DCM (5mL) under argon was added anhydrous cesium carbonate (660 mg, 
1.1eq.), 1,10-phenantroline (306 mg, 1.0 eq.) and benzylamine (280 µL, 1.5 eq.) 
at room temperature. After stirring at the same temperature for 24 hours, 
reaction mixture was quenched with water (20mL) and extracted with DCM (3x10 
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mL). The combined organic phases were dried with magnesium sulfate and 
evaporated to dryness. Purification by chromatography (flash column eluted with 
Hex:AcOEt 9:1) afforded 344 mg (61%) of 37 as colorless oil and  109 mg (28%) of 
(±)-(1R,4S,5S)‐6‐benzyl‐4‐[(tert‐butyldimethylsilyl)oxy]‐5‐methyl‐6‐
azabicyclo[3.1.0]hexan‐2‐one 37’ as white solid. 
1H NMR δ: 7.51 (2H, d, 3J=7.5, Ar(o)); 7.31 (2H, t, 3J=7.5, Ar(m)); 7.23 (1H, t, 3J =7.3 
Hz, Ar(p)); 4.20 (1H, t, J4,3=7.9, H-4); 4.12 (1H, d, 2J=15.2, CH2 Bn); 3.55 (1H, d, 
2J=15.2, CH2 Bn); 2.61 (1H, dd, 2J=16.3, J3,4=8.1, H-3); 2.22 (1H, dd, 2J=16.3, 
J3,4=7.7, H-3); 2.17 (1H, s, H-1); 1.48 (3H, s, Me); 0.94 (9H, s, tBu TBS); 0.10 (3H, s, 
Me TBS), 0.08 (3H, s, Me TBS). 13C NMR δ: 207.9 (C-2); 138.9 (Ar Cq); 128.3 
(Ar(m)); 126.8 (Ar(o)); 126.7 (Ar(p)); 73.4 (C-4); 54.2 (CH2 Bn); 53.4 (C-1); 53.1 (C-
5); 42.6 (C-3); 25.7 (3xMe tBu); 18.1 (Cq tBu); 10.7 (Me); -4.5 (Me TBS); -5.0 (Me 
TBS). FTIR (Neat): 1746 (C=O st); 1106 (Si-O-C st); 830 (Si-O-C bend). 
(±)-(1R,4S,5S)‐6‐Benzyl‐4‐[(tert‐butyldimethylsilyl)oxy]‐5‐methyl‐6‐
azabicyclo[3.1.0]hexan‐2‐one 37’ 
1H NMR δ: 7.34-7.23 (5H, m, Ar); 4.29 (1H, d, J4,3=5.6, H-4); 3.77 (1H, d, 2J=14.3, 
CH2 Bn); 3.67 (1H, d, 2J=14.3, CH2 Bn); 2.78 (1H, dd, 2J=17.5, J3,4=5.6, H-3); 2.13 
(1H, s, H-1); 1.85 (1H, d, 2J=17.5, H-3); 1.52 (3H, s, Me); 0.89 (9H, s, tBu TBS); 0.09 
(3H, s, Me TBS), 0.06 (3H, s, Me TBS). 13C NMR δ: 211.3 (C-2); 138.8 (Ar Cq); 128.5 
(Ar(m)); 127.3 (Ar(o)); 127.1 (Ar(p)); 72.8 (C-4); 55.2 (CH2 Bn); 54.9 (C-5); 52.4 (C-
1); 45.8 (C-3); 25.7 (3xMe tBu); 18.0 (Cq tBu); 8.4 (Me); -4.6 (Me TBS); -5.0 (Me 
TBS). FTIR (Neat): 1746 (C=O st); 1074 (Si-O-C st); 837 (Si-O-C bend). M.p.=65°C. 
(±)-(1S,4S,5R)‐6‐Benzyl‐4‐hydroxy‐5‐methyl‐6‐azabicyclo[3.1.0]hexan‐2‐one 38 
To a stirred solution of 37 (400 mg, 1.2 mmol) in dry THF (2mL) under 
argon was added TBAF (2.2 mL, 1 M in THF, 1.8 eq.) at room temperature. After 
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30 minutes, reaction mixture was quenched with water (10mL) and extracted 
with DCM (3x5 mL). The organic layer was dried with magnesium sulfate and 
evaporated to dryness. Purification by chromatography (flash column eluted with 
Hex:AcOEt 1:1) afforded 267 mg (100%) of pure compound 38 as colorless oil. 
1H NMR δ: 7.36-7.26 (5H, m, Ar); 4.12 (1H, dt, J4,OH=10.7, J4,3=7.6, H-4); 3.72 (2H, 
s, CH2 Bn); 2.44 (1H, dd, 2J=17.8, J3,4=8.3, H-3); 2.29 (1H, dd, 2J=17.8, J3,4=6.7, H-
3); 2.28 (1H, s, H-1); 2.09 (1H, d, JOH,4=11.0, OH); 1.65 (3H, s, Me). 13C NMR δ: 
207.7 (C-2); 138.5 (Ar Cq); 128.7 (Ar(m)); 127.6 (Ar(o)); 127.4 (Ar(p)); 72.8 (C-4); 
55.1 (C-1); 55.2 (CH2 Bn); 53.5 (C-5); 43.3 (C-3); 10.9 (Me). FTIR (Neat): 3420 (O-
H st); 1735 (C=O st). 
(±)-(1R,2S,5S)‐6‐Benzyl‐1‐methyl‐4‐oxo‐6‐azabicyclo[3.1.0]hexan‐2‐yl acetate 39 
 To a stirred solution of 38 (170 mg, 0.78 mmol) in dry DCM (3mL) under 
argon was added triethylamine (270 µL, 2.5 eq.) and acetic anhydride (150 µL, 2 
eq.) at room temperature. After 16 hours, the reaction mixture was quenched 
with water (5 mL) and extracted with DCM (3x5 mL). The combined organic 
phases were dried with magnesium sulfate and evaporated to dryness. 
Purification by chromatography (preparative plate eluted with Hex:AcOEt 2:1) 
afforded 184 mg (91%) of pure compound as colorless oil. 
1H NMR δ: 7.43 (2H, d, 3J=7.4, Ar(o)); 7.33 (2H, t, 3J=7.4, Ar(m)); 7.26 (1H, t, 3J =7.3 
Hz, Ar(p));  5.15 (1H, t, J2,3=8.0, H-2); 3.90 (1H, d, 2J=14.6, CH2 Bn); 3.72 (1H, d, 
2J=14.6, CH2 Bn); 2.52 (2H, d, J3,2=8.0, H-3); 2.24 (1H, s, H-5); 2.12 (3H, s, CH3 Ac); 
1.53 (3H, s, Me). 13C NMR δ: 206.2 (C-4); 170.9 (C=O Ac); 138.5 (Ar Cq); 128.3 
(Ar(m)); 127.2 (Ar(o)); 127.1 (Ar(p)); 74.1 (C-2); 54.7 (CH2 Bn); 53.6 (C-5); 50.4 (C-
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1); 39.8 (C-3); 20.9 (CH3 Ac); 11.1 (Me). FTIR (Neat): 1736 (C=O st); 1232 (C-O-C 
st). 
6‐Benzyl‐5‐methyl‐6‐azabicyclo[3.1.0]hex‐3‐en‐2‐one 40 
To a stirred solution of 39 (30 mg, 0.12 mmol) in dry DCM (1 mL) under 
argon was added DBU (26 µL, 1.5eq.) at 0°C. After 30 min of stirring at room 
temperature, reaction mixture was quenched with a saturated aqueous solution 
of ammonium chloride and extracted with DCM (3x5 mL). The combined organic 
layers were dried with magnesium sulfate and evaporated to dryness, affording 
24 mg (100%) of pure compound 40 as yellow oil. 
1H NMR δ: 7.49 (0.7H, d, J4,3=5.8, H-4); 7.33-7.22 (5H, m, Ar); 6.99 (0.3H, d, 
J4’,3’=5.8, H-4’); 6.08 (0.3H, dd, J3’,4’=5.8, J3’,1’=1.6, H-3’); 5.84 (0.7H, dd, J3,4=5.8, 
J3,1=1.4, H-3); 4.00 (0.3H, d, 2J=14.0, CH2 Bn’); 3.74 (0.7H, d, 2J=14.3, CH2 Bn); 3.71 
(0.3H, d, 2J=14.5, CH2 Bn’); 3.68 (0.7H, d, 2J=14.2, CH2 Bn); 2.67 (0.3H, d, J1’,3’=1.4, 
H-1’); 2.42 (0.7H, s, H-1); 1.68 (2.1H, s, Me); 1.63 (0.9H, s, Me’). 13C NMR δ: 202.8 
(C-2); 201.4 (C-2’); 163.6 (C-4); 155.1 (C-4’); 139.0 (Ar Cq’); 138.1 (Ar Cq); 131.80 
(C-3); 131.75 (C-3’); 128.5 (Ar(m)); 127.9 (Ar(o)’); 127.5 (Ar(o)’); 127.18 (Ar(p)); 
127.17 (Ar(p)’); 57.0 (CH2 Bn); 51.2 (C-5’); 49.4 (CH2 Bn’); 49.1 (C-1); 48.9 (C-5); 
46.6 (C-1’); 17.6 (Me); 9.5 (Me’). FTIR (Neat): 1712 (C=O st). 
6‐Benzyl‐5‐methyl‐4‐(prop‐2‐en‐1‐yl)‐6‐azabicyclo[3.1.0]hexan‐2‐one 41 
 To a stirred solution of allyl magnesium bromide (1M in Et2O, 2.8 eq., 340 
µL), CuI (3.2 eq., 73 mg), LiBr (3.2 eq., 33 mg) in dry THF (0.5mL) at -78°C was 
added a solution of 40 (24 mg, 0.12 mmol) in dry THF (0.5mL). After 30 minutes 
of stirring at this temperature, reaction mixture was quenched with a saturated 
aqueous solution of ammonium chloride and extracted with DCM (3x5 mL). The 
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combined organic layers were dried with magnesium sulfate and evaporated to 
dryness. Purification by chromatography (preparative TLC eluted with Hex:AcOEt 
8:2) afforded 10 mg (34%) of product as a mixture of two diastereomers (d.r.=6:4, 
41a:41b). The diastereomers 41a and 41b were further separated by 
chromatography (preparative TLC eluted with DCM). 
(±)-(1S,4S,5S)‐6‐Benzyl‐5‐methyl‐4‐(prop‐2‐en‐1‐yl)‐6‐azabicyclo[3.1.0]hexan‐2‐
one 41a 
1H NMR δ: 7.37-7.24 (5H, m, Ar); 5.37 (1H, ddt, J2’,3’=17.1, J2’,3’=10.2, J2’,1’=6.8, H-
2’); 4.97 (1H, d, J3’,2’=17.2, H-3’); 4.95 (1H, d, J3’,2’=9.9, H-3’); 3.75 (1H, d, 2J=14.0, 
CH2 Bn); 3.66 (1H, d, 2J=14.0, CH2 Bn); 2.40-2.33 (1H, m, H-1’); 2.23-2.07 (4H, m, 
H-3, H-4, H-1’); 2.05 (1H, s, H-1); 1.53 (3H, s, Me). 13C NMR δ: 212.0 (C-2); 138.9 
(Ar Cq); 136.7 (C-2’); 128.4 (Ar(m)); 127.8 (Ar(o)); 127.1 (Ar(p)); 116.1 (C-3’); 55.5 
(CH2 Bn); 54.0 (C-1); 52.1 (C-5); 42.6 (C-4); 40.1 (C-3); 34.6 (C-1’); 12.4 (Me). FTIR 
(Neat): 1740 (C=O st). 
(±)-(1S,4R,5S)‐6‐Benzyl‐5‐methyl‐4‐(prop‐2‐en‐1‐yl)‐6‐azabicyclo[3.1.0]hexan‐2‐
one 41b 
1H NMR δ: 7.36-7.30 (4H, m, Ar(o,m)); 7.27-7.23 (1H, m, Ar(p)); 5.69 (1H, m, H-
2’); 5.13-5.02 (2H, m, H-3’); 3.78 (1H, d, 2J=14.4, CH2 Bn); 3.73 (1H, d, 2J=14.5, CH2 
Bn); 2.64 (1H, dd, 2J=17.4, J3,4=8.2, H-3); 2.48 (1H, td, J4,3= J4,1’=8.9, J4,1’=3.8, H-4); 
2.42-2.36 (1H, m, H-1’); 2.06 (1H, s, H-1); 1.99 (1H, dt, 2J=17.3, J1’,4= J1’,2’=7.4, H-
1’); 1.85 (1H, d, 2J=17.4, H-3); 1.49 (3H, s, Me). 13C NMR δ: 212.8 (C-2); 139.0 (Ar 
Cq); 135.0 (C-2’); 128.4 (Ar(m)); 127.3 (Ar(o)); 127.0 (Ar(p)); 117.8 (C-3’); 55.1 (CH2 
Bn); 52.8 (C-1); 52.7 (C-5); 40.8 (C-4); 39.5 (C-3); 36.3 (C-1’); 9.8 (Me). FTIR (Neat): 
1741 (C=O st). 
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(±)-(1S,4R,5R)‐6‐Benzyl‐4‐methoxy‐5‐methyl‐6‐azabicyclo[3.1.0]hexan‐2‐one 42 
To a stirred solution of 39 (30 mg, 0.12 mmol) in methanol (1mL) was 
added potassium carbonate (32 mg, 2 eq.). After 20 minutes, ammonium chloride 
(40 mg) was added. The salts were then filtered and the solution evaporated to 
dryness, affording 24 mg (90%) of compound 42 as colorless oil. 
1H NMR δ: 7.35-7.23 (5H, m, Ar); 3.86 (1H, d, J4,3=5.5, H-4); 3.74 (2H, s, CH2 Bn); 
3.31 (3H, s, OMe); 2.61 (1H, dd, 2J=17.7, J3,4=5.5, H-3); 2.15 (1H, s, H-1); 2.05 (1H, 
d, 2J=17.7, H-3); 1.55 (3H, s, Me). 13C NMR δ: 210.8 (C-2); 138.7 (Ar Cq); 128.5 
(Ar(m)); 127.3 (Ar(o)); 127.1 (Ar(p)); 81.2 (C-4); 56.9 (OMe); 54.9 (CH2 Bn); 53.2 
(C-5); 51.9 (C-1); 40.2 (C-3); 8.1 (Me). FTIR (Neat): 1744 (C=O st); 1115, 1089 (C-
O-C st); 731, 696 (Ar C-H o.o.p bend). 
1,3‐Diethyl 2‐{6‐benzyl‐1‐methyl‐4‐oxo‐6‐azabicyclo[3.1.0]hexan‐2‐
yl}propanedioate 43 
To a stirred solution of 39 (28 mg, 0.11 mmol) in dry DCM (1 mL) was 
added DBU (24 µL, 1.5eq.) and diethyl malonate (33 µL, 2eq.) at 0°C. After 3 hours 
of stirring at room temperature, reaction mixture was quenched with water (10 
mL) and extracted with DCM (3x5 mL). The combined organic layers were dried 
with magnesium sulfate and evaporated to dryness. Purification by 
chromatography (preparative TLC eluted with Hex:AcOEt 2:1) afforded 36 mg 
(93%) of product as a mixture of two diastereomers (d.r.=9:1, 43a:43b). The 
diastereomers 43a and 43b were further separated by chromatography 
(preparative TLC eluted with DCM:AcOEt 95:5). 
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1,3‐Diethyl 2‐[(1S,2S,5S)‐6‐benzyl‐1‐methyl‐4‐oxo‐6‐azabicyclo[3.1.0]hexan‐2‐
yl]propanedioate 43a 
1H NMR δ: 7.33-7.32 (4H, m, Ar(o,m)); 7.28-7.23 (1H, m, Ar(p)); 4.20 (4H, q, 3J=7.1, 
2xCH2 Et); 3.82 (1H, d, 2J=14.4, CH2 Bn); 3.70 (1H, d, 2J=14.4, CH2 Bn); 3.69 (1H, d, 
JCH malonate,2=4.0, CH malonate); 3.00 (1H, dd, J2,3=8.8, J2,CH malonate=2.8, H-2); 2.68  
(1H, dd, 2J=18.1, J3,2=9.3, H-3); 2.16 (1H, d, 2J=18.1, H-3); 2.15 (1H, s, H-5); 1.45 
(3H, s, Me); 1.264 (3H, t, 3J=7.1, CH3 Et); 1.257 (3H, t, 3J=7.1, CH3 Et). 13C NMR δ: 
210.5 (C-4); 168.6, 168.0 (2xC=O malonate); 138.8 (Ar Cq); 128.8 (Ar(m)); 127.3 
(Ar(o)); 127.1 (Ar(p)); 61.9, 61.7 (2xCH2 Et); 55.1 (CH2 Bn); 53.3 (C-5); 52.6 (CH 
malonate); 50.3 (C-1); 41.2 (C-2); 37.9 (C-3); 14.0, 13.9 (2xCH3 Et); 9.7 (Me). FTIR 
(Neat): 1728 (C=O st). 
1,3‐Diethyl 2‐[(1S,2R,5S)‐6‐benzyl‐1‐methyl‐4‐oxo‐6‐azabicyclo[3.1.0]hexan‐2‐
yl]propanedioate 43a 
1H NMR δ: 7.34-7.23 (5H, m, Ar); 4.21-4.07 (4H, m, 2xCH2 Et); 3.88 (1H, d, 2J=14.0, 
CH2 Bn); 3.71 (1H, d, JCH malonate,2=7.6, CH malonate); 3.44 (1H, d, 2J=14.1, CH2 Bn); 
2.90 (1H, q, J2,3=J2,CH malonate=8.5, H-2); 2.40 (1H, dd, 2J=17.8, J3,2=8.8, H-3); 2.31 
(1H, dd, 2J=17.8, J3,2=8.8, H-3); 2.05 (1H, s, H-5); 1.56 (3H, s, Me); 1.23 (6H, t, 
3J=7.1, 2xCH3 Et). 13C NMR δ: 210.0 (C-4); 168.6, 168.2 (2xC=O malonate); 138.5 
(Ar Cq); 128.4 (Ar(m)); 127.6 (Ar(o)); 127.2 (Ar(p)); 61.60, 61.57 (2xCH2 Et); 55.1 
(CH2 Bn); 54.3 (C-5); 52.8 (CH malonate); 50.1 (C-1); 42.0 (C-2); 38.3 (C-3); 14.00, 
13.98 (2xCH3 Et); 12.7 (Me). FTIR (Neat): 1728 (C=O st). 
6‐Benzyl‐4‐methylidene‐1‐(prop‐2‐en‐1‐yl)‐6‐azabicyclo[3.1.0]hex‐2‐ene 44 
To a stirred solution of 39 (32 mg, 0.12 mmol) in dry THF (0.5 mL) under 
argon was added DBU (28 µL, 1.5eq.) at 0°C. After 30 min of stirring at this 
temperature, this solution was added to a mixture of allyl magnesium bromide 
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(1M in Et2O, 2.8 eq., 340 µL), CuI (3.2 eq., 75 mg), HMPA (5eq., 110 µL) and dry 
THF (0.5mL) at -78°C. After 30 minutes of stirring at this temperature, reaction 
mixture was quenched with a saturated aqueous solution of ammonium chloride 
and extracted with DCM (3x5 mL). The combined organic layers were dried with 
magnesium sulfate and evaporated to dryness. Purification by chromatography 
(preparative TLC eluted with Hex:AcOEt 8:2) afforded 10 mg (36%) of pure 
compound 44 as yellow oil. 
1H NMR δ: 7.42-7.26 (5H, m, Ar); 6.16 (1H, d, J3,2=5.7, H-3); 6.05 (1H, d, J2,3=5.7, 
H-2); 5.84 (1H, ddt, J2’,3’=17.2, J2’,3’=10.1, J2’,1’=7.2, H-2’); 5.09 (1H, d, J3’,2’=8.9, H-
3’);5.06 (1H, d, J3’,2’=16.8, H-3’); 5.00 (1H, s, =CH2); 4.84 (1H, s, =CH2); 3.96 (1H, d, 
2J=13.1, CH2 Bn); 3.90 (1H, d, 2J=13.1, CH2 Bn); 3.40 (1H, s, H-5); 2.36 (1H, dd, 
2J=13.9, J1’,2’=7.6, H-1’); 2.30 (1H, dd, 2J=14.1, J1’,2’=7.5, H-1’). 13C NMR δ: 154.8 (C-
4); 143.1 (C-2); 139.6 (Ar Cq); 134.1 (C-2’); 132.9 (C-3); 128.6 (Ar(m)); 128.4 
(Ar(o)); 127.4 (Ar(p)); 117.9 (C-3’); 106.5 (=CH2); 80.2 (C-1); 63.9 (C-5); 53.7 (CH2 
Bn); 44.9 (C-1’). 
6‐Benzyl‐3‐{6‐benzyl‐3‐bromo‐1‐methyl‐4‐oxo‐6‐azabicyclo[3.1.0]hexan‐2‐yl}‐4‐
bromo‐5‐methyl‐6‐azabicyclo[3.1.0]hexan‐2‐one 45 
To a stirred solution of 39 (30 mg, 0.12 mmol) in dry DCM (0.5 mL) under 
argon was added DBU (26 µL, 1.5eq.) at 0°C. After 30 min of stirring at this 
temperature, this solution was added to a mixture of magnesium bromide ethyl 
etherate (3 eq., 90 mg) and dry DCM (0.5 mL) at -78°C. After 30 minutes of stirring 
at this temperature, allyltrimethylsilane (10 eq., 188 µL) was added. After 4 hours 
of stirring at room temperature, reaction mixture was quenched with a saturated 
aqueous solution of sodium bicarbonate and extracted with DCM (3x5 mL). The 
combined organic layers were dried with magnesium sulfate and evaporated to 
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dryness. Purification by chromatography (preparative TLC eluted with Hex:AcOEt 
2:1) afforded 5 mg (16%) of pure compound 45 as yellow oil. 
1H NMR δ: 7.36-7.22 (10H, m, Ar); 3.80 (1H, d, 2J=13.6, CH2 Bn); 3.78 (1H, d, 
2J=13.4, CH2 Bn); 3.69-3.68 (1H, m, H-3’); 3.65 (1H, d, 2J=13.4, CH2 Bn); 3.57 (1H, 
d, 2J=13.4, CH2 Bn); 3.37 (1H, d, J4,3=4.9, H-4); 2.97-2.95 (1H, m, H-2’); 2.88 (1H d, 
J5’,3’=1.9, H-5’); 2.71 (1H, tt, J3,4=J3,2’=5.2, J3,1=J3,3’=1.6, H-3); 2.42 (1H, s, H-1); 1.32 
(3H, s, Me); 1.18 (3H, s, Me). 13C NMR δ: 206.2, 202.5 (C-2, C-4’); 137.6, 137.5 (Ar 
Cq); 128.6 (Ar(m)); 128.5, 128.4 (Ar(o)); 127.7, 127.2 (Ar(p)); 80.1 (C-3’); 75.4 (C-
5); 70.4 (C-5’); 68.7 (C-4); 67.8 (C-1); 57.8 (CH2 Bn); 55.2 (C-2’); 49.7 (C-3); 48.6 
(CH2 Bn); 47.9 (C-1’); 20.7, 18.5 (Me). FTIR (Neat): 1733 (C=O st); 734, 699 (Ar C-
H o.o.p bend). 
5‐[(tert‐Butyldimethylsilyl)oxy]‐3‐oxocyclopent‐1‐ene‐1‐carbaldehyde 47 
To a stirred solution of 36 (50 mg, 0.14 mmol) in dry Toluene (1 mL) under 
argon was added anhydrous cesium carbonate (51 mg, 1.1eq.), 1,10-
phenantroline (26 mg, 1.0 eq.) and cyclohexylamine (23 µL, 1.5 eq.) at room 
temperature. After stirring at 60°C for 24 hours, reaction mixture was quenched 
with water (10mL) and extracted with DCM (3x5 mL). The combined organic 
phases were dried with magnesium sulfate and evaporated to dryness. 
Purification by chromatography (preparative plate eluted with Hex:AcOEt 9:1) 
afforded 7 mg (22%) of 4‐[(tert‐butyldimethylsilyl)oxy]‐3‐methylcyclopent‐2‐en‐
1‐one as colorless oil and  2 mg (6%) of 47. 
1H NMR δ: 10.15 (1H, s, aldehyde); 6.70 (1H, s, H-2); 5.27 (1H, d, J5,4=5.3, H-4); 
2.85 (1H, dd, 2J=18.7, J4,5=6.1, H-4); 2.43 (1H, dd, 2J=18.7, J4,5=1.8, H-4); 0.88 (9H, 
s, tBu TBS); 0.17 (3H, s, Me TBS); 0.16 (3H, s, Me TBS). 13C NMR δ: 204.4 (C-3); 
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189.2 (aldehyde); 166.5 (C-1); 140.2 (C-2); 67.7 (C-5); 46.3 (C-4); 25.6 (3xMe tBu); 
18.0 (Cq tBu); -5.0 (Me TBS); -5.1 (Me TBS). 
(±)-(1R,5R,6S)‐5‐[(tert‐Butyldimethylsilyl)oxy]‐7‐(prop‐2‐en‐1‐yl)‐7‐
azabicyclo[4.1.0]heptan‐2‐one 55 
In a flask under argon a mixture of racemic 4-((tert-
butyldimethylsilyl)oxy)-2-iodocyclohex-2-en-1-one16b (1.1 g, 3.1 mmol), 
anhydrous cesium carbonate (1.2 g, 1.1 eq.), anhydrous 1,10-phenantroline (590 
mg, 1.0 eq.), allylamine (370 µL, 1.5 eq.) and dry toluene (7 mL) was stirred at 
room temperature. After 4 hours, the reaction mixture was diluted with DCM (10 
mL) and washed with water (10 mL). The organic layer was dried with magnesium 
sulfate and evaporated to dryness. Purification by flash column chromatography, 
eluted with Hex/AcOEt (9:1), afforded 770 mg (88%) of the pure compound 55 as 
a colorless oil. 
(±)-(1R,5R,6S)‐5‐Hydroxy‐7‐(prop‐2‐en‐1‐yl)‐7‐azabicyclo[4.1.0]heptan‐2‐one 56 
To a stirred solution of (±)-55 (1.9 g, 6.75 mmol) in dry tetrahydrofuran 
(30 mL) under argon was added tetrabutylammonium fluoride (12.2 mL, 1 M in 
THF, 1.8 eq.). After 30 minutes, the reaction mixture was diluted with DCM (30 
mL) and washed with water (30 mL). The organic layer was dried with magnesium 
sulfate and evaporated to dryness. Purification by flash column chromatography, 
eluted with Hex/AcOEt (1:1), afforded 1.15 g (100%) of the pure compound 56 as 
colorless oil. 
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(+)-(1S,2R,6R)‐5‐Oxo‐7‐(prop‐2‐en‐1‐yl)‐7‐azabicyclo[4.1.0]heptan‐2‐yl acetate 57 
A mixture of (±)-56 (1.36 g, 2.9 mmol), vinyl acetate (1.3 mL, 5 eq.), 
novozym 435 (680 mg) and diisopropyl ether (30mL) was agitated (700 r.p.m.) in 
a closed tube for 4 hours at 24°C. The solid-supported enzyme was then removed 
by decantation and the organic solution was evaporated to dryness. Purification 
by flash column chromatography, eluting with Hex/AcOEt (1:1), afforded 829 mg 
of (+)-57 (49%) and 685 mg of (-)-56 (50%, >99% e.e. HPLC), both as colorless oils. 
1H RMN δ: 5.87 (1H, ddt, J2’,3’=17.3, J2’,3’=10.6, J2’,1’=5.4, H-2’); 5.29 (1H, dq, 
J3’,2’=17.3, 2J=J3’,1’=1.5, H-3’); 5.16 (1H, dq, J3’,2’=10.6, 2J=J3’,1’=1.3, H-3’); 5.12 (1H, 
ddd, J2,3=9.9, J2,3=5.3, J2,1=2.3, H-2); 3.19 (1H, dd, 2J=14.2, J1’,2’=5.4, H-2’); 2.86 (1H, 
dd, 2J=14.2, J1’,2’=5.6, H-2’); 2.53-2.44 (2H, m, H-1, H-4); 2.28-2.06 (3H, m, H-3, H-
4, H-6); 2.11 (3H, s, CH3 Ac); 1.85-1.75 (1H, m, H-3). 13C RMN δ: 204.4 (C-5); 170.8 
(C=O Ac); 134.0 (C-2’); 117.0 (C-3’); 69.2 (C-2); 61.6 (C-1’); 46.5 (C-6); 43.9 (C-1); 
34.8 (C-4); 22.8 (C-3); 21.1 (CH3 Ac). IR: 1736, 1706 (C=O st); 1235 (C-O-C st); 1027 
(C-O-C st). [∝]𝐷
20𝑜𝐶= +184 (c=1.3; DCM). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C11H17NO3 210.1125; Found 210.1120. 
(+)-(1R,5R,6S)‐5‐Hydroxy‐7‐(prop‐2‐en‐1‐yl)‐7‐azabicyclo[4.1.0]heptan‐2‐one 56 
To a stirred solution of (+)-57 (540 mg, 2.58 mmol) in methanol (5 mL) 
was added potassium carbonate (37 mg, 10 mol%). After 1 hour, ammonium 
chloride (40 mg) was added. The salts were then filtered and the solution 
evaporated to dryness. 425 mg of alcohol 56 (99%,>99% e.e. HPLC) were 
obtained as a colorless oil. HPLC conditions: AD-H; 95:5 Hex:isopropanol; 
1.0ml.min-1; 210nm. 
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1H RMN δ: 5.91 (1H, ddt, J2’,3’=17.0, J2’,3’=10.4, J2’,1’=5.9, H-1’); 5.26 (1H, dq, 
J3’,2’=17.2, 2J=J3’,1’=1.5, H-3’); 5.19 (1H, dq, J3’,2’=10.3, 2J=J3’,1’=1.2, H-3’); 4.17-4.14 
(1H, m, H-5); 3.11 (1H, dd, 2J=13.8, J1’,2’=5.8, H-1’); 2.99 (1H, dd, 2J=13.8, J1’,2’=5.9, 
H-1’); 2.56-2.47 (2H, m, H-3, H-6);2.45 (1H, s br, OH); 2.19 (1H, d, J1,6=5.9, H-1); 
2.09-1.96 (2H, m, H-3, H-4); 1.86-1.77 (1H, m, H-4). 13C RMN δ: 206.2 (C-2); 133.9 
(C-2’); 117.9 (C-3’); 64.5 (C-5); 62.1 (C-1’); 48.1 (C-6); 47.4 (C-1); 33.8 (C-3); 29.7 
(C-4). IR: 3400 (OH st); 1694 (C=O st); 1054 (C-O st); 924 (CH bend).[∝]𝐷
20𝑜𝐶= +126 
(c=0.8; DCM). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C9H14NO2 168.1019; Found 
168.1015. 
(+)-(1R,5R,6S)‐5‐[(tert‐Butyldimethylsilyl)oxy]‐7‐(prop‐2‐en‐1‐yl)‐7‐
azabicyclo[4.1.0]heptan‐2‐one 55 
To a stirred solution of (+)-56 (50 mg, 0.30 mmol) in dry DCM (1 mL) under 
argon was added DBU (54 µL, 1.2 eq.) and tert-butyldimethylsilyl chloride (50 mg, 
1.1 eq.) at 0oC. After 1 hour, the reaction was quenched with a saturated sodium 
bicarbonate aqueous solution (2mL). The mixture was then extracted with DCM 
(3x5 mL). The combined organic phases were dried with magnesium sulfate and 
evaporated to dryness. Purification by flash column chromatography, eluted with 
Hex/AcOEt (95:5), afforded 80 mg (95%) of the pure compound 55 as colorless 
oil. 
1H RMN δ: 5.88 (1H, ddt, J2’,3’=17.1, J2’,3’=10.5, J2’,1’=5.3, H-2’); 5.37 (1H, dq, 
J3’,2’=17.3, 2J=J3’,1’=1.6, H-3’); 5.14 (1H, dq, J3’,2’=10.5, 2J=J3’,1’=1.5, H-3’); 4.10 (1H, 
ddd, J5,4=10.4, J5,4=5.0, J5,6=1.8, H-5); 3.25 (1H, ddt, 2J=14.5, J1’,2’=5.3, J1’,3’=1.5, H-
1’); 2.82 (1H, ddt, 2J=14.5, J1’,2’=5.1, J1’,3’=1.5, H-1’); 2.42 (1H, ddd, 2J=18.2, J3,4=5.0, 
J3,4=2.5, H-3), 2.21-2.00 (4H, m, H-1, H-3, H-4, H-6); 1.66-1.59 (1H, m, H-4); 0.92 
(9H, s, tBu TBS); 0.11 (3H, s, Me TBS); 0.10 (3H, s, Me TBS). 13C RMN δ: 205.8 (C-
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2); 134.1 (C-2’); 116.8 (C-3’); 67.7 (C-5); 61.8 (C-1’); 47.6, 46.8 (C-1, C-6); 35.4 (C-
3); 25.9 (C-4); 25.8 (3xMe tBu); 18.1 (Cq tBu); -4.58 (Me TBS); -4.63 (Me TBS). IR: 
1712 (C=O st), 1095 (Si-O st), 838 (Si-O-C bend). [∝]𝐷
20𝑜𝐶= +147 (c=0.8; DCM). 
Anal. Calcd for C15H27NO2Si: C 64.01; H 9.67; N 4.98. Found: C 64.21; H 9.46; N 
4.81. 
Ethyl (-)-(1R,5R,6S)‐5‐[(tert‐butyldimethylsilyl)oxy]‐2‐hydroxy‐7‐(prop‐2‐en‐1‐yl)‐7‐
azabicyclo[4.1.0]hept‐2‐ene‐3‐carboxylate 58 
To a solution of diisopropylamine (350 µL, 1.6 eq.) in THF (2.5 mL) under 
argon at 0°C was added n-butyllithium (1.46 mL, 1.6 M in Hexanes, 1.5 eq.) drop 
by drop, and the reaction mixture was stirred at this temperature for 15 minutes, 
then cooled at –78 °C and a solution of (+)-55 (440 mg, 1.56 mmol) in THF (2.5 
mL) was slowly added. Stirring at –78 °C was continued for further 30 minutes 
and ethyl cyanoformate (150 µL, 1.2 eq.) was then added. The reaction mixture 
was stirred at –78 °C for 1 hour. The reaction was quenched with saturated 
ammonium chloride aqueous solution (5mL).  The mixture was then extracted 
with DCM (3 x 5 mL), the combined organic phases were dried (MgSO4), and the 
solvent evaporated. Purification by flash column chromatography, eluted with 
Hex/AcOEt (95:5), afforded 440 mg (80%) of the pure compound 58 as a colorless 
oil. 
Although the two ketone tautomers can be observed in the 1H and 13C NMR 
spectra, only the enol is described. 
1H RMN δ: 12.30 (1H, s, OH); 5.80 (1H, ddt, J2’,1’=17.2, J2’,1’=10.5, J2’,3’=5.2, H-2’); 
5.37 (1H, dq, J3’,2’=17.3, 2J=J3’,1’=1.6, H-3’); 5.14 (1H, dq, J3’,2’=10.4, 2J=J3’,1’=1.5, H-
3’); 4.26-4.11 (2H, m, CH2 Et); 3.97 (1H, ddd, J5,4=9.6, J5,4=6.4, J5,6=2.4, H-5); 3.29 
(1H, dd, 2J=14.5, J1’,2’=5.2, H-1’); 2.74 (1H, dd, 2J=14.5, J1’,2’=5.2, H-1’); 2.44 (1H, 
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ddd, 2J=14.9, J4,5=6.6, J=1.5, H-4); 2.20-2.11 (2H, m, H-4, H-6); 2.07 (1H, d, J1,6=6.5, 
H-1); 1.27 (3H, t, 3J=7.1, CH3 Et); 0.91 (9H, s, tBu TBS); 0.11 (6H, s, 2x Me TBS). 13C 
RMN δ: 201.5 (C-2); 169.3 (C=O CO2Et); 134.2 (C-2’); 116.7 (C-3’); 101.6 (C-3); 67.2 
(C-5); 61.5 (C-1’); 60.5 (CH2 Et); 47.4 (C-6), 39.8 (C-1); 27.2 (C-4); 25.8 (3xMe tBu); 
18.1 (Cq tBu); 14.3 (CH3 Et); -4.59 (Me TBS); -4.63 (Me TBS). IR: 1651 (C=O st); 
1277, 1254, 1229 (C-O-C st, C-O st); 1090 (Si-O st), 837 (Si-O-C bend). [∝]𝐷
20𝑜𝐶= -
29 (c=0.7; DCM). Anal. Calcd for C18H31NO4Si: C 61.15; H 8.84; N 3.96. Found: C 
61.35; H 8.40; N 3.77. 
Ethyl (-)-(1S,5R,6S)‐5‐[(tert‐butyldimethylsilyl)oxy]‐7‐(prop‐2‐en‐1‐yl)‐7-
azabicyclo[4.1.0]hept‐2‐ene‐3‐carboxylate 59 
To a stirred solution of 58 (400 mg, 1.13 mmol) in ethanol abs. (3.5 mL) at 
0oC was added sodium borohydride (43 mg, 1 eq.) portionwise. After 1 hour, the 
reaction was quenched with a saturated ammonium chloride aqueous solution 
(3.5mL) and the mixture was extracted with DCM (2x 5mL). The combined organic 
phases were dried with magnesium sulfate and evaporated to dryness. The 
obtained crude (400 mg) was dissolved in dry pyridine (3.5 mL) under argon and 
mesyl chloride (175 µL, 2 eq.) was added at 0oC. After 1 hour of stirring at room 
temperature the reaction mixture was diluted with DCM (5 mL) and washed with 
water (5mL). The organic layer was dried with magnesium sulfate and evaporated 
to dryness. The obtained crude (515 mg) was dissolved in ethanol abs. (3.5 mL) 
and potassium carbonate (310 mg, 2 eq.) was added. After 1 hour, ammonium 
chloride (310 mg) was added. The salts were then filtered and the solution 
evaporated to dryness. Purification by flash column chromatography, eluted with 
Hex/AcOEt (9:1), afforded 190 mg (50%) of the pure compound 59 as colorless 
oil. 
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1H RMN δ: 7.12 (1H, dd, J2,1=4.6, J2,4=3.3, H-2); 5.88 (1H, ddt, J2’,3’=17.2, J2’,3’=10.5, 
J2’,1’=5.3, H-2’); 5.35 (1H, dq, J3’,2’=17.2, 2J=J3’,1’=1.7, H-3’); 5.11 (1H, dq, J3’,2’=10.5, 
2J=J3’,1’=1.4, H-3’); 4.17 (2H, q, 3J=7.1, CH2 Et); 4.00 (1H, ddd, J5,4=9.4, J5,4=6.8, 
J5,6=2.3, H-5); 3.21 (1H, ddt, 2J=14.4, J1’,2’=5.3, J1’,3’=1.4, H-1’); 2.77 (1H, ddt, 
2J=14.5, J1’,2’=5.1, J1’,3’=1.5, H-1’); 2.67 (1H, dd, 2J=16.5, J4,5=6.5, H-4); 2.20 (1H, 
ddd, 2J=16.4, J4,5=9.7, J4,2=3.1, H-4); 2.08 (1H, dt, J6,1=6.3, J6,5= J6,4=2.0, H-6); 2.00 
(1H, dd, J1,6=6.1, J1,2=4.9, H-1); 1.27 (3H, t, 3J=7.1, CH3 Et); 0.92 (9H, s, tBu TBS); 
0.11 (6H, s, 2x Me TBS). 13C RMN δ: 166.3 (C=O CO2Et); 135.8 (C-2); 134.6 (C-2’); 
130.7 (C-3); 116.5 (C-3’); 67.1 (C-5); 61.9 (C-1’); 60.5 (CH2 Et); 47.6 (C-6), 37.1 (C-
1); 30.5 (C-4); 25.8 (3xMe tBu); 18.1 (Cq tBu); 14.3 (CH3 Et); -4.56 (Me TBS); -4.61 
(Me TBS). IR: 1712 (C=O st); 1250 (C-O-C st); 1070 (Si-O st), 836 (Si-O-C bend). 
[∝]𝐷
20𝑜𝐶= -70 (c=0.7; DCM). Anal. Calcd for C18H31NO3Si: C 64.05; H 9.26; N 4.15. 
Found: C 64.08; H 9.37; N 4.21. 
Ethyl (-)-(1S,5R,6S)‐5‐hydroxy‐7‐(prop‐2‐en‐1‐yl)‐7‐azabicyclo[4.1.0]hept‐2‐ene‐3‐
carboxylate 60 
To a stirred solution of 59 (100 mg, 0.296 mmol) in dry tetrahydrofuran 
(3 mL) under argon was added tetrabutylammonium fluoride (530 µL, 1 M in THF, 
1.8 eq.). After 1 hour, the reaction mixture was diluted with DCM (3 mL) and 
washed with water (3 mL). The organic layer was dried with magnesium sulfate 
and evaporated to dryness. Purification by flash column chromatography, eluted 
with Hex/AcOEt (1:1), afforded 66 mg (100%) of the pure compound 60 as white 
solid. 
1H RMN δ: 7.14 (1H, dd, J2,1=4.6, J2,4=3.3, H-2); 5.92 (1H, ddt, J2’,3’=16.2, J2’,3’=10.5, 
J2’,1’=5.8, H-2’); 5.26 (1H, dq, J3’,2’=17.2, 2J=J3’,1’=1.6, H-3’); 5.16 (1H, dq, J3’,2’=10.4, 
2J=J3’,1’=1.2, H-3’); 4.18 (2H, q, 3J=7.1, CH2 Et); 4.00 (1H, tdd, J5,4=J5,OH=8.8, J5,4=6.6, 
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J5,6=2.3, H-5); 3.06 (1H, dd, 2J=13.9, J1’,2’=5.4, H-1’); 2.95 (1H, dd, 2J=14.0, J1’,2’=5.7, 
H-1’); 2.86 (1H, ddd, 2J=16.4, J4,5=6.6, J4,6=1.3, H-4); 2.30 (1H, dt, J6,1=6.3, 
J6,5=J6,4=2.0, H-6); 2.14-2.04 (2H, m, H-1, H-4); 1.66 (1H, d, JOH,5=8.6, OH); 1.27 
(3H, t, 3J=7.1, CH3 Et). 13C RMN δ: 166.1 (C=O CO2Et); 135.5 (C-2); 134.7 (C-2’); 
130.5 (C-3); 117.2 (C-3’); 66.1 (C-5); 62.1 (C-1’); 60.7 (CH2 Et); 46.7 (C-6); 37.9 (C-
1); 30.5 (C-4); 14.2 (CH3 Et). IR: 3400 (OH st); 1705 (C=O st); 1242 (C-O-C st, C-O 
st); 1036 (C-O-C st). [∝]𝐷
20𝑜𝐶= -140 (c=0.7; DCM). M.p. = 82oC. Anal. Calcd for 
C12H17NO3: C 64.55; H 7.67; N 6.27. Found: C 64.67; H 7.87; N 6.50. 
Ethyl (-)-(3R,4R,5R)‐5‐hydroxy‐3‐(pentan‐3‐yloxy)‐4‐[(prop‐2‐en‐1‐
yl)amino]cyclohex‐1‐ene‐1‐carboxylate 61 
To a stirred solution of 60 (120 mg, 0.54 mmol) in 3-pentanol (3.5 mL) 
under argon was added boron trifluoride diethyl etherate (100 µL, 1.5 eq.). After 
30 minutes of stirring at 70oC the reaction was quenched with a saturated sodium 
bicarbonate aqueous solution (5mL) and the mixture was extracted with AcOEt 
(3x5mL). The combined organic phases were dried with magnesium sulfate and 
evaporated to dryness. Purification by flash column chromatography, eluted with 
AcOEt, afforded 150 mg (90%) of the pure compound 61 as white solid. 
1H RMN δ: 6.86 (1H, q, J2,3=J2,6=1.9, H-2); 5.90 (1H, dddd, J2’,3’=16.8, J2’,3’=10.3, 
J2’,1’=6.3, J2’,1’=5.4, H-2’); 5.22 (1H, dq, J3’,2’=17.2, 2J=J3’,1’=1.5, H-3’); 5.12 (1H, dq, 
J3’,2’=10.3, 2J=J3’,1’=1.4, H-3’); 4.20 (2H, q, 3J=7.1, CH2 Et); 4.17-4.14 (1H, m, H-5); 
4.03 (1H, dq, J3,4=8.1, J3,2= J3,6=2.2, H-3); 3.39-3.32 (2H, m, H-1’, CH pentyl); 3.23 
(1H, ddt, 2J=14.2, J1’,2’=6.4, J1’,3’=1.2, H-1’); 2.72 (1H, dd, J4,3=8.1, J4,5=2.5, H-4); 
2.58 (1H, ddt, 2J=18.8, J6,5=3.1, J6,2=J6,3=1.6, H-6); 2.48 (1H, ddt, 2J=18.9, J6,5=4.9, 
J6,2=J6,3=2.6, H-6); 2.40 (2H, s br, OH, NH); 1.64-1.44 (4H, m, CH2 pentyl); 1.28 (3H, 
t, 3J=7.1, CH3 Et); 0.94 (3H, t, 3J=7.4, CH3 pentyl); 0.92 (3H, t, 3J=7.5, CH3 pentyl). 
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13C RMN δ: 166.6 (C=O CO2Et); 136.4 (C-2’); 136.3 (C-2); 128.5 (C-1); 116.1 (C-3’); 
81.0 (CH pentyl); 73.2 (C-3); 63.8 (C-5); 60.8 (C-4); 60.6 (CH2 Et); 49.3 (C-1’); 29.9 
(C-6); 26.5, 25.6 (2xCH2 pentyl); 14.2 (CH3 Et); 9.7, 9.5 (2xCH3 pentyl). IR: 3400 
(OH st, NH st); 1715 (C=O st); 1251 (C-O-C st); 1054 (C-O-C st). [∝]𝐷
20𝑜𝐶= -123 
(c=1.0; DCM). M.p. = 95-95.5oC. Anal. Calcd for C12H17NO3: C 65.57; H 9.39; N 
4.50. Found: C 65.83; H 9.61; N 4.75. 
Ethyl (-)-(3R,4R,5R)‐4‐acetamido‐5‐hydroxy‐3‐(pentan‐3‐yloxy)cyclohex‐1‐ene‐1‐
carboxylate 62 
In a flask under argon a mixture of bis(dibenzylideneacetone)palladium(0) 
(26 mg, 10 mol%), 1,4-Bis(diphenylphosphino)butane (20 mg, 10 mol%) and dry 
tetrahydrofuran (1 mL) was stirred at room temperature for 15 minutes. This 
mixture was then added to a stirred solution of 61 (140 mg, 0.45 mmol) in 
tetrahydrofuran (1 mL) under argon followed by addition of thiosalicylic acid (143 
mg, 2 eq.). After 30 minutes of stirring at 60oC the reaction was cooled to 0oC and 
pyridine (180 µL, 5 eq.) and acetic anhydride (47 µL, 1.1 eq.) were added. After 
additional 15 minutes of stirring at room temperature the reaction was quenched 
with a saturated sodium bicarbonate aqueous solution (2mL) and the mixture 
was extracted with AcOEt (3x 2mL). The combined organic phases were dried 
with magnesium sulfate and evaporated to dryness. Purification by flash column 
chromatography, eluted with AcOEt, afforded 117 mg (83%) of the pure 
compound 62 as white solid. 
1H RMN δ: 6.84 (1H, dt, J2,3=3.3, J2,6=1.8, H-2); 5.93 (1H, d, JNH,4=7.0, NH); 4.30 
(1H, td, J5,6=4.9, J5,4=2.3, H-5); 4.25-4.21 (1H, m, H-3); 4.21 (2H, q, 3J=7.1, CH2 Et); 
3.90 (1H, td, J4,3=J4,NH=7.2, J4,5=2.3, H-4); 3.40 (1H, p, 3J=5.8, CH pentyl); 2.69 (1H, 
ddt, 2J=18.5, J6,5=4.3, J6,2=J6,3=2.1, H-6); 2.43 (1H, ddt, 2J=18.5, J6,5=5.3, 
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J6,2=J6,3=1.3, H-6); 2.04 (3H, s, CH3 Ac); 1.58-1.48 (4H, m, 2xCH2 pentyl); 1.29 (3H, 
t, 3J=7.1, CH3 Et); 0.92 (6H, t, 3J=7.4, 2xCH3 pentyl). 13C RMN δ: 171.7 (C=O Ac); 
166.5 (C=O CO2Et); 136.0 (C-2); 129.3 (C-1); 81.9 (CH pentyl); 72.6 (C-3); 67.1 (C-
5); 60.9 (CH2 Et); 55.1 (C-4); 31.5 (C-6); 26.3, 26.0 (2xCH2 pentyl); 23.5 (CH3 Ac); 
14.2 (CH3 Et); 9.6, 9.5 (2xCH3 pentyl). IR: 3300 (OH st, NH st); 1714 (C=O st ester); 
1651 (C=O st amide); 1545 (Amide II); 1250 (C-O-C st); 1092, 1054 (C-O-C st). 
[∝]𝐷
20𝑜𝐶= -100 (c=1.7; AcOEt) [lit39: [∝]𝐷
25𝑜𝐶= -104 (c=3.0; AcOEt)]. M.p. = 132oC 
(lit39: 131.9-132.2oC). 
(+)-(1R,5R,6S)‐5‐[(tert‐Butyldimethylsilyl)oxy]‐7‐(prop‐2‐en‐1‐yl)‐7‐
azabicyclo[4.1.0]hept‐2‐en‐2‐yl diethyl phosphate 63 
To a solution of diisopropylamine (600 µL, 1.6 eq.) in THF (5 mL) under 
argon at 0°C was added n-butyllithium (2.5 mL, 1.6 M in Hexanes, 1.5 eq.) drop 
by drop, and the reaction mixture was stirred at this temperature for 15 minutes, 
then cooled at –78 °C and a solution of (+)-55 (750 mg, 2.7 mmol) in THF (5 mL) 
was slowly added. Stirring at –78 °C was continued for further 30 minutes and 
diethyl cyanophosphonate (480 µL, 1.2 eq.) was then added. The reaction 
mixture was stirred at –78 °C for 1 hour. The reaction was quenched with 
saturated ammonium chloride aqueous solution (10mL).  The mixture was then 
extracted with DCM (3 x 10 mL), the combined organic phases were dried 
(MgSO4), and the solvent evaporated. Purification by flash column 
chromatography, eluted with Hex:AcOEt (2:1), afforded 962 mg (80%) of the pure 
compound 63 as colorless oil. 
1H RMN δ: 5.89 (1H, ddt, J2’,3’=17.2, J2’,3’=10.5, J2’,1’=5.3, H-2’); 5.37 (1H, dq, 
J3’,2’=17.3, 2J=J3’,1’=1.7, H-3’); 5.29-5.23 (1H, m, H-3); 5.11 (1H, dq, J3’,2’=10.5, 
2J=J3’,1’=1.5, H-3’); 4.22-4.13 (4H, m, 2xCH2 Et); 4.04 (1H, t, J=8.0, H-5); 3.25 (1H, 
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ddt, 2J=14.5, J1’,2’=5.2, J1’,3’=1.5, H-1’); 2.69 (1H, ddt, 2J=14.6, J1’,2’=5.2, J1’,3’=1.4, H-
1’); 2.23-2.03 (4H, m, H-1, H-4, H-6); 1.37 (3H, td, 3J=7.1, 4JH,P=1.0, CH3 Et); 1.36 
(3H, td, 3J=7.1, 4JH,P=1.0, CH3 Et); 0.91 (9H, s, tBu TBS); 0.09 (3H, s, Me TBS); 0.07 
(3H, s, Me TBS). 13C RMN δ: 145.5 (d, 2JC,P=9, C-2); 134.6 (C-2’); 116.4 (C-3’); 107.6 
(d, 3JC,P=5, C-3); 66.6 (C-5); 64.44 (d, 2JC,P=6, CH2 Et); 64.38 (d, 2JC,P=6, CH2 Et); 61.5 
(C-1’); 46.7 (C-6), 39.1 (d, 3JC,P=6, C-1); 29.3 (C-4); 25.8 (3xMe tBu); 18.1 (Cq tBu); 
16.1 (d, 3JC,P=7, CH3 Et); -4.63 (Me TBS); -4.66 (Me TBS). 31P RMN δ: -6.2. IR (Neat): 
1033 (P-O-C st). [∝]𝐷
20𝑜𝐶= +45 (c=1.1; DCM). HRMS (ESI-TOF) m/z: [M+H]+ Calcd 
for C19H37NO5PSi 418.2173; Found 418.2177. 
Diethyl (+)-[(1R,5R,6S)‐5‐[(tert‐butyldimethylsilyl)oxy]‐2‐oxo‐7‐(prop‐2‐en‐1‐yl)‐7-
azabicyclo[4.1.0]heptan‐3‐yl]phosphonate 64 
To a solution of diisopropylamine (875 µL, 2.4 eq.) in THF (5 mL) under 
argon at 0°C was added n-butyllithium (3.6 mL, 1.6 M in Hexanes, 2.2 eq.) drop 
by drop, and the reaction mixture was stirred at this temperature for 15 minutes, 
then cooled at –78 °C and a solution of 63 (1.1 g, 2.6 mmol) in THF (5 mL) was 
slowly added. After 30 minutes of stirring at this temperature the reaction was 
quenched with saturated ammonium chloride aqueous solution (10mL).  The 
mixture was then extracted with DCM (3 x 10 mL), the combined organic phases 
were dried (MgSO4), and the solvent evaporated. Purification by flash column 
chromatography, eluted with Hex:AcOEt (2:1), afforded 996 mg (91%) of the pure 
compound 64 as colorless oil. 
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1H NMR δ: 10.92 (0.1H, s, OH II), 5.93-5.81 (1H, m, H-2’); 5.40-5.34 (1H, 
m, H-3’); 5.29-5.23 (1H, m, H-3); 5.13 (1H, d, J3’,2’=10.5, H-3’); 4.56-4.51 (0.5H, m, 
H-5 I); 4.3-3.9 (4.5H, m, 2xCH2 Et, H-5); 3.31-3.12 (1H, m, H-1’); 2.99-2.69 (1.9H, 
m, H-3, H-1’); 2.54 (0.4H, p, 2J=3JH,P=J4,3= J4,2=12.4, H-4 II); 2.39-1.85 (3.6H, H-1, H-
4, H-6); 1.36-1.31 (3H, m, CH3 Et); 0.926, 0.914, 0.910 (9H, s, tBu TBS); 0.13, 0.103, 
0.095 (6H, s, Me TBS).13C NMR δ: 200.2 (d, 2JC,P=7, C-2 III); 199.7 (d, 2JC,P=5, C-2 I); 
168.0 (d, 2JC,P=7, C-2 II); 134.4 (II), 134.0 (I), 133.8 (III) (C-2’); 116.9 (I), 116.8 (III), 
116.5 (II) (C-3’); 84.5 (d, 1JC,P=183, C-3 II); 67.5 (d, 3JC,P=4, C-5 II); 67.5 (d, 3JC,P=11, 
C-5 II); 67.4 (d, 3JC,P=18, C-5 III); 65.1 (d, 3JC,P=1, C-5 I); 63.0 (d, 2JC,P=7), 62.6 (d, 
2JC,P=6), 62.4 (d, 2JC,P=7), 61.7 (d, 2JC,P=4) (CH2 Et); 61.9 (I), 61.5 (II), 61.2 (III) (C-1’); 
48.3 (d, 4JC,P=1, C-6 III); 48.1 (d, 3JC,P=4, C-1 III); 46.8 (C-6 I); 46.5 (d, 3JC,P=1, C-1 III); 
46.3 (d, 4JC,P=2, C-6 III); 45.5 (d, 1JC,P=126, C-3 I); 44.9 (d, 1JC,P=134, C-3 III); 40.6 (d, 
3JC,P=19, C-1 II); 27.5 (d, 3JC,P=5, C-4 II); 27.4 (d, 3JC,P=3, C-4 III); 27.0 (d, 3JC,P=6, C-4 
I); 25.8, 25.7 (3xMe tBu); 18.14 (II), 18,10 (I), 18.0 (III) (Cq tBu); 16.43, 16.37, 16.34, 
16.28, 16.21, 16.19, 16.14 (CH3 Et); -4.65, -4.67, -4.73 (Me TBS). 31P NMR δ: 26.1; 
22.9; 21.4. FTIR (Neat): 1705 (C=O st); 1253 (P=O st; Si-C st); 1094, 1052, 1026 (P-
O-C st, Si-O-C st); 838 (Si-O-C bend); 774 (P-O-C st). [∝]𝐷
20𝑜𝐶= +71 (c=1.2; DCM). 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C19H37NO5PSi 418.2173; Found 418.2169. 
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Diethyl (-)-[(1S,5R,6S)‐5‐[(tert‐butyldimethylsilyl)oxy]‐7‐(prop‐2‐en‐1‐yl)‐7‐
azabicyclo[4.1.0]hept‐2‐en‐3‐yl]phosphonate 65 
To a stirred solution of 64 (750 mg, 1.8 mmol) in ethanol abs. (7 mL) under 
argon at -78oC was added sodium borohydride (68 mg, 1 eq.) portionwise. After 
1 hour, the reaction was quenched with a saturated ammonium chloride aqueous 
solution (7mL) and the mixture was extracted with DCM (3x 10mL). The combined 
organic phases were dried with magnesium sulfate and evaporated to dryness. 
The obtained crude (750 mg) was dissolved in dry DCM (7 mL) under argon and 
triethylamine (920 µL, 3 eq.) and mesyl chloride (280 µL, 2 eq.) were added at 
0oC. After 3 hours of stirring at room temperature, the reaction mixture was 
quenched with water (10mL) and then extracted with DCM (3x 10mL). The 
organic layer was dried with magnesium sulfate and evaporated to dryness. The 
obtained crude (1.2 g) was dissolved in dry DCM (7 mL) under argon and DBU 
(400 µL, 1.5 eq.) was added at 0oC. After 1 hour of stirring at room temperature 
the reaction was treated using the same procedure above. Purification by flash 
column chromatography, eluted with Hex:AcOEt (1:2), afforded 339 mg (47%) of 
the pure compound 65 as colorless oil. 
1H RMN δ: 6.91 (1H, ddd, 3JH,P=20.0, J2,1=4.3, J2,5=3.2, H-2); 5.87 (1H, ddt, 
J2’,3’=17.2, J2’,3’=10.4, J2’,1’=5.2, H-2’); 5.33 (1H, dq, J3’,2’=17.2, 2J=J3’,1’=1.7, H-3’); 
5.11 (1H, dq, J3’,2’=10.5, 2J=J3’,1’=1.5, H-3’); 4.10-3.95 (5H, m, H-5, 2xCH2 Et); 3.10 
(1H, ddt, 2J=14.6, J1’,2’=5.3, J1’,3’=1.4, H-1’); 2.85 (1H, ddt, 2J=14.6, J1’,2’=5.0, 
J1’,3’=1.6, H-1’); 2.38-2.20 (2H, m, H-4); 2.04 (1H, dt, J6,1=6.3, 5JH,P=J6,5=1.8, H-6); 
1.98 (1H, dt, 4JH,P=10.9, J1,6=J1,2=4.8, H-1);  1.31 (3H, t, 3J=7.0, CH3 Et); 1.30 (3H, t, 
3J=7.0, CH3 Et); 0.92 (9H, s, tBu TBS); 0.11 (3H, s, Me TBS); 0.10 (3H, s, Me TBS). 
13C RMN δ: 140.0 (d, 2JC,P=10, C-2); 134.7 (C-2’); 128.3 (d, 1JC,P=184, C-3); 116.3 (C-
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3’); 66.6 (d, 3JC,P=12, C-5); 61.9 (C-1’); 61.8 (d, 2JC,P=5, CH2 Et); 61.6 (d, 2JC,P=5; CH2 
Et); 46.7 (d, 4JC,P=2, C-6), 37.8 (d, 3JC,P=24, C-1); 30.9 (d, 2JC,P=8, C-4); 25.8 (3xMe 
tBu); 18.1 (Cq tBu); 16.3 (d, 3JC,P=6, CH3 Et); -4.6 (2xMe TBS). 31P RMN δ: 18.2. IR 
(Neat): 1250 (P=O st; Si-C st); 1090, 1069, 1054, 1026, 965 (P-O-C st, Si-O-C st); 
837 (Si-O-C bend); 777 (P-O-C st). [∝]𝐷
20𝑜𝐶= -1 (c=1.0; DCM). HRMS (ESI-TOF) m/z: 
[M+H]+ Calcd for C19H37NO4PSi 402.2224; Found 402.2230. 
Diethyl (-)-[(1S,5R,6S)‐5‐hydroxy‐7‐(prop‐2‐en‐1‐yl)‐7‐azabicyclo[4.1.0]hept‐2‐en‐
3‐yl]phosphonate 66 
To a stirred solution of 65 (330 mg, 0.82 mmol) in dry tetrahydrofuran (3 
mL) under argon was added tetrabutylammonium fluoride (1.5 mL, 1 M in THF, 
1.8 eq.). After 1 hour of stirring at room temperature the reaction mixture was 
quenched with water (5mL) and then extracted with AcOEt (3x 5mL). The organic 
layer was dried with magnesium sulfate and evaporated to dryness. Purification 
by flash column chromatography, eluted with DCM/methanol (95:5), afforded 
238 mg (100%) of the pure compound 66 as colorless oil. 
1H RMN δ: 6.93 (1H, dt, 3JH,P=20.0, J2,1=J2,5=3.1, H-2); 5.90 (1H, ddt, J2’,3’=16.6, 
J2’,3’=11.0, J2’,1’=5.5, H-2’); 5.25 (1H, d, J3’,2’=17.2, H-3’); 5.15 (1H, d, J3’,2’=10.4, H-
3’); 4.16-3.95 (5H, m, H-5, 2xCH2 Et); 3.02 (1H, dd, 2J=14.3, J1’,2’=3.5, H-1’); 2.96 
(1H, dd, 2J=14.2, J1’,2’=5.6, H-1’); 2.54 (1H, ddd, 2J=16.3, 3JH,P=11.1, J4,5=5.7, H-4); 
2.26 (1H, d, J6,1=6.0, H-6); 2.16-1.96 (1H, m, H-1, H-4, OH); 1.31 (3H, t, 3J=6.4, CH3 
Et); 1.30 (3H, t, 3J=6.1, CH3 Et). 13C RMN δ: 139.6 (d, 2JC,P=10, C-2); 134.8 (C-2’); 
128.3 (d, 1JC,P=185, C-3); 117.0 (C-3’); 65.7 (d, 3JC,P=11, C-5); 62.0 (C-1’); 61.9 (d, 
2JC,P=6, CH2 Et); 61.8 (d, 2JC,P=6; CH2 Et); 45.8 (C-6), 38.4 (d, 3JC,P=23, C-1); 30.9 (d, 
2JC,P=8, C-4); 16.4 (d, 3JC,P=6, CH3 Et); 16.3 (d, 3JC,P=6, CH3 Et). 31P RMN δ: 17.8. IR 
(Neat): 3370 (O-H st); 1227 (P=O st); 1021, 966 (P-O-C st, C-OH st). [∝]𝐷
20𝑜𝐶= -37 
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(c=0.5; DCM). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C13H23NO4P 288.1359; 
Found 288.1358. 
Diethyl (-)-[(3R,4R,5R)‐5‐hydroxy‐3‐(pentan‐3‐yloxy)‐4‐[(prop‐2‐en‐1‐
yl)amino]cyclohex‐1‐en‐1‐yl]phosphonate 67 
To a stirred solution of 66 (150 mg, 0.52 mmol) in 3-pentanol (3.5 mL) 
under argon was added boron trifluoride diethyl etherate (100 µL, 1.5 eq.). After 
30 minutes of stirring at 70oC the reaction was quenched with a saturated sodium 
bicarbonate aqueous solution (5mL) and the mixture was extracted with AcOEt 
(3x 5mL). The combined organic phases were dried with sodium sulfate and 
evaporated to dryness, affording 200 mg (100%) of the pure compound 67 as 
colorless oil. 
1H RMN δ: 6.66 (1H, d, 3JH,P=21.8, H-2); 5.93 (1H, dd, J2’,3’=16.7, J2’,3’=11.1, 
J2’,1’=5.6, H-2’); 5.27 (1H, d, J3’,2’=17.2, H-3’); 5.18 (1H, d, J3’,2’=10.0, H-3’); 4.22 (1H, 
br s, H-5); 4.12-4.03 (5H, m, H-3, 2xCH2 Et); 3.47-3.33 (3H, m, H-1’, CH pentyl); 
2.79 (1H, br d, J=7.8, H-4); 2.51-2.38 (2H, m, H-6); 1.63-1.40 (4H, m, 2xCH2 pentyl); 
1.32 (6H, td, 3J=7.1, 4JH,P=3.0, 2xCH3 Et); 0.92 (3H, t, 3J=7.7, CH3 pentyl); 0.91 (3H, 
t, 3J=7.5, CH3 pentyl). 13C RMN δ: 139.9 (d, 2JC,P=7, C-2); 135 (br, C-2’); 126.4 (d, 
1JC,P=181, C-1); 118 (br, C-3’); 80.8 (CH pentyl); 72.7 (d, 3JC,P=21, C-3); 63.8 (d, 
3JC,P=12, C-5); 62.0 (d, 2JC,P=5; CH2 Et); 61.9 (d, 2JC,P=6; CH2 Et); 60.8 (C-4); 49.4 (H-
1’); 30.0 (d, 3JC,P=79, C-6); 26.4, 25.4 (2x CH2 pentyl); 16.4 (d, 3JC,P=6, 2xCH3 Et); 
9.7, 9.4 (2xCH3 pentyl). 31P RMN δ: 18.1. IR (Neat): 3370 (O-H st, NH st); 1226 
(P=O st); 1091, 1052, 1024, 969 (P-O-C st, C-OH st, C-O-C st). [∝]𝐷
20𝑜𝐶= -107 (c=0.9; 
DCM). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C18H35NO5P 376.2247; Found 
376.2257. 
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Diethyl (-)-[(3R,4R,5R)‐4‐acetamido‐5‐hydroxy‐3‐(pentan‐3‐yloxy)cyclohex‐1‐en‐1‐
yl]phosphonate 68 
In a flask under argon a mixture of bis(dibenzylideneacetone)palladium(0) 
(11.5 mg, 10 mol%), 1,4-Bis(diphenylphosphino)butane (8.7 mg, 10 mol%) and 
dry tetrahydrofuran (0.5 mL) was stirred at room temperature for 15 minutes. 
This mixture was then added to a stirred solution of 67 (75 mg, 0.20 mmol) in 
tetrahydrofuran (0.5 mL) under argon followed by addition of 1,3-
dimethylbarbituric acid (62 mg, 2 eq.). After 30 minutes of stirring at 60oC the 
reaction was cooled to 0oC and triethylamine (170 µL, 6 eq.) and acetic anhydride 
(80 µL, 4 eq.) were added. After additional 60 minutes of stirring at room 
temperature the reaction was quenched with a saturated sodium bicarbonate 
aqueous solution (2mL) and the mixture was extracted with AcOEt (3x 2mL). The 
combined organic phases were dried with magnesium sulfate and evaporated to 
dryness. The obtained crude was dissolved in ethanol abs. (1 mL) and potassium 
tert-butoxide  (4.4 mg, 20 mol%) was added. After 1 hour, ammonium chloride 
(5 mg) was added. The salts were then filtered and the solution evaporated to 
dryness. Purification by flash column chromatography, eluted with DCM:MeOH 
(93:7), afforded 53 mg (70%) of the pure compound 68 as colorless oil. 
1H RMN δ: 6.66-6.60 (1H, br s, NH); 6.58 (1H, d, 3JH,P=22.0, H-2); 4.21 (1H, br s, H-
5); 4.16 (1H, br d, J=6.5, H-3); 4.12-4.03 (4H, m, 2xCH2 Et); 3.96 (1H, br t, J=7.5, H-
4); 3.7 (1H, br s, OH); 3.35 (1H, p, 3J=5.5,CH pentyl); 2.51 (1H, br d, 2J=17.8, H-6); 
2.36 (1H, dt, 2J=18.0, J=4.6, H-6); 2.03 (3H, s, CH3 Ac); 1.54-1.47 (4H, m, 2xCH2 
pentyl); 1.33 (6H, t, 3J=7.1, 2xCH3 Et); 0.90 (6H, t, 3J=7.5, 2xCH3 pentyl). 13C RMN 
δ: 171,6 (C=O Ac); 140.2 (C-2); 126.5 (d, 1JC,P=185, C-1); 82.0 (CH pentyl); 73.0 (d, 
3JC,P=21, C-3); 67.4 (d, 3JC,P=12, C-5); 62.3 (d, 2JC,P=6; CH2 Et); 62.1 (d, 2JC,P=6; CH2 
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Et); 54.6 (C-4); 31.8 (d, 3JC,P=9, C-6); 26.3, 25.8 (2xCH2 pentyl); 23.3 (CH3 Ac); 16.3 
(d, 3JC,P=6, 2xCH3 Et); 9.54, 9.45 (2xCH3 pentyl). 31P RMN δ: 17.6. IR (Neat): 3300 
(O-H st, NH st); 1652 (C=O st); 1553 (amide II); 1230 (P=O st); 1087, 1052, 1022, 
965 (P-O-C st, C-OH st, C-O-C st). [∝]𝐷
20𝑜𝐶= -132 (c=0.7; DCM). HRMS (ESI-TOF) 
m/z: [M+H]+ Calcd for C17H32NO6P 378.2040; Found 378.2055. 
(-)-(1R,5R,6S)‐3‐(Diethoxyphosphoryl)‐6‐acetamido‐5‐(pentan‐3‐yloxy)cyclohex‐3‐
en‐1‐yl methanesulfonate 69 
To a stirred solution of 68 (40 mg, 0.11 mmol) in dry DCM (1 mL) under 
argon was added triethylamine (30 µL, 2 eq.) and mesyl chloride (12 µL, 1.5 eq.) 
at 0oC. After 1 hour of stirring at room temperature the reaction was quenched 
with a saturated sodium bicarbonate aqueous solution (2mL) and the mixture 
was extracted with AcOEt (3x 2mL). The combined organic phases were dried 
with magnesium sulfate and evaporated to dryness, affording 48 mg (99%) of the 
pure compound 69 as a white solid. 
1H RMN δ: 6.67 (1H, d, 3JH,P=21.6, H-4); 5.83 (1H, d, JNH,6=8.1, NH); 5.24-5.20 (1H, 
m, H-1); 4.31 (1H, td, J6,NH=J6,5=8.2, J6,1=2.2, H-6); 4.14-4.05 (4H, m, 2xCH2 Et); 4.01 
(1H, dm, J=8.2, H-5); 3.36 (1H, p, 3J=5.4, CH pentyl); 3.05 (3H, s, CH3 Ms); 2.77-
2.61 (2H, m, H-2); 2.03 (3H, s, CH3 Ac); 1.56-1.48 (4H, m, 2xCH2 pentyl); 1.34 (6H, 
td, 3J=7.1, JH,P=0.7, 2xCH3 Et); 0.91 (3H, t, 3J=7.4, CH3 pentyl); 0.90 (3H, t, 3J=7.4, 
CH3 pentyl). 13C RMN δ: 170,7 (C=O Ac); 140.7 (d, 2JC,P=7, C-4); 125.7 (d, 1JC,P=184, 
C-3); 82.3 (CH pentyl); 78.1 (d, 3JC,P=13, C-1); 72.7 (d, 3JC,P=20, C-5); 62.4 (d, 2JC,P=6; 
CH2 Et); 62.2 (d, 2JC,P=6; CH2 Et); 51.6 (d, 4JC,P=2, C-6); 38.6 (CH3 Ms); 29.9 (d, 
3JC,P=10, C-2); 26.3, 25.8 (2xCH2 pentyl); 23.2 (CH3 Ac); 16.3 (d, 3JC,P=6, 2xCH3 Et); 
9.43, 9.38 (2xCH3 pentyl). 31P RMN δ: 16.3. IR (Neat): 3276 (NH st); 1658 (C=O st); 
1549(amide II); 1354 (O=S=O st); 1234 (P=O st); 1176 (O=S=O st); 1093, 1051, 
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1022, 970, 906 (P-O-C st, S-O-C st, C-O-C st). [∝]𝐷
20𝑜𝐶= -110 (c=1.2; AcOEt) [lit35: 
[∝]𝐷
22𝑜𝐶= -102.5 (c=0.4; AcOEt)]. M.p. = 106-108°C. 
1-(Cyclohexylsulfanyl)ethan-1-one 7661 
To a stirred solution of cyclohexyl 4-methylbenzene-1-sulfonate62 (4,0 g, 
15.7 mmol) in dry acetonitrile (60 mL) under argon was added potassium acetate 
(2.2 g, 1.2 eq.) at room temperature. The reaction mixture was stirred for 20 
hours at 60°C. Afterwards, was quenched with water (60mL) and the mixture was 
extracted with Et2O (3x 30mL). The combined organic phases were dried with 
magnesium sulfate and evaporated to dryness. Purification by flash column 
chromatography, eluted with Hex:AcOEt (98:2), afforded 492 mg (20%) of the 
pure compound as 76 yellow oil. 
Methyl cyclohexanesulfonate 78 
To a stirred solution of 76 (50 mg, 0.32 mmol) in dry acetonitrile (1 mL) 
under argon was added water (17 µL, 3 eq.) and tert-butyl hypochlorite (110 µL, 
3 eq.) at 0°C. After 30 min of stirring at this temperature, diisopropylethylamine 
(220 µL, 4 eq.) and methanol (30 µL, 2 eq.) were added and the reaction mixture 
was allowed to stir for 3 hours at room temperature. Afterwards, was quenched 
with saturated sodium bicarbonate aqueous solution (5 mL) and the mixture was 
extracted with DCM (3x5mL). The combined organic phases were dried with 
magnesium sulfate and evaporated to dryness. Purification by flash column 
chromatography, eluted with Hex:AcOEt (9:1), afforded 29 mg (51%) of the pure 
compound 78 as colorless oil. 
1H NMR δ: 3.89 (3H, s, OMe); 3.04 (1H, tt, J1,2=12.1, J1,2=3.4, H-1); 2.21 (2H, d, 
2J=13.0, H-2); 1.91 (2H, d, 2J=13.1, H-3); 1.72 (1H, d, 2J=11.2, H-4); 1.59 (2H, qd, 
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2J=J2,1= J2,3=12.4, J2,3=2.9, H-2); 1.36-1.17 (3H, m, H-3, H-4). 13C NMR δ: 59.5 (C-1); 
55.0 (OMe); 26.4 (C-2); 25.0 (C-3); 24.9 (C-4). FTIR(Neat): 1338, 1162 (O=S=O st); 
984 (S-O-C st).  
N-Benzylcyclohexanesulfonamide 79 
By means of the same procedure as for 78, except that 5 eq. of 
benzylamine were used instead of diisopropylethylamine and methanol, 41 mg 
(78% yield) of the pure product 79 were obtained as white solid after purification 
by chromatography (preparative plate eluted with 6:4 Hex:EtOAc). 
1H NMR δ: 7.38-7.28 (5H, m, Ar); 4.39 (1H, br s, NH); 4.30 (2H, s, CH2 Bn); 2.77 
(1H, tt, J1,2=12.1, J1,2=3.3, H-1); 2.15 (2H, d, 2J=12.8, H-2); 1.89-1.85 (2H, m, H-3); 
1.70-1.66 (2H, m, H-4);  1.50 (2H, qd, 2J=J2,1= J2,3=12.2, J2,3=3.5, H-2); 1.27-1.14 
(3H, m, H-3, H-4). 13C NMR δ: 137.3 (Ar Cq); 128.8 (Ar(m)); 128.0 (Ar(p)); 127.9 
(Ar(o)); 61.8 (C-1); 47.5 (CH2 Bn); 26.4 (C-2); 25.2 (C-3); 25.1 (C-1). FTIR (Neat): 
3266 (N-H st); 1312, 1135 (O=S=O st). M.p.=132°C. 
Methyl chloranesulfonate48  
An equimolar amount of methanol (5mL) was slowly added (30min) to 
sulfuryl chloride (10mL) under argon at 0ºC. After complete addition, the mixture 
was allowed to stir for 2h at room temperature with a continuous argon flux for 
partially releasing off dissolved hydrochloric acid. Title compound (6.7g, 41% 
yield) was distilled (b.p.=54-55°C) from the crude at reduced pressure (30 Torr). 
1H NMR δ: 4.20. 13C NMR δ: 61.2. 
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α-chlorination of ketones 
To a solution of diisopropylamine (170µL, 1.2 eq.) in dry THF (2 mL) in a flame 
dried round bottom flask under argon at 0°C was added n-butyllithium (690µL, 
1.6 M in Hexanes, 1.1 eq.), and the reaction mixture was stirred at this 
temperature for 15 minutes. It was then cooled to –78 °C and a solution of ketone 
82 (1 mmol) in THF (2 mL) was slowly added. Stirring at –78 °C was continued for 
further 30 minutes and methyl chlorosulfate (100µL, 1.1 eq.) was then added. 
After stirring at –78 °C for 30 minutes, the reaction was quenched with saturated 
ammonium chloride aqueous solution (5mL).  The mixture was then extracted 
with DCM (3 x 5mL), the combined organic phases were dried with anhydrous 
magnesium sulfate and the solvent evaporated affording the desired α-
chloroketone 83. 
2‐Chlorocyclohexan‐1‐one 83a63 
By means of the general procedure, 108 mg (81%) of product 83a were 
obtained as colorless oil. 
2‐Chlorocyclopentan‐1‐one 83b44 
By means of the general procedure, 89 mg (75%) of product 83b were 
obtained as colorless oil. 
2‐Chlorocyclooctan‐1‐one 83c41 
By means of the general procedure, 166 mg (quantitative yield) of product 
83c were obtained as colorless oil. 
2‐Chlorocyclododecan‐1‐one 83d41 
By means of the general procedure, 222 mg (quantitative yield) of product  
83d were obtained as white solid. 
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2‐Chloro‐1,2,3,4‐tetrahydronaphthalen‐1‐one 83e63 
By means of the general procedure, 190 mg (quantitative yield) of product  
83e were obtained as white solid. 
6‐Chlorocyclohex‐2‐en‐1‐one 83f64 
By means of the general procedure, 119 mg (91%) of product 83f were 
obtained as colorless oil. 
2‐Chloro‐2‐methyl‐1,2,3,4‐tetrahydronaphthalen‐1‐one 83g65 
By means of the general procedure, 146 mg (quantitative yield) of product 
83g were obtained as colorless oil. 
2‐Chloro‐1‐phenylpropan‐1‐one 83h46h 
By means of the general procedure, 171 mg (quantitative yield) of product 
83h were obtained as colorless oil. 
2‐Chloro‐6‐methylcyclohexan‐1‐one 83i66 
By means of the general procedure, 146 mg (quantitative yield) of product 
83i were obtained as colorless oil. 
4‐tert‐Butyl‐2‐chlorocyclohexan‐1‐one 83j47h 
By means of the general procedure, 189 mg (quantitative yield) of product 
83j (77:23 cis:trans RMN) were obtained as colorless oil. 
2‐Chloro‐4‐phenylcyclohexan‐1‐one 83k63 
By means of the general procedure, 210 mg (quantitative yield) of product 
83k (78:22 cis:trans RMN) were obtained as colorless oil. 
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(1S,3S,5S,6R)‐5‐[(tert‐Butyldimethylsilyl)oxy]‐3‐chloro‐7‐(prop‐2‐en‐1‐yl)‐7-
azabicyclo[4.1.0]heptan‐2‐one 83l 
By means of the general procedure, 604 mg (quantitative yield) of product 
83l were obtained as colorless oil. 
1H NMR δ: 5.87 (1H, ddt, J2’,3’=17.1, J2’,3’=10.7, J2’,1’=5.4, H-2’); 5.32 (1H, dq, 
J3’,2’=17.2, 2J=J3’,1’=1.6, H-3’); 5.15 (1H, dq, J3’,2’=10.5, 2J=J3’,1’=1.4, H-3’); 4.44 (1H, 
ddd, J5,4=8.7, J5,4=5.5, J5,6=2.9, H-5); 4.38 (1H, t, J3,4=4.4, H-3); 3.24 (1H, ddt, 
2J=14.3, J1’,2’=5.5, J1’,3’=1.4, H-1’); 2.90 (1H, ddt, 2J=14.3, J1’,2’=5.4, J1’,3’=1.3, H-1’); 
2.50 (1H, ddd, 2J=14.1, J4,5=9.3, J4,3=4.6, H-4), 2.28 (1H, dd, J6,1=5.8, J6,5=2.4, H-6), 
2.22 (1H, d, J1,6=5.9, H-1), 2.04 (1H, dtd, 2J=14.3, J4,3= J4,5=4.8, J4,6=0.6, H-4), 0.92 
(9H, s, tBu TBS); 0.13 (3H, s, Me TBS); 0.12 (3H, s, Me TBS). 13C NMR δ: 198.0 (C-
2); 133.8 (C-2’); 117.3 (C-3’); 64.0 (C-5); 62.0 (C-1’); 56.5 (C-3), 47.1 (C-6); 44.3 (C-
1); 36.7 (C-4); 25.8 (3xMe tBu); 18.1 (Cq tBu); -4.65 (Me TBS); -4.73 (Me TBS). 
FTIR(Neat): 1729 (C=O st), 1254 (CHCl wag), 1097 (Si-O st), 836 (Si-O-C bend), 777 
(C-Cl st). [∝]𝐷
20𝑜𝐶= -118 (c=1.0; DCM). HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C15H27ClNO2Si 316.1494; Found 316.1495. 
3‐Chloro‐1,7,7‐trimethylbicyclo[2.2.1]heptan‐2‐one 83m67 
By means of the general procedure, 190 mg (quantitative yield) of product 
83m (87:13 exo:endo RMN) were obtained as colorless oil. 
4‐Chloro‐3‐hydroxy‐1,3‐diphenylbutan‐1‐one 83n68 
By means of the general procedure, 112 mg (quantitative yield) of product 
83n were obtained as colorless oil after chromatographic purification 
(preparative plate eluted with Hex:AcOEt 8:2). 
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Chlorination of different functional groups 84 
Chlorination of ethyl 2‐phenylacetate 84b 
By means of the general procedure, 200 mg (100% yield) of a mixture of ethyl 
2‐chloro‐2‐phenylacetate 85b69 and 84b (98:2 RMN) were obtained as colorless 
oil. 
Chlorination of methyl 3‐phenylpropanoate 84c 
By means of the general procedure, 71 mg (36%) of methyl 2‐chloro‐3‐
phenylpropanoate 85c70, 50 mg (30%) of methyl 2‐benzyl‐4‐chloro‐3‐oxo‐5‐
phenylpentanoate 85c’ and 25 mg (17%) of methyl 2‐benzyl‐3‐oxo‐5‐
phenylpentanoate 85c’’71 were obtained all as colorless oils after 
chromatographic purification (preparative plate eluted with Hex:AcOEt 9:1). 
Methyl 2‐benzyl‐4‐chloro‐3‐oxo‐5‐phenylpentanoate 85c’ 
1H NMR δ: 12.99 (0.1H, s, OH’’); 7.30-7.06 (9.8H, Ar); 6.87-6.85 (0.2H, Ar’’); 4.80 
(0.1H, t, J4’’,5’’=7.5, H-4’’); 4.61 (0.5H, t, J4,5=7.1, H-4); 4.25 (0.4H, dd, J4’,5’=8.4, 
J4’,5’=5.9, H-4’); 4.19 (0.5H, t, J2,CH2Bn=7.4, H-2); 4.07 (0.4H, t, J2’,CH2Bn’=7.6, H-2’); 
3.69 (0.3H, s, OMe’’); 3.67 (1.2H, s, OMe’); 3.56 (0.1H; 2J=16.9, CH2 Bn’’); 3.46 
(1.5H, s, OMe); 3.44 (0.1H, 2J=17, CH2 Bn’’); 3.38 (0.1H, dd, 2J=14, J5’’,4’’=8, H-5’’); 
3.33 (0.5H, dd, 2J=14.2, J5,4=7.0, H-5); 3.22-3.14 (1.9H, m, CH2 Bn, 5’, CH2 Bn’, 5’’); 
3.07 (0.4H, 2J=13.9, JCH2Bn’,2’=7.9,  CH2 Bn’); 2.95 (0.5H, dd, 2J=14.1, J5,4=7.3, H-5); 
2.94 (0.4H, dd, 2J=14.1, J5’,4’=8.6, H-5’). 13C NMR δ: 199.0 (C-3’); 197.3 (C-3); 173.6 
(C-1’’); 169.6 (C-3’’); 168.6 (C-1’); 168.5 (C-1); 139.6 (Cq Ar Bn’’); 137.8 (Cq Ar Bn); 
137.5 (Cq Ar Bn’); 136.5 (Cq Ar Ph’’); 136.2 (Cq Ar Ph); 136.0 (Cq Ar Ph’); 129.5, 
129.0, 128.53, 128.52 (Ar(o,m)); 129.42, 128.47, 127.6 (Ar(o,m)’’); 129.37, 128.9, 
128.8, 128.6 (Ar(o,m)’); 127.2, 127.0 (Ar(p)’); 127.1, 126.8 (Ar(p)); 127.1, 126.1 
(Ar(p)’’); 100.9 (C-2’’); 63.1 (C-4’’); 61.7 (C-4); 57.9 (C-2’); 57.6 (C-2); 56.3 (C-4’’); 
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52.7 (OMe’); 52.6 (OMe); 52.2 (OMe’’); 40.7 (C-5’’); 39.2 (C-5’); 38.7 (C-5); 34.9 
(CH2 Bn’); 33.8 (CH2 Bn); 30.6 (CH2 Bn’’). FTIR(NEAT): 1749, 1722 (C=O st), 696 (Ar 
C-H o.o.p. bend, C-Cl st). HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C19H19ClNaO3 
353.0915; Found 353.0914. 
Chlorination of oxolan‐2‐one 84d 
By means of the general procedure, 116 mg (100%) of a mixture of 3‐
chlorooxolan‐2‐one 85d72 and 84d (85:15 RMN) were obtained as colorless oil. 
Chlorination of N,N‐diethylpropanamide 84e 
By means of the general procedure, 166 mg (quantitative yield) of 2‐chloro‐
N,N‐diethylpropanamide 85h were obtained as colorless oil. 
2‐Chloro‐N,N‐diethylpropanamide 85e 
1H NMR δ: 4.55 (1H, q, J2,3=6.5, H-2); 3.54 (1H, p, J=7.3, CH2 Et); 3.49 (1H, p, J=6.9, 
CH2 Et); 3.32 (1H, qd, J=7.1, J=3.7, CH2 Et); 3.28 (1H, qd, J=7.1, J=1.6, CH2 Et); 1.67 
(3H, d, J3,2=6.5, H-3); 1.24 (3H, t, 2J=7.2, CH3 Et); 1.14 (3H, t, 2J=7.1, CH3 Et). 13C 
NMR δ: 168.2 (C-1); 49.5 (C-2); 42.0, 40.8 (CH2 Et); 21.2 (C-3); 14.7, 12.6 (CH3 Et). 
FTIR(NEAT): 1651 (C=O st), 1462, 1434 (C-N st). HRMS (ESI-TOF) m/z: [M+H]+ 
Calcd for C7H15ClNO 164.0837; Found 164.0838. 
Chlorination of N,N‐dimethylacetamide 84f 
By means of the general procedure, 87 mg (99%) of a mixture of 2‐chloro‐
N,N‐dimethylacetamide 85f73 and 4‐chloro‐N,N‐dimethyl‐3‐oxobutanamide 86k 
(28:72 RMN) were obtained as yellow oil. 
Chlorination of 1‐methylpyrrolidin‐2‐one 84g 
By means of the general procedure, 107 mg (80%) of 3‐chloro‐1‐
methylpyrrolidin‐2‐one 85g47a were obtained as colorless oil. 
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Chlorination of 1,3‐diethyl propanedioate 84h 
By means of the general procedure, 181 mg (100%) of a mixture of 1,3‐diethyl 
2‐chloropropanedioate 85h74 and 84h (66:34 RMN) were obtained as colorless 
oil. 
Chlorination of ethyl 2‐oxocycloHex‐1‐carboxylate 84j 
By means of the general procedure, 177 mg (100%) of a mixture of ethyl 1‐
chloro‐2‐oxocycloHex‐1‐carboxylate 85j75 and 84j (14:86 RMN) were obtained as 
colorless oil. 
Chlorination of N,N‐dimethyl‐3‐oxobutanamide 84k 
By means of the general procedure, 139 mg (96%) of a mixture of 2‐chloro‐
N,N‐dimethyl‐3‐oxobutanamide 85k76 and 84k (50:50 RMN) were obtained as 
colorless oil. 
Chlorination of 2‐phenylacetonitrile 84l 
The general procedure was followed except that were used 2.4 eq. of 
DIPA, 2.2 eq. of BuLi and 2.2 eq. of MeOSO2Cl. After purification by 
chromatography (preparative plate eluted with Hex:AcOEt 95:5), 99 mg (66%) of 
2,3‐dichloro‐2,3‐diphenylbutanedinitrile 85l were obtained as colorless oil. 
2,3‐Dichloro‐2,3‐diphenylbutanedinitrile 85l 
1H NMR δ: 7.86-7.81 (4H, m, Ar); 7.51-7.48 (6H, m, Ar). 13C NMR δ: 137.34 (Cq Ar); 
131.37 (Ar(p)); 129.18, 125.40 (Ar(m,o)); 115.16 (CN); 68.2 (Cq). FTIR(NEAT): 719 
(Ar C-H o.o.p. bend, C-Cl st). HRMS (EI-B) m/z: [1/2M]+ Calcd for C8H5ClN 
150.0105; Found 150.0114.  
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Chlorination of lithium dianion of 1,3-dicarbonyl compounds 
To a solution of diisopropylamine (340µL, 2.4 eq.) in dry THF (2 mL) in a flame 
dried round bottom flask under argon at 0°C was added n-butyllithium (1.4 mL, 
1.6 M in Hexanes, 2.2 eq.), and the reaction mixture was stirred at this 
temperature for 15 minutes. At the same temperature, a solution of dicarbonyl 
compound 84 (1 mmol) in THF (2 mL) was slowly added. After 1 hour of stirring 
at 0 °C  the solution was cooled to -78 °C and methyl chlorosulfate (110µL, 1.2 
eq.) was then added. After stirring at –78 °C for 30 minutes, the reaction was 
quenched with saturated ammonium chloride aqueous solution (5mL).  The 
mixture was then extracted with DCM (3 x 5mL), the combined organic phases 
were dried with anhydrous magnesium sulfate and the solvent evaporated 
affording the desired 4-chloro dicarbonyl compound 86. 
Ethyl 4‐chloro‐3‐oxobutanoate 86i77 
By means of the general procedure, 167 mg (100%) of product 86i were 
obtained as yellow oil. 
Ethyl 3‐chloro‐2‐oxocycloHex‐1‐carboxylate 86j 
By means of the general procedure, 209 mg (100%) of product 86j were 
obtained as yellow oil. 
Enol: 1H NMR δ: 12.08 (1H, s, OH); 4.54 (1H, t, J3,4=3.6, H-3); 4.28-4.20 (2H, m, CH2 
Et); 2.42 (1H, ddd, 2J=16.6, J6,5=5.3, J6,5=2.9, H-6); 2.18 (1H, ddd, 2J=16.8, J6,5=11.0, 
J6,5=5.8, H-6); 2.16-2.10 (1H, m, H-4); 2.03 (1H, tdd, 2J= J4,5=14.2, J4,5=4.2, J4,3=3.1, 
H-4); 1.95-1.83 (1H, m, H-5); 1.76-1.69 (1H, m, H-5); 1.31 (1H, t, 2J=16.8, CH2 Et). 
13C NMR δ: 172.3 (C-2); 165.9 (C=O ester); 100.4 (C-1); 60.9 (CH2 Et); 54.5 (C-3); 
31.9 (C-4); 22.3 (C-6); 17.3 (C-5); 14.2 (CH2 Et). FTIR(NEAT): 1657 (C=O st); 1284, 
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1229, 1205, 1180 (C-O st, C-O-C st); 807 (Ar C-H o.o.p. bend, C-Cl st). HRMS (ESI-
TOF) m/z: [M+Na]+ Calcd for C9H13ClNaO3 227.0445; Found 227.0442. 
4‐Chloro‐N,N‐dimethyl‐3‐oxobutanamide 86k 
By means of the general procedure, 126 mg (77%) of product 86k were 
obtained as yellow oil. 
1H NMR δ: 15.07 (0.5H, s, OH’); 5.48 (0.5H, s, H-2’); 4.29 (1H, s, H-4); 4.02 (1H, s, 
H-4’); 3.71 (1H, s, H-2); 3.03 (1.5H, s, Me); 3.02 (3H, br s, Me’); 2.98 (1.5H, s, Me). 
13C NMR δ: 196.3 (C-3); 171.5 (C-1’); 170.7 C-3’); 166.0 (C-1); 87.6 (C-2’); 48.3 (C-
4); 45.6 (C-2); 43.4 (C-4’); 37.8, 35.5 (Me). FTIR(NEAT): 3467 (O-H st); 1740 (C=O 
st ketone); 1635 (C=O st Amide). HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for 
C6H10ClNNaO2 186.0292; Found 186.0297. 
Chlorination of equimolar mixtures of compounds 
Chlorination of an equimolar mixture of 1‐phenylethan‐1‐one 82n and methyl 3‐
phenylpropanoate 84c  
The general procedure was followed except that a solution of 0.5 mmol 
of 82n and 0.5 mmol of 84c was used instead of 1 mmol of a single compound. 
After purification by chromatography (preparative plate eluted with Hex:AcOEt 
8:2), 60 mg (42%) of methyl 2‐benzyl‐3‐hydroxy‐3‐phenylbutanoate 87 and 29 
mg (20%) of the other diastereoisomer 87’ were obtained both as white solids. 
2‐Benzyl‐3‐hydroxy‐3‐phenylbutanoate 87 
1H NMR δ: 7.43 (2H, d, 3J=7.3, Ar(o) Ph); 7.31 (2H, t, 3J=7.7, Ar(m) Ph); 7.28-7.17 
(4H, m, Ar(p) Ph, Ar(m,p) Bn); 7.15 (2H, d, 3J=7.9, Ar(o) Bn); 4.00 (1H, br s, OH); 
3.06 (1H, dd, J2,CH2Bn=9.8, J2,CH2Bn=5.6, H-2); 3.13 (3H, s, OMe); 3.13-3.10 (2H, m, 
CH2 Bn); 1.61 (3H, s, H-4). 13C NMR δ: 175.9 (C-1); 147.1 (Cq Ar Ph); 139.0 (Cq Ar 
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Bn); 128.8 (Ar(o) Bn); 128.5 (Ar(m) Bn); 128.2 (Ar(m) Ph); 127.0 (Ar(p) Ph); 126.5 
(Ar(p) Bn); 124.7 (Ar(o) Ph); 75.0 (C-3); 57.5 (C-2); 51.3 (OMe); 33.9 (CH2 Bn); 27.1 
(C-4). FTIR(NEAT): 3487 (O-H st); 1708 (C=O st); 1201, 1165 (C-O st, C-O-C st); 697 
(Ar C-H o.o.p. bend). M.p.= 113 °C. Anal. Calcd for C18H20O3: C 76.03; H 7.09. 
Found: C 76.21; H 7.35. 
2‐Benzyl‐3‐hydroxy‐3‐phenylbutanoate 87’ 
1H NMR δ: 7.52 (2H, d, 3J=7.4, Ar(o) Ph); 7.39 (2H, t, 3J=7.7, Ar(m) Ph); 7.28 (1H, 
t, 3J=7.3, Ar(p) Ph); 7.19 (2H, t, 3J=7.2, Ar(m) Bn); 7.13 (1H, t, 3J=7.2, Ar(p) Bn); 
6.94 (2H, d, 3J=7.0, Ar(o) Bn); 3.80 (1H, br s, OH); 3.52 (3H, s, OMe); 3.06 (1H, dd, 
J2,CH2Bn=11.9, J2,CH2Bn=3.5, H-2); 2.91 (1H, t, 2J=JCH2Bn,2=12.7, CH2 Bn); 2.46 (1H, dd, 
2J=13.6, JCH2Bn,2=3.5, CH2 Bn); 1.55 (3H, s, H-4). 13C NMR δ: 176.5 (C-1); 145.0 (Cq 
Ar Ph); 139.2 (Cq Ar Bn); 128.6 (Ar(o) Bn); 128.4, 128.3 (Ar(m)); 126.9 (Ar(p) Ph); 
126.3 (Ar(p) Bn); 124.8 (Ar(o) Ph); 74.6 (C-3); 58.4 (C-2); 51.6 (OMe); 34.1 (CH2 
Bn); 30.3 (C-4). FTIR(NEAT): 3509 (O-H st); 1712 (C=O st); 1206, 1167 (C-O st, C-
O-C st); 700 (Ar C-H o.o.p. bend). M.p.= 89 °C. Anal. Calcd for C18H20O3: C 76.03; 
H 7.09. Found: C 75.78; H 7.33. 
Chlorination of an equimolar mixture of 1‐phenylethan‐1‐one 82n and N,N‐
dimethylacetamide 84i 
The general procedure was followed except that a solution of 0.5 mmol of 
82n and 0.5 mmol of 84i was used instead of 1 mmol of a single compound. After 
purification by chromatography (preparative plate eluted with AcOEt), 64 mg 
(62%) of 3‐hydroxy‐N,N‐dimethyl‐3‐phenylbutanamide 88 were obtained as 
white solid (m.p.=87-88 °C, lit78 85-87°C). 
Experimental 
 
182 
 
Chlorination of an equimolar mixture of methyl 3‐phenylpropanoate 84c and N,N‐
dimethylacetamide 84i 
The general procedure was followed except that a solution of 0.5 mmol 
of 84c and 0.5 mmol of 84i was used instead of 1 mmol of a single compound. 
After purification by chromatography (preparative plate eluted with Hex:AcOEt 
2:1), 54 mg (54%) of 85c,  30 mg (49%) of 85f,  23 mg (18 %) of 4‐chloro‐N,N‐
dimethyl‐3‐oxo‐5‐phenylpentanamide 89 (yellow oil) and 5 mg (4%) of 2‐chloro‐
N,N‐dimethyl‐3‐oxo‐5‐phenylpentanamidethe 90 (colorless oil) were obtained. 
4‐Chloro‐N,N‐dimethyl‐3‐oxo‐5‐phenylpentanamide 89 
1H NMR δ: 15.19 (0.5H, s, OH’); 7.32-7.15 (5H, m, Ar); 5.30 (0.5H, s, H-2’); 4.72 
(0.5H, dd, J4,5=8.6, J4,5=5.5, H-4); 4.39 (0.5H, t, J4’,5’=7.2, H-4’); 3.85 (0.5H, d, 
2J=15.7, H-2); 3.63 (0.5H, d, 2J=15.7, H-2); 3.42 (1H, dd, dd, J=14.1, J=6.3, H-5, H-
5’); 3.20-3.02 (1H, m, H-5, H-5’); 2.95 (3H, br s, Me’); 2.93 (1.5H, s, Me); 2.92 
(1.5H, s, Me). 13C NMR δ: 198.3 (C-3); 172.4 (C-3’); 171.5 C-1’); 136.8 (Cq Ar); 136.3 
(Cq Ar’); 129.5 (Ar(m)); 129.4 (Ar(m)’); 128.5 (Ar(o)); 128.4 (Ar(o)’); 127.1 (Ar(p)); 
127.0 (Ar(p)’); 87.6 (C-2’); 62.5 (C-4); 61.3 (C-4’); 45.9 (C-2); 41.5 (C-5’); 38.9 (C-
5’); 37.7, 35.4 (Me). FTIR(NEAT): 1634 (C=O); 700 (Ar C-H o.o.p. bend, C-Cl st). 
HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C13H16ClNNaO2 276.0762; Found 
276.0760. 
2‐Chloro‐N,N‐dimethyl‐3‐oxo‐5‐phenylpentanamidethe 90 
1H NMR δ: 7.28 (2H, t, J=7.6, Ar(m)); 7.21-7.18 (3H, m, Ar(o,p)); 4.93 (1H, s, H-2); 
3.10-3.06 (2H, m, H-4); 2.99 (3H, s, Me); 2.97-2.93 (2H, m, H-5); 2.95 (3H, s, Me). 
13C NMR δ: 200.1 (C-3); 164.8 C-1); 140.4 (Cq Ar); 128.5, 128.4 (Ar(o,m)); 126.2 
(Ar(p)); 60.0 (C-2); 40.6 (C-4); 37.7, 36.3 (Me); 29.6 (C-5). FTIR(NEAT): 1645 (C=O); 
Experimental 
 
183 
 
698 (Ar C-H o.o.p. bend, C-Cl st). HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for 
C13H16ClNNaO2 276.0762; Found 276.0761. 
General procedure for the synthesis of 2-oxo-S-carbonyl or thiocarbonyl 
compounds 91 
 To a stirred solution of 2-chloroketone 83 (6.4mmol) in dry acetone 
(13mL) under argon atmosphere was added potassium ethyl xanthate, potassium 
thioacetate or other salt (1.2eq.). After reaction completion (followed by TLC, 2-
8h), water was added (20mL) and extracted with DCM (3X10mL). The combined 
organic layers were dried with MgSO4 and evaporated to dryness. Products 91 
were purified by chromatography (flash column or preparative TLC). 
Ethyl [(2-oxocyclopentyl)sulfanyl]methanethioate 91b 
 A described procedure79 for the preparation of the compound 91b was 
followed. 
1H NMR δ: 4.15 (2H, q, 3J=7.1, CH2 Et); 4.15 (1H, t, J=9.4, J=1.6, H-1); 2.66-
2.59 (1H, m, H-5); 2.45 (1H, dm, 2J=18.8, H-3); 2.30 (1H, dt, 2J=18.8, J3,4=9.5, H-3); 
2.18-2.11 (1H, m, H-4); 2.08-1.89 (2H, m, H-4, H-5); 1.42 (3H, t, 3J=7.1, CH3 Et). 13C 
NMR δ: 212.5, 212.4 (C-2, C=S); 70.6 (CH2 Et); 55.0 (C-1)); 37.0 (C-3); 30.2 (C-5); 
20.7 (C-4); 13.7 (CH3 Et). FTIR (Neat): 1743 (C=O st), 1209 (C-O-C st), 1039 (C=S 
st). 
Ethyl [(3-methyl-2-oxocyclohexyl)sulfanyl]methanethioate 91c 
By means of the general procedure, 127 mg (55% yield) of product 91c 
were obtained as colorless oil after purification by preparative TLC (eluted with 
4:6 Hex:DCM). 
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1H NMR δ: 4.65-4.55 (2.8H, m, CH2 Et, H-1); 4.54 (0.2H, t, J=5.2, H-1’); 2.90-
2.81 (0.2H, m, H-3’); 2.67-2.54 (1.6H, m, H-3, H-6); 2.36-2.00 (1.4H, m, H-4, H-4’, 
H-6’); 1.99-1.70 (2.8H, m, H-5, H-5’, H-6); 1.56-1.43 (1H, m, H-4, H-4’); 1.40 (3H, 
t, 3J=7.1, CH3 Et), 1.11 (0.6H, d, J=6.7, Me’), 1.09 (2.4H, d, J=6.5, Me’). 13C NMR δ: 
213.8 (211.2) (C=S); 206.5 (208.4) (C-2); 70.1 (70.4) (CH2 Et); 60.6 (56.0) (C-1); 
46.0 (42.8) (C-3); 36.7 (35.5) (C-4); 35.2 (33.5) (C-6); 25.8 (21.5) (C-5), 14.6 (15.1) 
(Me); 13.8 (13.6) (CH3 Et). FTIR (Neat): 1712 (C=O st), 1209 (C-O-C st), 1046 (C=S 
st). HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C10H16NaO2S2 255.0484; Found 
255.0480. 
Ethyl [(5‐tert‐butyl‐2‐oxocyclohexyl)sulfanyl]methanethioate 91d 
 By means of the general procedure, 1.3g (74% yield) of product 91d were 
obtained as colorless oil (74% yield) after purification by flash column 
chromatography (eluted with 95:5 Hex:EtOAc). 
1H NMR δ: 4.68-4.43 (3H, m, H-1, CH2 Et); 2.78-1.96 (4H, m); 1.80-1.48 
(3H, m); 1.41 (3H, t, 3J=7.2, CH3 Et); 0.94 (0.90) (9H, s, tBu). 13C NMR δ: 213.5 
(210.5) (C=S); 205.2 (207.1) (C-2); 70.2 (70.5) (CH2 Et); 60.0 (55.1) (C-1)); 47.7 
(43.1) (C-5); 41.3 (38.2) (CH2); 35.7 (33.2) (CH2); 32.7 (32.4) (Cq tBu); 28.3 (27.42) 
(CH2); 27.6 (27.39) (3xCH3 tBu); 13.8 (13.6) (CH3 Et). FTIR (Neat): 1717 (C=O st), 
1216 (C-O-C st), 1052 (C=S st). HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C13H22NaO2S2 297.0953; Found 297.0949. 
Ethyl [(2‐oxo‐5‐phenylcyclohexyl)sulfanyl]methanethioate 91e 
By means of the general procedure, 221 mg (75% yield) of product 91e 
were obtained as colorless oil after purification by flash column chromatography 
(eluted with 95:5 Hex:EtOAc). 
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1H NMR δ: 7.36-7.23 (5H, m, Ar); 4.79 (0.85H, dd, J=13.4, J=5.7, H-1); 4.67-
4.58 (2H, m, CH2 Et); 4.54 (0.15H, dt, J=4.7, J=1.6, H-1); 3.33-3.17 (1H, m, H-5); 
2.93-1.97 (6H, m, H-3, H-4, H-6); 1.43 (1.40) (3H, t, 3J=7.1, CH3 Et). 13C NMR δ: 
213.3 (210.1) (C=S); 204.2 (205.7) (C-2); 143.3 (143.2) (Cq Ar); 128.8 (Ar(m)); 127.0 
(126.9) (Ar(p)); 126.7 (126.8) (Ar(o)); 70.4 (70.6) (CH2 Et); 59.7 (55.2) (C-1); 43.7 
(38.8) (C-5); 41.5, 41.2, 34.4 (39.2, 38.4, 33.7) (C-3, C-4, C-6); 13.8 (13.6) (CH3 Et). 
FTIR (Neat): 1716 (C=O st), 1220 (C-O-C st), 1049 (C=S st). HRMS (ESI-TOF) m/z: 
[M + Na]+ Calcd for C15H18NaO2S2 317.0640; Found 317.0644. 
Ethyl {[(1S,5S,6R)-5-[(tert-butyldimethylsilyl)oxy]-2-oxo-7-(prop-2-en-1-yl)-7-
azabicyclo[4.1.0]heptan-3-yl]sulfanyl}methanethioate 91g 
By means of the general procedure, 696 mg (84% yield) of product 91g 
were obtained as colorless oil after purification by flash column chromatography 
(eluted with 95:5 Hex:EtOAc). 
1H NMR δ: 5.94-5.82 (1H, m, H-2’); 5.39-5.32 (1H, m, H-3’); 5.18-5.13 (1H, 
m, H-3’); 4.75 (0.3H, dd, J3,4=6.8, J3,4=5.0, H-3b); 4.71-4.60 (2H, m, CH2 Et); 4.27-
4.19 (1.7H, m, H-3a, H-5); 3.32 (0.7H, ddt, 2J=14.4, J1’,2’=5.3, J1’,3’=1.4, H-1’a); 3.19 
(0.3H, ddt, 2J=14.4, J1’,2’=5.4, J1’,3’=1.4, H-1’b); 2.94 (0.3H, ddt, 2J=14.4, J1’,2’=5.3, 
J1’,3’=1.4, H-1’b); 2.81 (0.7H, ddt, 2J=14.4, J1’,2’=5.3, J1’,3’=1.4, H-1’a); 2.63 (0.3H, 
ddd, 2J=14.0, J4,5=8.7, J4,3=6.9, H-4b); 2.36-2.17 (2.7H, m, H-1, H-4a, H-6); 2.11 
(0.7H, dtd, 2J=12.1, J4,5=J4,3=6.0, J4,6=0.6, H-4a); 1.94 (0.3H, dtd, 2J=13.9, 
J4,5=J4,3=5.3, J4,6=0.6, H-4b); 1.42 (3H, t, 3J=7.1, CH3 Et); 0.92 (9H, s, tBu TBS); 0.13 
(2.1H, Me TBS a); 0.12 (2.1H, Me TBS a); 0.11 (0.9H, Me TBS b); 0.09 (0.9H, Me 
TBS b). 13C NMR δ: 213.4 (211.2) (C=S); 199.1 (201.4) (C-2); 133.8 (133.9) (C-2’); 
117.05 (117.14) (C-3’); 70.8 (70.5) (CH2 Et); 67.6 (65.5) (C-5); 61.81 (61.75) (C-1’); 
53.6 (51.4) (C-3); 46.8, 45.5 (49.1, 46.1) (C-1, C-6); 32.5 (36.0) (C-4); 25.7 (25.8) 
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(3x CH3 tBu); 18.08 (18.11) (Cq tBu); 13.8 (13.7) (CH3 Et); -4.60, -4.66, -4.71 (Me 
TBS). FTIR(NEAT): 1716 (C=O st); 1219 (C-O-C st); 1096 (Si-O st); 1049 (C=S st); 
837 (Si-O-C bend); 777. [∝]𝐷
20𝑜𝐶= -125 (c=1.0; DCM). HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C18H31NNaO3S2Si 424.1407; Found 424.1414. 
Ethyl [(2-oxocyclohex-3-en-1-yl)sulfanyl]methanethioate 91h 
The general procedure was followed except that 2eq. of potassium ethyl 
xanthate were used instead of 1.2. After purification by flash column 
chromatography (eluted with 9:1 Hex:EtOAc), 158 mg (48% yield) of product 91h 
were obtained as colorless oil. 
1H NMR δ: 7.02 (1H, dt, J4,3=9.1, J4,5=4.0, H-4); 6.12 (1H, d, J3,4=10.1, H-4); 
4.72-4.61 (3H, m, CH2 Et, H-1); 2.62-2.45 (3H, m, H-5, H-6); 2.29-2.18 (1H, m, H-
6); 1.42 (3H, t, 3J=7.1, CH3 Et). 13C NMR δ: 211.9 (C=S); 193.4 (C-2); 150.4 (C-4); 
129.1 (C-3); 70.4 (CH2 Et); 56.1 (C-1); 29.7 (C-6); 25.9 (C-5); 13.8 (CH3 Et). FTIR 
(Neat): 1679 (C=O st), 1210 (C-O-C st), 1042 (C=S st). HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C9H12NaO2S2 239.0171; Found 239.0176. 
2-(Acetylsulfanyl)-1-phenylpropan-1-one 91i80 
By means of the general procedure, 129 mg (62% yield) of product 91i 
were obtained as colorless oil after purification by preparative TLC (eluted with 
9:1 Hex:EtOAc). 
2-(Acetylsulfanyl)-1-phenylethan-1-one 91j80-81 
By means of the general procedure, 604 mg (96% yield) of product 91j 
were obtained as white solid after purification by flash column chromatography 
(eluted with 9:1 Hex:EtOAc). 
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6-(Acetylsulfanyl)cyclohex-2-en-1-one 91k 
By means of the same procedure as for 91h (but with KSAc), 107 mg (53% 
yield) of the pure product 91k were obtained as colorless oil after purification by 
flash column chromatography (eluted with 95:5 Hex:EtOAc). 
1H NMR δ: 7.02 (1H, dddd, J3,2=10.0, J3,4=4.7, J3,4=3.5, J3,5=0.9, H-3); 6.11 
(1H, ddd, J2,3=10.1, J2,4=2.4, J2,4=1.6, H-2); 4.35 (1H, dd, J6,5=11.7, J6,5=4.7, H-6); 
2.61-2.44 (2H, m, H-4); 2.40-2.29 (1H, m, H-5); 2.39 (3H, s, CH3 Ac); 2.15 (1H, 
dddd, 2J=13.3, J5,6=11.7, J5,4=9.3, J5,4=5.3, H-5). 13C NMR δ: 194.14, 194.12 (C-1, 
C=O Ac); 150.5 (C-3); 129.2 (C-2); 49.7 (C-6); 30.6 (CH3 Ac); 30.2 (C-5); 25.7 (C-4). 
FTIR (Neat): 1674 (C=O st). HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C8H10NaO2S 
193.0294; Found 193.0293. 
2-(Acetylsulfanyl)-4-tert-butylcyclohexan-1-one 91l 
By means of the general procedure, 1.3g (88% yield) of product 91l were 
obtained as white solid after purification by flash column chromatography 
(eluted with 95:5 Hex:EtOAc). 
1H NMR δ: 4.31 (1H, dd, J2,3=13.3, J2,3=5.8, H-2); 2.59 (1H, dt, 2J=14.0, 
J6,5=3.5, H-6); 2.39-2.32 (1H, m, H-3); 2.36 (3H, s, CH3 Ac); 2.15 (1H, ddq, 2J=12.7, 
J5,6=6.2, J5,4=J5,6= J5,3=3.1, H-5); 1.74 (1H, tt, J4,5=J4,3=12.1, J4,5=J4,3=2.8, H-4); 1.56 
(1H, q, 2J=J3,4=J3,2=12.4, H-3); 1.50 (1H, qd, 2J=J5,4=J5,6=12.7, J5,6=4.8, H-5); 0.92 
(9H, s, tBu). 13C NMR δ: 205.5 (207.6) (C-1); 194.6 (192.5) (C=O Ac); 53.4 (49.6) (C-
2); 47.5 (43.4) (C-4); 41.2 (38.7) (C-6); 36.2 (33.6) (C-3); 32.6 (32.4) (Cq tBu); 30.6 
(30.5) (CH3 Ac); 28.1 (26.7) (C-5); 27.6 (27.4) (3XCH3 tBu). FTIR (Neat): 1721 (C=O 
st ketone), 1686 (C=O st thioacetate). M.p.=47-49°C. Anal. Calcd for C12H20O2S: C 
63.12; H 8.83; S 14.04. Found: C 62.85; H 8.53; S 13.90. 
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2-(Acetylsulfanyl)cyclooctan-1-one 91m 
The general procedure was followed except that reaction temperature 
was 70°C (in a pressure tube), 2.0 eq. of potassium thioacetate were used and 
the reaction time was 70 hours. After purification by flash column 
chromatography (eluted with 95:5 Hex:EtOAc), 433mg (70% yield) of product 
91m were obtained as colorless. 
1H NMR δ: 4.50 (1H, dd, J2,3=10.9, J2,3=3.7, H-2); 2.77 (1H, ddd, 2J=14.2, 
J8,7=8.1, J8,7=3.2, H-8); 2.41 (1H, ddd, 2J=14.1, J8,7=10.8, J8,7=3.2, H-8); 2.31 (3H, s, 
CH3 Ac); 2.17-2.07 (2H, m); 1.89-1.48 (7H, m); 1.19-1.09 (1H, m). 13C NMR δ: 213.2 
(C-1); 195.2 (C=O Ac); 51.3 (C-2); 42.2 (C-8); 30.1 (CH3 Ac); 32.2, 27.6, 25.1, 24.8, 
24.3 (5XCH2). FTIR (Neat): 1708 (C=O st ketone), 1686 (C=O st thioacetate). HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C10H16NaO2S 223.0763; Found 223.0761. 
2-(Acetylsulfanyl)cyclododecan-1-one 91n 
By means of the same procedure as for 91m, 145 mg (57% yield) of the 
pure product 91n were obtained as white solid after purification by flash column 
chromatography (eluted with 98:2 Hex:EtOAc). 
1H NMR δ: 4.55 (1H, dd, J2,3=9.7, J2,3=3.6, H-2); 2.81 (1H, ddd, 2J=15.7, 
J12,11=8.5, J12,11=3.4, H-12); 2.35 (1H, ddd, 2J=15.6, J12,11=9.0, J12,11=3.6, H-12); 
2.35 (3H, s, CH3 Ac); 2.09-2.00 (1H, m, H-3); 1.85-1.66 (3H, m); 1.45-1.17 (14H, 
m). 13C NMR δ: 207.5 (C-1); 194.5 (C=O Ac); 50.0 (C-2); 38.5 (C-12); 30.3 (CH3 
Ac); 29.2 (C-3); 24.9, 24.8, 24.6, 24.3, 24.2, 23.0, 22.4, 22.2 (8XCH2). FTIR (Neat): 
1694 (C=O st). M.p.=65-66°C. Anal. Calcd for C14H24O2S: C 65.58; H 9.44; S 12.50. 
Found: C 65.50; H 9.53; S 12.48. 
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N,N-Dimethyl-1-[(1-oxo-1,2,3,4-tetrahydronaphthalen-2-
yl)sulfanyl]methanethioamide 91o 
By means of the general procedure (using sodium dimethyl-
dithiocarbamate hydrate), 1.3g (91% yield) of product 91o were obtained as 
white solid after purification by flash column chromatography (eluted with 1:2 
Hex:DCM). 
1H NMR δ: 8.07 (1H, dd, J8,7=7.9, J8,6=1.0, H-8); 7.50 (1H, td, J6,5=J6,7=7.5, 
J6,8=1.3, H-6); 7.33 (1H, t, J7,6=J7,8=7.6, H-7); 7.27 (1H, d, J5,6=7.6, H-5); 5.37 (1H, 
dd, J2,3=12.6, J2,3=4.6, H-2); 3.58 (3H, s, Me); 3.44 (3H, s, Me); 3.28 (1H, ddd, 
2J=16.9, J4,3=11.8, J4,3=4.5, H-4); 3.06 (1H, dt, 2J=16.9, J4,3=4.0, H-4); 2.69 (1H, dq, 
2J=12.9, J3,4=J3,2=4.3, H-3); 2.32 (1H, qd, 2J= J3,4=J3,2=12.4, J3,4=4.3, H-3). 13C NMR 
δ: 195.3, 193.5 (C-1, C=S); 143.7 (C-4a); 133.8 (C-6); 132.2 (C-8a); 128.8 (C-5); 
127.9 (C-8); 126.8 (C-7); 60.0 (C-2); 45.9, 41.7 (2xMe); 31.5 (C-3); 29.7 (C-4). FTIR 
(Neat): 1682 (C=O st); 1497, 1375, 981 (N-C-S); 1145 (C=S st); 741 (Ar C-H o.o.p. 
bend). M.p.=149°C. Anal. Calcd for C13H15NOS2: C 58.84; H 5.70; N 5.28; S 24.16. 
Found: C 59.09; H 5.98; N 5.50; S 23.90. 
2-{[(tert-Butylsulfanyl)methanethioyl]sulfanyl}-1,2,3,4-tetrahydronaphthalen-1-
one 91p 
 A described procedure82 for the preparation of compound 91p was 
followed. 
1H NMR δ: 8.05 (1H, d, J8,7=7.8, H-8); 7.51 (1H, t, J6,5=J6,7=7.5, H-6); 7.33 
(1H, t, J7,6=J7,8=7.6, H-7); 7.26 (1H, d, J5,6=7.6, H-5); 5.25 (1H, dd, J2,3=11.8, J2,3=4.5, 
H-2); 3.20 (1H, ddd, 2J=16.9, J4,3=10.9, J4,3=4.4, H-4); 3.07 (1H, dt, 2J=16.9, J4,3=4.4, 
H-4); 2.60 (1H, dq, 2J=13.3, J3,4=J3,2=4.4, H-3); 2.30 (1H, qd, 2J=J3,4=J3,2=11.9, 
J3,4=4.4, H-3); 1.65 (9H, s, tBu). 13C NMR δ: 221.4 (C=S); 193.1 (C-1); 143.6 (C-4a); 
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134.0 (C-6); 132.1 (C-8a); 128.8 (C-5); 128.0 (C-8); 126.9 (C-7); 56.6 (C-2); 54.8 (Cq 
tBu); 30.2 (C-3); 29.4 (3xCH3 tBu); 29.2 (C-4). FTIR (Neat): 1683 (C=O st); 1065 (C=S 
st); 804; 794; 740 (Ar C-H o.o.p. bend). M.p.=95-96°C (lit. 100-101°C). 
Ethyl [(1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)sulfanyl]formate 91q 
 To a solution of 91f (1g, 3.8 mmol) in DCM (15mL) was added m-CPBA 
(77%, 1.7g, 2eq.) at 0°C and the mixture was stirred for 30 min at room 
temperature. Afterward 20 mL of NaHCO3 aqueous saturated solution were 
added and extracted with DCM (3x10mL). The combined organic layers were 
dried with MgSO4 and evaporated to dryness. After purification by flash column 
chromatography (eluted with 95:5 Hex:EtOAc), 218 mg (23%)  of pure product 
91q were obtained as yellowish white solid. 
1H NMR δ: 8.06 (1H, d, J8,7=7.9, H-8); 7.50 (1H, t, J6,5=J6,7=7.5, H-6); 7.33 
(1H, t, J7,6=J7,8=7.6, H-7); 7.26 (1H, d, J5,6=7.4, H-5); 4.38 (1H, dd, J2,3=11.9, J2,3=4.5, 
H-2); 4.34-4.27 (2H, m, CH2 Et); 3.17 (1H, ddd, 2J=16.9, J4,3=10.8, J4,3=4.5, H-4); 
3.08 (1H, dt, 2J=16.9, J4,3=4.5, H-4); 2.60 (1H, dq, 2J=13.3, J3,4=J3,2=4.5, H-3); 2.37 
(1H, qd, 2J= J3,4=J3,2=12.0, J3,4=4.6, H-3); 1.32 (3H, t, 2J=7.1; CH2 Et). 13C NMR δ: 
193.1 (C-1); 169.7 (C=O thiocarbonate); 143.4 (C-4a); 133.9 (C-6); 131.8 (C-8a); 
128.7 (C-5); 128.1 (C-8); 127.0 (C-7); 64.0 (CH2 Et); 52.7 (C-2); 31.1 (C-3); 29.1 (C-
4); 14.3 (CH3 Et). FTIR (Neat): 1698 (C=O st); 1131 (C-O-C st); 738 (Ar C-H o.o.p. 
bend). M.p.=53°C. Anal. Calcd for C13H14O3S: C 62.38; H 5.64; S 12.81. Found: C 
62.60; H 5.85; S 12.60. 
N,N-Dimethyl-1-[(1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)sulfanyl]formamide 
91r 
A described procedure for the oxidation of dithiocarbamates was used 
with some modifications.83 To a solution of 91o (950 mg, 3.6 mmol), benzoic acid 
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(1 eq., 440 mg)  and benzyltriethylammonium chloride (10 mol%, 83 mg) in DCM 
(36 mL) was added a solution of KMnO4 (3 eq., 1.7 g) in water (72 mL) and the 
reaction mixture was vigorously stirred for 5 hours. Afterward solid sodium 
metabisulfite was added until the reaction mixture color turned white which was 
then diluted with NaHCO3 aqueous saturated solution (50 mL) and extracted with 
DCM (3X50 mL). The combined organic layers were dried with MgSO4 and 
evaporated to dryness. After purification by flash column chromatography 
(eluted with 95:5 DCM:EtOAc), 406 mg (45%)  of pure product 91r were obtained 
as yellowish white solid. 
1H NMR δ: 8.06 (1H, d, J8,7=7.9, H-8); 7.48 (1H, t, J6,5=J6,7=7.5, H-6); 7.32 
(1H, t, J7,6=J7,8=7.6, H-7); 7.25 (1H, d, J5,6=7.7, H-5); 4.54 (1H, dd, J2,3=11.8, J2,3=4.5, 
H-2); 3.17 (1H, ddd, 2J=16.4, J4,3=11.3, J4,3=4.7, H-4); 3.09-3.03 (1H, m, H-4); 3.04 
(6H, s, 2xMe); 2.55 (1H, dq, 2J=13.2, J3,4=J3,2=4.4, H-3); 2.35 (1H, qd, 
2J=J3,4=J3,2=11.9, J3,4=4.4, H-3). 13C NMR δ: 194.2 (C-1); 166.6 (C=O 
monothiocarbamate); 143.6 (C-4a); 133.7 (C-6); 132.1 (C-8a); 128.7 (C-5); 128.0 
(C-8); 126.8 (C-7); 52.4 (C-2); 36.8 (2xMe); 31.6 (C-3); 29.3 (C-4). FTIR (Neat): 1685 
(C=O st ketone); 1648 (C=O st monothiocarbamate); 1365; 1100; 743 (Ar C-H 
o.o.p. bend). M.p.=95-96°C. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C13H16NO2S 
250.0896; Found 250.0891. 
2-{[(tert-Butylsulfanyl)carbonyl]sulfanyl}-1,2,3,4-tetrahydronaphthalen-1-one 91s 
By means of the same procedure as for 91r except the reaction time was 
30 min, 947 mg (93% yield) of the pure product 91s were obtained as colorless 
oil after purification by flash column chromatography (eluted with 2:1 Hex:DCM). 
Experimental 
 
192 
 
1H NMR δ: 8.04 (1H, d, J8,7=7.8, H-8); 7.49 (1H, td, J6,5=J6,7=7.6, J6,8=0.9, H-
6); 7.32 (1H, t, J7,6=J7,8=7.6, H-7); 7.25 (1H, d, J5,6=7.7, H-5); 4.59 (1H, dd, J2,3=11.0, 
J2,3=4.5, H-2); 3.14 (1H, ddd, 2J=17.0, J4,3=9.8, J4,3=4.6, H-4); 3.06 (1H, dt, 2J=17.0, 
J4,3=5.0, H-4); 2.55 (1H, dq, 2J=13.3, J3,4=J3,2=4.8, H-3); 2.31 (1H, dtd, 2J=13.3, 
J3,2=J3,4=10.4, J3,4=4.8, H-3); 1.51 (9H, s, tBu). 13C NMR δ: 193.0 (C-1); 187.8 (C=O 
dithiocarbonate); 143.5 (C-4a); 133.9 (C-6); 131.8 (C-8a); 128.7 (C-5); 128.1 (C-8); 
126.9 (C-7); 51.55 (Cq tBu); 51.46 (C-2); 30.9 (C-3); 30.3 (3xCH3 tBu); 28.8 (C-4). 
FTIR (Neat): 1686 (C=O st ketone); 1636 (C=O st dithiocarbonate); 853. HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C15H18O3NaO2S2 317.0640; Found 317.0640. 
2‐{[(tert‐Butylsulfanyl)(oxo‐lambda4‐sulfanylidene)methyl]sulfanyl}‐1,2,3,4-
tetrahydronaphthalen‐1‐one 91t 
By means of the same procedure as for 91q but only 1 eq. of m-CPBA was 
used, 339 mg (28% yield) of the pure product 91t were obtained as colorless oil 
after purification by flash column chromatography (eluted with DCM). 
1H NMR δ: 8.05 (1H, dd, J8,7=7.9, J8,6=1.0, H-8); 7.51 (1H, td, J6,5=J6,7=7.5, 
J6,8=1.3, H-6); 7.34 (1H, t, J7,6=J7,8=7.6, H-7); 7.26 (1H, d, J5,6=7.7, H-5); 5.87 (1H, 
dd, J2,3=11.5, J2,3=4.6, H-2); 3.20 (1H, ddd, 2J=17.0, J4,3=10.5, J4,3=4.5, H-4); 3.09 
(1H, dt, 2J=17.0, J4,3=4.7, H-4); 2.62 (1H, dq, 2J=13.1, J3,4=J3,2=4.7, H-3); 2.32 (1H, 
dddd, 2J=13.1, J3,2=11.4, J3,4=10.7, J3,4=4.6, H-3); 1.43 (9H, s, tBu). 13C NMR δ: 192.7 
(C-1); 179.2 (C=S=O); 143.3 (C-4a); 134.1 (C-6); 131.4 (C-8a); 128.8 (C-5); 128.0 
(C-8); 127.1 (C-7); 51.8 (C-2); 50.5 (Cq tBu); 30.8 (3xCH3 tBu); 30.6 (C-3); 28.4 (C-
4). FTIR (Neat): 1682 (C=O st); 1120; 740 (Ar C-H o.o.p. bend). HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C15H18NaO2S3 349.0361; Found 349.0361. 
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2-(Benzoylsulfanyl)-1,2,3,4-tetrahydronaphthalen-1-one 91u 
By means of the general procedure (using potassium thiobenzoate), 712 
mg (91% yield) of product 91u were obtained as white solid after purification by 
flash column chromatography (eluted with 1:1 Hex:DCM). 
1H NMR δ: 8.09 (1H, d, J8,7=7.8, H-8); 8.00 (2H, d, 3J=7.6, Ar(o) Bz); 7.59 
(1H, t, 3J=7.4, Ar(p) Bz); 7.52 (1H, t, J6,5=J6,7=7.4, H-6); 7.46 (2H, t, 3J=7.7, Ar(m) 
Bz); 7.34 (1H, t, J7,6=J7,8=7.6, H-7); 7.28 (1H, d, J5,6=7.7, H-5); 4.76 (1H, dd, 
J2,3=11.6, J2,3=4.6, H-2); 3.24 (1H, ddd, 2J=16.9, J4,3=10.7, J4,3=4.4, H-4); 3.11 (1H, 
dt, 2J=16.9, J4,3=4.5, H-4); 2.59 (1H, dq, 2J=13.2, J3,4=J3,2=4.6, H-3); 2.38 (1H, qd, 
2J= J3,4=J3,2=11.8, J3,4=4.4, H-3). 13C NMR δ: 193.5, 190.4 (C-1, C=O thioester); 
143.6 (C-4a); 136.6 (Ar Cq Bz); 133.9 (C-6); 133.7 (Ar(p) Bz); 132.0 (C-8a); 128.8 
(C-5); 128.7 (Ar(m) Bz); 128.1 (C-8); 127.5 (Ar(o) Bz); 127.0 (C-7); 50.9 (C-2); 31.0 
(C-3); 29.2 (C-4). FTIR (Neat): 1686 (C=O st ketone); 1662 (C=O st thioester); 1207; 
912, 687 (Ar C-H o.o.p. bend). M.p.=126°C. Anal. Calcd for C17H14O2S: C 72.32; H 
5.00; S 11.35. Found: C 72.12; H 5.32; S 11.51. 
1‐Oxo‐1,2,3,4‐tetrahydronaphthalen‐2‐yl benzenecarbodithioate 91v 
By means of the general procedure (using sodium dithiobenzoate and 2-
bromo-1-tetralone ), 650 mg (72% yield) of product 91v were obtained as pink 
solid after purification by flash column chromatography (eluted with 2:1 
Hex:DCM). 
1H NMR δ: 8.09 (1H, dd, J8,7=7.9, J8,6=1.1, H-8); 8.04 (2H, d, 3J=7.3, Ar(o) 
Bz); 7.56-7.51 (2H, m, H-6, Ar(p) Bz); 7.39 (2H, t, 3J=7.9, Ar(m) Bz); 7.35 (1H, t, 
J7,6=J7,8=7.5, H-7); 7.29 (1H, d, J5,6=7.7, H-5); 5.26 (1H, dd, J2,3=12.3, J2,3=4.6, H-2); 
3.28 (1H, ddd, 2J=16.9, J4,3=11.5, J4,3=4.4, H-4); 3.10 (1H, dt, 2J=16.9, J4,3=4.2, H-
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4); 2.67 (1H, dq, 2J=13.0, J3,4=J3,2=4.4, H-3); 2.35 (1H, qd, 2J=J3,4=J3,2=12.3, J3,4=4.3, 
H-3). 13C NMR δ: 226.0 (C=S dithioester), 193.1 (C-1); 144.8 (Ar Cq Bz); 143.7 (C-
4a); 134.1 (C-6); 132.7 (Ar(p) Bz); 132.1 (C-8a); 128.9 (C-5); 128.4 (Ar(m) Bz); 
128.0 (C-8); 127.1 (Ar(o) Bz); 127.0 (C-7); 58.3 (C-2); 29.7 (C-3); 29.4 (C-4). FTIR 
(Neat): 1680 (C=O st); 1215; 1041; 759, 739, 683 (Ar C-H o.o.p. bend). 
M.p.=109°C. Anal. Calcd for C17H14OS2: C 68.42; H 4.73; S 21.49. Found: C 68.10; 
H 4.94; S 21.40. 
1‐Oxo‐1,2,3,4‐tetrahydronaphthalen‐2‐yl pentanedithioate 91w 
To a stirred solution of K2CO3 (1.2 eq., 370 mg) in dry acetone (5 mL) at 
0°C under argon atmosphere was added dithiopentanoic acid (1.2 eq., 360 mg) 
dropwise. After 15 min 2-bromo-1-tetralone (500 mg, 2.2mmol) was added and 
stirring was continued at r.t. for 30min.  Afterward H2O (5 mL) was added and 
extracted with DCM (3x5mL). The combined organic layers were dried with 
MgSO4 and evaporated to dryness. After purification by flash column 
chromatography (eluted with 2:1 Hex:DCM), 483 mg (78%)  of pure product 91w 
were obtained as yellow greenish solid. 
1H NMR δ: 8.06 (1H, d, J8,7=7.9, H-8); 7.52 (1H, td, J6,5=J6,7=7.5, J6,8=1.3, H-
6); 7.33 (1H, t, J7,6=J7,8=7.6, H-7); 7.27 (1H, d, J5,6=7.7, H-5); 5.10 (1H, dd, J2,3=12.4, 
J2,3=4.6, H-2); 3.24 (1H, ddd, 2J=16.9, J4,3=11.6, J4,3=4.4, H-4);  3.08 (2H, t, 3J=7.6, 
H-2’); 3.06 (1H, dt, 2J=17.0, J4,3=4.1, H-4); 2.57 (1H, dq, 2J=13.0, J3,4=J3,2=4.4, H-3); 
2.26 (1H, qd, 2J=J3,4=J3,2=12.3, J3,4=4.3, H-3); 1.86 (2H, p, 3J=7.6, H-3’); 1.42 (2H, 
sex, 3J=7.4, H-4’); 0.94 (3H, t, 3J=7.4, H-5’). 13C NMR δ: 236.9 (C-1’); 193.1 (C-1); 
143.6 (C-4a); 134.1 (C-6); 132.0 (C-8a); 128.8 (C-5); 127.9 (C-8); 126.9 (C-7); 57.5 
(C-2); 51.7 (C-2’); 33.5 (C-3’); 29.5 (C-3); 29.4 (C-4); 22.0 (C-4’); 13.8 (C-5’). FTIR 
(Neat): 1684 (C=O st); 1304; 1218 (C=S st); 893; 740 (Ar C-H o.o.p. bend). 
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M.p.=85°C. Anal. Calcd for C15H18OS2: C 64.71; H 6.52; S 23.03. Found: C 65.00; H 
6.22; S 23.08. 
O,O‐Diethyl [(1‐oxo‐1,2,3,4‐tetrahydronaphthalen‐2‐yl)sulfanyl]phosphonothioate 
91x 
To a stirred solution of K2CO3 (1.2 eq., 660 mg) in dry DMF (10 mL) at 0°C 
under argon atmosphere was added O,O-diethyl dithiophosphate (1.2 eq., 
1.1mL) dropwise. After 15 min 2-bromo-1-tetralone (1.07g, 4.75mmol) was 
added and stirring was continued at r.t. for 2h.  Afterward NH4Cl aqueous 
saturated solution (20 mL) was added and extracted with DCM (3x10mL). The 
combined organic layers were dried with MgSO4 and evaporated to dryness. 
After purification by flash column chromatography (eluted with 1:1 Hex:DCM), 
1.13g (72%)  of pure product 91x were obtained as colorless oil. 
1H NMR δ: 8.04 (1H, d, J8,7=7.9, H-8); 7.50 (1H, td, J6,5=J6,7=7.5, J6,8=1.2, H-
6); 7.33 (1H, t, J7,6=J7,8=7.6, H-7); 7.25 (1H, d, J5,6=7.7, H-5); 4.36-4.14 (5H, m, H-2, 
2xCH2 Et); 3.19-3.05 (2H, m, H-4); 2.64 (1H, ddt, 2J=13.5, J=6.3, J=4.6, H-3); 2.37 
(1H, tdd, 2J=13.5, J=8.9, J=4.9, H-3); 1.40 (3H, t, 3J=6.8, CH3 Et); 1.39 (3H, t, 3J=7.0, 
CH3 Et). 13C NMR δ: 192.9 (d, 3JC,P=7, C-1); 143.3 (C-4a); 134.0 (C-6); 131.5 (C-8a); 
128.8 (C-5); 128.1 (C-8); 127.0 (C-7); 64.6 (d, 2JC,P=6, CH2 Et); 64.3 (d, 2JC,P=6, CH2 
Et); 55.0 (d, 2JC,P=3, C-2); 31.7 (d, 3JC,P=4, C-3); 28.1 (C-4); 15.9 (d, 3JC,P=8, CH3 Et); 
15.8 (d, 3JC,P=8, CH3 Et). 31P NMR δ: 93.0. FTIR (Neat): 1684 (C=O st); 1008, 957 (P-
O-C st); 652 (P=S st). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C14H20O3PS2 
331.0586; Found 331.0588. 
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General procedure for the basic rearrangement of 2-oxo-carbonyl or thiocarbonyl 
compounds 91 
To a stirred solution of 91 (0.5 mmol) in dry THF (2 mL) at 0°C under argon 
atmosphere was added NaH (1.6 eq., 13 mg). After 30 minutes of stirring at 0°C 
NH4Cl aqueous saturated solution (5 mL) was added and extracted with Et2O 
(3x5mL). The combined organic layers were dried with Na2SO4 and evaporated to 
dryness. Products were purified by chromatography (preparative TLC). 
Basic rearrangement of ethyl [(2‐oxocyclohexyl)sulfanyl]methanethioate 91a79,84 
 By means of the general procedure, 55 mg (81% yield) of ethyl 2‐hydroxy‐
5‐phenylcyclohex‐1‐ene‐1‐carbothioate 92a85 were obtained as yellow oil after 
purification by chromatography (preparative plate eluting with Hex:AcOEt 95:5). 
Basic rearrangement of ethyl [(2-oxocyclopentyl)sulfanyl]methanethioate 91b 
 By means of the general procedure, 44 mg (65% yield) of thionoester 92b 
were obtained as yellow solid after purification by chromatography (preparative 
plate eluting with Hex:AcOEt 95:5). 
Ethyl 2‐hydroxycyclopent‐1‐ene‐1‐carbothioate 92b86 
1H NMR δ: 12.97 (1H, s, OH); 4.53 (2H, q, 3J=7.1, CH2 Et); 2.65 (4H, t, 3J=7.6, 
H-3, H-5); 1.78 (2H, quint, 3J=7.6, H-4); 1.40 (3H, t, 3J=7.1, CH3 Et). 13C NMR δ: 
205.3 (C=S); 181.3 (C-2); 111.9 (C-1); 65.3 (CH2 Et); 34.8, 28.9 (C-3, C-5); 17.6 (C-
4); 13.9 (CH3 Et). FTIR (Neat): 1204 (C-O-C st, C=S st). M.p.=43-44°C (lit. 48°C). 
Basic rearrangement of ethyl [(3-methyl-2-oxocyclohexyl)sulfanyl]methanethioate 
91c 
 By means of the general procedure, 75 mg (79% yield) of thionoester 92c 
were obtained as yellow oil after purification by chromatography (preparative 
plate eluting with Hex:AcOEt 95:5). 
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Ethyl 2‐hydroxy‐3‐methylcyclohex‐1‐ene‐1‐carbothioate 92c 
1H NMR δ: 14.30 (0.5H, s, OH I); 4.60-4.52 (1H, m, CH2 Et II, III); 4.48 (1H, 
q, 3J=7.1, CH2 Et I); 3.82 (0.3H, dd, J3,4=12.7, J3,4=5.8, H-3 II); 3.63 (0.2H, t, J3,4=4.9, 
H-3 III); 2.76-1.37 (10H, m); 1.25 (1.5H, d, JMe,3=7.1, H-3 I); 1.08 (0.6H, d, JMe,3=6.6, 
H-3 III); 1.25 (0.9H, d, JMe,3=6.5, H-3 II). 13C NMR δ: 218.8 (C=S II); 218.1 (C=S III); 
209.1 (C-1 III); 207.7 (C-1 II); 207.3 (C=S I); 179.2 (C-2 I); 110.3 (C-1 I); 68.6 (CH2 Et 
III); 68.4 (CH2 Et II); 67.1 (C-1 III); 65.7 (CH2 Et I); 65.2 (C-1 II); 46.0 (C-3 II); 43.9 (C-
3 III); 35.1 (C-3 I); 36.5, 33.5, 24.5 (3xCH2 II); 35.5, 32.4, 21.1 (3xCH2 III); 30.2, 24.6, 
19.9 (3xCH2 I); 18.6 (Me I); 15.1 (Me III); 14.5 (Me II); 13.8 (CH3 Et I); 13.54 (CH3 
Et II); 13.45 (CH3 Et III). FTIR (Neat): 1206, 1175 (C-O-C st, C=S st). HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C10H16NaO2S 223.0763; Found 223.0772. 
Basic rearrangement of ethyl [(5‐tert‐butyl‐2‐
oxocyclohexyl)sulfanyl]methanethioate 91d 
 By means of the general procedure, 69 mg (93% yield) of thionoester 92d 
were obtained as yellow oil after purification by chromatography (preparative 
plate eluting with Hex:AcOEt 95:5). 
Ethyl 5‐tert‐butyl‐2‐hydroxycyclohex‐1‐ene‐1‐carbothioate 92d 
1H NMR δ: 14.12 (1H, s, OH); 4.51 (2H, q, 3J=7.1, CH2 Et); 2.61-2.55 (1H, m, 
H-6); 2.51-2.35 (2H, m, H-3); 2.03-1.94 (1H, m, H-6); 1.88-1.83 (1H, m, H-4); 1.42 
(3H, t, 3J=7.1, CH3 Et); 1.27-1.20 (2H, m, H-4, H-5); 0.91 (9H, s, tBu). 13C NMR δ: 
207.3 (C=S); 175.8 (C-2); 110.4 (C-1); 65.7 (CH2 Et); 44.0 (C-5); 32.4 (Cq tBu); 32.1 
(C-3); 27.3 (3xCH3 tBu); 25.4 (C-6); 22.8 (C-4); 13.8 (CH3 Et). FTIR (Neat): 1581 (C=C 
st), 1195 (C-O-C st, C=S st). HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C13H22NaO2S 
265.1233; Found 265.1232. 
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Basic rearrangement of ethyl [(2‐oxo‐5‐phenylcyclohexyl)sulfanyl]methanethioate 
91e 
 By means of the general procedure, 96 mg (90% yield) of thionoester 92e 
were obtained as yellow oil after purification by chromatography (preparative 
plate eluting with Hex:AcOEt 95:5).  
Ethyl 2‐hydroxy‐5‐phenylcyclohex‐1‐ene‐1‐carbothioate 92e 
1H NMR δ: 14.20 (1H, s, OH); 7.33 (2H, t, 3J=7.5, Ar(m)); 7.25-7.21 (3H, m, 
Ar(o, p)); 4.48 (2H, q, 3J=7.1, CH2 Et); 2.88-2.72 (2H, m, H-5, H-6); 2.65-2.49 (2H, 
m, H-3); 2.36 (1H, dd, 2J=15.7, J6,5=10.9, H-6); 2.00 (1H, dtd, 2J=13.3, J=5.4, J=2.3, 
H-4); 1.92 (1H, m, H-4); 1.35 (3H, t, 3J=7.1, CH3 Et). 13C NMR δ: 207.1 (C=S); 175.2 
(C-2); 145.7 (Cq Ar); 128.6 (Ar(m)); 126.9 (Ar(p)); 126.5 (Ar(o)); 110.1 (C-1); 65.9 
(CH2 Et); 40.2 (C-5); 32.3 (C-6); 31.4 (C-3); 28.3 (C-4); 13.8 (CH3 Et). FTIR (Neat): 
1577 (C=C st), 1206 (C-O-C st, C=S st). HRMS (ESI-TOF) m/z: [M + Na]+ Calcd  
Basic rearrangement of ethyl [(1-oxo-1,2,3,4-tetrahydronaphthalen-2-
yl)sulfanyl]methanethioate 91f87 
 By means of the general procedure, 73 mg (92% yield) of thionoester 92f 
were obtained as yellow solid after purification by chromatography (preparative 
plate eluting with Hex:AcOEt 95:5). 
Ethyl 1‐hydroxy‐3,4‐dihydronaphthalene‐2‐carbothioate 92f85  
1H NMR δ: 14.53 (0.9H, s, OH); 8.04 (1H, d, J8’,7’=7.8, H-8’); 7.93 (0.9H, dd, 
J8,7=7.7, J8,6=1.0,  H-8);  7.48 (0.1H, td, J6’,5’=J6’,7’=7.5, J6’,8’=1.3;  H-6’); 7.37-7.28 
(1.9H, m, H-6, H-7, H-7’); 7.24 (0.1H, d, J5’,6’=7.5, H-5’); 7.17 (0.9H, d, J5,6=7.3, H-
5); 4.64-4.58 (0.2H, m, CH2 Et’); 4.55 (1.8H, q, 2J=7.1; CH2 Et); 3.99 (0.1H, dd, 
J2’,3’=10.8, J2’,3’=4.7, H-2’); 3.10-2.89 (0.2H, m, H-4’); 2.81-2.72 (3.6H, m, H-3, H-4); 
2.70-2.60 (0.1H, m, H-3’); 2.40 (0.1H, dq, 2J=13.5, J3,2=J3,4=4.6, H-3); 1.32 (3H, t, 
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2J=7.1; CH2 Et). 13C NMR δ: 218.7 (C=S’); 206.2 (C=S); 193.1 (C-1’); 168.0 (C-1); 
143.6 (C-4a'); 140.3 (C-4a); 133.7 (C-6’); 132.2 (C-8a'); 131.1 (C-6); 130.9 (C-8a); 
128.8 (C-5’); 127.8 (C-8’); 127.3 (C-5); 126.9 (C-7’); 126.7 (C-8); 125.5 (C-7); 109.8 
(C-2); 68.6 (CH2 Et’); 65.9 (CH2 Et); 64.2 (C-2’);  29.4 (C-3’); 27.9 (C-4’);  27.7, 22.1 
(C-3, C-4); 13.9 (CH3 Et); 13.5 (CH3 Et’). FTIR (Neat): 1190, 1153 (C-O-C st, C=S st). 
M.p.=73-74°C (lit. 69-70°C). 
Basic rearrangement of ethyl {[(1S,5S,6R)-5-[(tert-butyldimethylsilyl)oxy]-2-oxo-7-
(prop-2-en-1-yl)-7-azabicyclo[4.1.0]heptan-3-yl]sulfanyl}methanethioate 91g 
 By means of the general procedure, 43 mg (94% yield) of thionoester 92g 
were obtained as yellow oil after purification by chromatography (preparative 
plate eluting with Hex:AcOEt 9:1). 
Ethyl (1S,5S,6R)‐5‐[(tert‐butyldimethylsilyl)oxy]‐2‐hydroxy‐7‐(prop‐2‐en‐1‐yl)‐7‐
azabicyclo[4.1.0]hept‐2‐ene‐3‐carbothioate 92g 
1H NMR δ: 14.27 (1H, s, OH); 5.88 (1H, ddt, J2’,3’=17.2, J2’,3’=10.5, J2’,1’=5.4, H-2’); 
5.39 (1H, d, J3’,2’=17.3, H-3’); 5.14 (1H, d, J3’,2’=10.5, H-3’); 4.53-4.41 (2H, m, CH2 
Et); 3.95 (1H, dd, J=10.1, J=6.5, H-5); 3.30 (1H, dd, 2J=14.6, J1’,2’=5.1 H-1’); 2.81-
2.73 (2H, m, H-1’, H-4); 2.24-2.18 (3H, m, H-1, H-4, H-6); 1.38 (3H, t, 3J=7.1, CH3 
Et); 0.93 (9H, s, tBu TBS); 0.11 (6H, 2xMe TBS). 13C NMR δ: 206.1 (C=S); 172.8 (C-
2); 134.1 (C-2’); 116.7 (C-3’); 106.6 (C-3); 67.3 (C-5); 65.9 (CH2 Et); 61.5 (C-1’); 
47.7, 41.5 (C-1, C-6); 27.9 (C-4); 25.8 (3x CH3 tBu); 18.1 (Cq tBu); 13.7 (CH3 Et); -
4.6, -4.7 (2xMe TBS). FTIR(NEAT): 1214 (C=S, C-O-C st); 1092 (C-O-C st). [∝]𝐷
20𝑜𝐶= 
-282 (c=0.4; DCM). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C18H32NO3SSi 
370.1867; Found 370.1862. 
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Basic rearrangement of ethyl [(2-oxocyclohex-3-en-1-yl)sulfanyl]methanethioate 
91h 
 By means of the general procedure, 45 mg (75% yield) of 92h and 7 mg 
(11% yield) of 92h’ were obtained after purification by chromatography 
(preparative plate eluting with Hex:AcOEt 9:1), both as yellow oils. 
Ethyl 2‐oxocyclohex‐3‐ene‐1‐carbothioate 92h 
1H NMR δ: 14.20 (0.4H, s, OH’); 6.98 (0.6H, dt, J4,3=10.1, J4,5=3.8, H-4); 6.52 
(0.4H, dt, J4’,3’=9.8, J4’,5’=4.4, H-4’); 6.10 (1H, dt, J3’,4’=9.9, J3’,5’=2.0, H-4’); 6.06 (1H, 
dt, J3,4=10.1, J3,5=2.0, H-4); 4.63-4.53 (1.2H, m, CH2 Et); 4.51 (0.8H, q, 3J=7.1, CH2 
Et’); 3.79 (0.6H, dd, J1,6=10.3, J1,6=4.8, H-1); 2.62 (0.8H, t, J6’,5’=8.7, H-6’); 2.59-2.47 
(1.2H, m, H-5, H-6); 2.45-2.35 (0.6H, m, H-5); 2.29-2.22 (1.4H, m, H-6, H-5’); 1.412 
(1.2H, t, 3J=7.1, CH3 Et’); 1.406 (1.8H, t, 3J=7.1, CH3 Et). 13C NMR δ: 218.4 (C=S); 
205.2 (C=S’); 194.5 (C-2); 169.1 (C-2’); 150.2 (C-4); 141.6 (C-4’); 129.4 (C-3); 125.6 
(C-3’); 107.4 (C-1’); 68.6 (CH2 Et); 65.5 (CH2 Et’); 63.1 (C-1); 28.6 (C-6); 24.7 (C-5); 
23.9 (C-5’); 20.9 (C-6’); 13.9 (CH3 Et’); 13.5 (CH3 Et). FTIR (Neat): 1218 (C=S st C-
O-C st). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C9H13O2S 185.0631; Found 
185.0625. 
Ethyl 4b‐[(ethoxymethanethioyl)sulfanyl]‐1,8a‐dihydroxy‐3,4,4a,4b,5,6,8a,8b‐
octahydrobiphenylene‐2‐carbothioate 92h’ 
1H NMR δ: 14.46 (1H, s, OH enol); 5.86 (1H, dd, J7,8=10.1, J7,6=5.5, H-7); 
5.55 (1H, d, J8,7=10.1, H-8); 4.69-4.56 (2H, m, CH2 Et xanthate); 4.51 (2H, q, 3J=7.1, 
CH2 Et thionoester); 4.18 (1H, d, J8b,4a=9.2, H-8b); 3.69 (1H, s, OH); 3.57 (1H, ddd, 
J4a,4=12.0, J4a,8b=9.2, J4a,4=5.5, H-4a); 2.70 (1H, dt, 2J=16.3, J3,4=3.8, H-3); 2.42-2.29 
(2H, m, H-5, H-6); 2.22-2.02 (3H, m, H-3, H-5, H-6); 1.82-1.68 (2H, m, H-4); 1.46 
(3H, t, 3J=7.1, CH3 Et xanthate); 1.43 (3H, t, 3J=7.1, CH3 Et thionoester). 13C NMR δ: 
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224.1 (C=S xanthate); 207.2 (C=S thionoester); 172.4 (C-1); 129.3 (C-7); 128.3 (C-
8); 112.9 (C-2); 81.8 (C-8a); 69.3 (CH2 Et xanthate); 68.1 (C-4b); 66.4 (CH2 Et 
thionoester); 51.8 (C-8b); 40.5 (C-4a); 29.1 (C-4); 27.3 (C-5); 24.1 (C-3); 22.7 (C-
6); 13.7 (CH3 Et xanthate); 13.6 (CH3 Et thionoester). FTIR (Neat): 1211 (C-O-C st, 
C=S st). HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C18H24NaO4S3 423.0729; Found 
423.0719. 
Basic rearrangement of 2-(acetylsulfanyl)-1-phenylpropan-1-one 91i 
 By means of the general procedure, 55 mg (88% yield) of 2‐methyl‐1‐
phenylbutane‐1,3‐dione 92i88 were obtained as yellow oil after purification by 
chromatography (preparative plate eluting with Hex:AcOEt 8:2). 
Basic rearrangement of 2-(acetylsulfanyl)-1-phenylethan-1-one 91j 
 By means of the general procedure, 76 mg (90% yield) of 3‐hydroxy‐1‐
phenylbut‐2‐en‐1‐one 92j89 were obtained as yellow oil after purification by 
chromatography (preparative plate eluting with Hex:AcOEt 9:1). 
Basic rearrangement of 6-(acetylsulfanyl)cyclohex-2-en-1-one 91k 
 By means of the general procedure, 27 mg (83% yield) of 92k were 
obtained as yellow oil after purification by chromatography (preparative plate 
eluting with DCM). 
6‐Acetylcyclohex‐2‐en‐1‐one 92k 
1H NMR δ: 15.86 (1H, s, OH’); 7.02 (1H, dt, J3,2=9.7, J3,4=3.5, H-3); 6.68 (1H, 
dt, J3’,2’=9.9, J3’,4’=4.3, H-3’); 6.08-6.03 (2H, m, H-2, H-2’); 3.48 (1H, dd, J6,5=8.3, 
J6,5=5.1, H-6); 2.61-2.51 (1H, m, H-5); 2.52 (2H, t, J5’,4’=7.7, H-5’); 2.41-2.30 (4H, 
m, H-4, H-4’); 2.27 (3H, s, CH3 Ac); 2.15-2.07 (1H, m, H-5); 2.10 (3H, s, CH3 Ac). 13C 
NMR δ: 205.0 (C=O Ac); 195.4 (C-1); 185.4, 183.4 (C-1’, C=O Ac’); 151.4 (C-3); 
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145.3 (C-3’); 129.2, 127.8 (C-2, C-2’); 104.3 (C-6’); 60.2 (C-6); 30.0 (CH3 Ac); 24.4 
(CH2); 24.3 (2XCH2); 22.0 (C-5’); 21.5 (CH3 Ac). FTIR (Neat): 1716, 1673 (C=O st). 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C8H11O2 139.0754; Found 139.0766. 
Basic rearrangement of 2-(acetylsulfanyl)-4-tert-butylcyclohexan-1-one 91l 
 By means of the general procedure, 39 mg (91% yield) of 1‐(5‐tert‐butyl‐
2‐hydroxycyclohex‐1‐en‐1‐yl)ethan‐1‐one 92l90 were obtained as yellow oil. 
Basic rearrangement of 2-(acetylsulfanyl)cyclooctan-1-one 91m 
 By means of the general procedure, 44 mg (95% yield) of 1‐(2‐
hydroxycyclooct‐1‐en‐1‐yl)ethan‐1‐one 92m91 were obtained as yellow oil after 
purification by chromatography (preparative plate eluting with Hex:AcOEt 9:1). 
Basic rearrangement of 2-(acetylsulfanyl)cyclododecan-1-one 91n 
 By means of the general procedure, 49 mg (95% yield) of 2‐
acetylcyclododecan‐1‐one 92n were obtained as yellow oil after purification by 
chromatography (preparative plate eluting with Hex:AcOEt 9:1). 
2‐Acetylcyclododecan‐1‐one 92n92 
1H NMR δ: 3.82 (1H, dd, J2,3=11.5, J2,3=3.0, H-2); 2.63 (1H, ddd, 2J=16.0, 
J12,11=11.0, J12,11=3.3, H-12); 2.41 (1H, ddd, 2J=16.2, J12,11=6.8, J12,11=3.3, H-12); 
2.38 (0.5H, t, J12’,11’=7.3, H-12’); 2.32 (0.5H, t, J3’,4’=7.1, H-3’); 2.25-2.18 (1H, m, H-
3); 2.19 (0.75H, s, CH3 Ac’); 2.15 (3H, s, CH3 Ac); 2.0-1.2 (17H + 16X0.25H, m). 13C 
NMR δ: 207.8, 204.7 (C-1, C=O Ac); 196.4, 190.4 (C-1’, C=O Ac’); 110.2 (C-2’); 67.0 
(C-2); 39.2 (C-12); 31.2 (C-12’); 28.66 (CH3 Ac); 24.39 (CH3 Ac’); 27.0, 25.4, 24.9, 
24.44, 24.3, 24.2, 24.1 (9XCH2); 28.71, 26.2, 25.8, 25.1, 24.6, 24.1, 23.43, 22.25 
(CH2’). FTIR (Neat): 1697 (C=O st). 
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Basic rearrangement of N,N-dimethyl-1-[(1-oxo-1,2,3,4-tetrahydronaphthalen-2-
yl)sulfanyl]methanethioamide 91o 
 By means of the general procedure, except that the solvent used was DMF 
and the reaction temperature was 60°C, 40 mg (91% yield) of 92o were obtained 
as white solid after purification by chromatography (preparative plate eluting 
with Hex:AcOEt 2:1). 
N,N‐Dimethyl‐1‐oxo‐1,2,3,4‐tetrahydronaphthalene‐2‐carbothioamide 92o 
1H NMR δ: 8.03 (1H, d, J8,7=7.9, H-8); 7.49 (1H, t, J6,5=J6,7=7.1, H-6); 7.31 
(1H, t, J7,6=J7,8=7.6, H-7); 7.27 (1H, d, J5,6=6.9, H-5); 4.14 (1H, dd, J2,3=11.7, J2,3=4.6, 
H-2); 3.58 (3H, s, Me); 3.35 (3H, s, Me); 3.17-3.02 (2H, m, H-4); 2.88 (1H, qd, 2J= 
J3,4=J3,2=12.2, J3,4=4.8, H-3); 2.35 (1H, dq, 2J=13.4, J3,4=J3,2=4.2, H-3). 13C NMR δ: 
199.9 (C=S); 193.6 (C-1); 144.0 (C-4a); 133.8 (C-6); 132.2 (C-8a); 128.8 (C-5); 127.9 
(C-8); 126.8 (C-7); 58.3 (C-2); 44.7, 42.1 (2xMe); 30.5 (C-3); 28.8 (C-4). FTIR (Neat): 
1677 (C=O st); 1517; 1277. M.p.=104-106°C. Anal. Calcd for C13H15NOS: C 66.92; 
H 6.48; N 6.00; S 13.74. Found: C 66.90; H 6.80; N 6.27; S 13.92. 
Basic rearrangement of 2-{[(tert-butylsulfanyl)methanethioyl]sulfanyl}-1,2,3,4-
tetrahydronaphthalen-1-one 91p 
 By means of the general procedure, 67 mg (95% yield) of 92p were 
obtained as yellow oil after purification by chromatography (preparative plate 
eluting with Hex:AcOEt 98:2). 
2-(tert-Butylsulfanylcarbothioyl)-1,2,3,4-tetrahydronaphthalen-1-one 92p  
1H NMR δ: 16.21 (0.4H, s, OH’); 8.03 (0.6H, dd, J8,7=7.8, J8,6=0.8, H-8); 7.96 
(0.4H, dd, J8’,7’=7.7, J8’,6’=0.8,  H-8’); 7.47 (0.6H, td, J6,5=J6,7=7.5, J6,8=1.3;  H-6); 7.36 
(0.4H, td, J6’,5’=J6’,7’=7.4, J6’,8’=1.4;  H-6’); 7.32-7.28 (1H, m, H-7, H-7’); 7.23 (0.6H, 
d, J5,6=7.7, H-5); 7.17 (0.4H, d, J5’,6’=7.4, H-5’); 4.21 (0.6H, dd, J2,3=11.0, J2,3=4.7, H-
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2); 3.09 (0.6H, dt, 2J=16.7, J4,3=4.9, H-4); 3.02 (0.6H, ddd, 2J=16.8, J4,3=10.1, 
J4,3=4.3, H-4); 2.95-2.91 (0.8H, m, H-3’); 2.83-2.73 (1.4H, m, H-3, H-4’); 2.36 (0.6H, 
dq, 2J=13.8, J3,2=J3,4=4.6, H-3); 1.70 (3.6H, s, tBu’); 1.63 (5.4H, s, tBu). 13C NMR δ: 
234.4 (C=S); 216.3 (C=S’); 194.1 (C-1); 166.7 (C-1’); 143.6 (C-4a); 140.1 (C-4a'); 
133.6 (C-6); 132.5 (C-8a); 131.4 (C-6’); 131.3 (C-8a'); 128.7 (C-5); 127.8 (C-8); 
127.1 (C-5’); 126.90 (C-7’); 126.87 (C-7); 126.2 (C-8’); 117.5 (C-2’); 68.6 (C-2); 52.4 
(Cq tBu); 51.8 (Cq tBu’); 31.3 (C-3); 29.3 (3xCH3 tBu’); 28.3 (C-4); 28.1 (3xCH3 tBu); 
27.9 (C-4’); 26.0 (C-3’). FTIR (Neat): 1521 (C=C st); 1151 (C=S st). HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C15H18NaOS2 301.0691; Found 301.0690. 
Basic rearrangement of Ethyl [(1-oxo-1,2,3,4-tetrahydronaphthalen-2-
yl)sulfanyl]formate 91q 
By means of the general procedure, 31 mg (71% yield) of ethyl 1-hydroxy-3,4-
dihydronaphthalene-2-carboxylate 92q93 (yellow oil) and 8 mg (21% yield) of 92q’ 
(white solid) were obtained after purification by chromatography (preparative 
plate eluting with Hex:AcOEt 8:2).  
3,3'',4,4''-Tetrahydro-1H,1''H-dispiro[naphthalene-2,2'-[1,3,5]trithiolane-4',2''-
naphthalene]-1,1''-dione 92q’ 
1H NMR δ: 8.14 (2H, d, J8,7=7.7, H-8); 7.51 (2H, t, J6,5=J6,7=7.5, H-6); 7.36 
(2H, t, J7,6=J7,8=7.6, H-7); 7.24 (2H, d, J5,6=7.7, H-5); 3.28 (2H, ddd, 2J=17.6; J4,3=8.6; 
J4,3=6.2, H-4); 3.18 (2H, dt, 2J=17.5, J4,3=4.8, H-4); 3.11-3.00 (4H, m, H-3). 13C NMR 
δ: 187.4 (C-1); 142.2 (C-4a); 133.9 (C-6); 130.5 (C-8a); 129.1 (C-8); 128.6 (C-9); 
127.3 (C-7); 83.9 (C-2); 34.7 (C-3); 29.4 (C-4). FTIR (Neat): 1679 (C=O st); 1286; 
1212. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C20H16NaO2S3 407.0205; Found 
407.0199. 
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Basic rearrangement of N,N-dimethyl-1-[(1-oxo-1,2,3,4-tetrahydronaphthalen-2-
yl)sulfanyl]formamide 91r 
By means of the general procedure, except that the solvent used was DMF 
and the reaction temperature was 80°C, 70 mg (100%) of 92r were obtained as 
yellow oil after purification by chromatography (preparative plate eluting with 
DCM). 
2‐({1‐[(Dimethylcarbamoyl)oxy]‐3,4‐dihydronaphthalen‐2‐yl}disulfanyl)‐3,4-
dihydronaphthalen‐1‐yl N,N‐dimethylcarbamate 92r 
1H NMR δ: 7.19-7.09 (8H, m, H-5, H-6, H-7, H-8); 3.17 (6H, s, Me); 3.03 
(6H, s, Me); 2.94-2.89 (4H, m, H-4); 2.86-2.82 (4H, m, H-3). 13C NMR δ: 153.7 
(C=O); 143.7, 135.8, 131.0, 126.6 (C-1, C-2, C-4a, C-8a); 128.1, 127.3, 124.4, 121.4 
(C-5, C-6, C-7, C-8); 37.0, 36.5 (2xMe); 28.3 (C-4); 26.5 (C-3). FTIR (Neat): 1721 
(C=O st); 1156 (C-O-C st). HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C26H28NaN2O4S2 519.1383; Found 519.1383. 
Basic rearrangement of 2-{[(tert-butylsulfanyl)carbonyl]sulfanyl}-1,2,3,4-
tetrahydronaphthalen-1-one 91s 
By means of the general procedure, 58 mg (65% yield) of 92s (yellow oil) and 10 
mg (13% yield) of 92s’ (yellow solid) were obtained after purification by 
chromatography (preparative plate eluting with Hex:AcOEt 9:1). 
(tert-Butylsulfanyl)(1-hydroxy-3,4-dihydronaphthalen-2-yl)methanone 92s 
1H NMR δ: 13.72 (0.7H, s, OH); 8.03 (0.3H, d, J8’,7’=7.8, H-8’); 7.83 (0.7H, 
dd, J8,7=7.5, J8,6=1.0,  H-8); 7.47 (0.3H, td, J6’,5’=J6’,7’=7.5, J6’,8’=1.1;  H-6’); 7.34-7.26 
(1.7H, m, H-6, H-7, H-7’); 7.23 (0.3H, d, J5’,6’=7.7, H-5’); 7.16 (0.7H, d, J5,6=7.2, H-
5); 3.67 (0.3H, dd, J2’,3’=9.0, J2,3=4.8, H-2’); 3.10 (0.3H, ddd, 2J=16.8, J4’,3’=6.9, 
J4’,3’=4.6, H-4’); 2.94 (0.3H, ddd, 2J=16.8, J4’,3’=8.6, J4’,3’=4.6, H-4’); 2.82 (1.4H, t, 
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J4,3=7.6, H-4); 2.57 (1.4H, t, J3,4=7.7, H-3); 2.50 (0.3H, qd, 2J= J3’,2’= J3’,4’=8.9, 
J3’,4’=4.5, H-3’); 2.34 (0.3H, ddt, 2J=13.5,  J3’,4’=7.0,  J3’,4’=J3’,2’=4.8, H-3’); 1.56 (6.3H, 
s, tBu); 1.49 (2.7H, s, tBu’). 13C NMR δ: 197.9 (C=O thioester); 197.3 (C-1’); 193.6 
(C=O thioester’); 163.2 (C-1); 143.7 (C-4a'); 139.2 (C-4a); 133.9 (C-6’); 132.0 (C-
8ª’); 130.8 (C-6); 130.1 (C-8a); 128.8 (C-5’); 127.7 (C-8’); 127.3 (C-5); 126.9 (C-7’); 
126.7 (C-7); 125.0 (C-8); 106.5 (C-2’); 62.0 (C-2); 48.9 (Cq tBu’); 48.2 (Cq tBu); 30.1 
(3xCH3 tBu); 29.8 (3xCH3 tBu’); 27.9 (C-4); 27.4 (C-3’); 27.0 (C-4’); 21.7 (C-3). FTIR 
(Neat): 1614, 1559 (C=O st, C=C st); 1154; 1006; 805. HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C15H18NaO2S 285.0920; Found 285.0920. 
2‐(tert‐Butylsulfanyl)naphthalen‐1‐ol 92s’ 
1H NMR δ: 8.27-8.24 (1H, m, H-8); 7.76-7.74 (1H, m, H-5); 7.56 (1H, d, 
J4,3=8.6, H-4); 7.52-7.47 (2H, m, H-6, H-7); 7.34 (1H, d, J3,4=8.6, H-3); 7.02 (1H, br 
s, OH); 1.33 (9H, s, tBu). 13C NMR δ: 153.2 (C-1); 135.1 (C-4a); 130.0 (C-3); 127.52, 
127.46 (C-5, C-7); 125.8 (C-6); 124.1 (C-8a); 122.8 (C-8); 120.3 (C-4); 115.1 (C-2); 
49.1 (Cq tBu); 30.0 (3xCH3 tBu). FTIR (Neat): 3445 (O-H st); 801 (Ar C-H o.o.p. 
bend). HRMS (ESI-TOF) m/z: [M - tBu]+ Calcd for C10H7OS 175.0212; Found 
175.0213. 
Basic rearrangement of 2‐{[(tert‐butylsulfanyl)(oxo‐lambda4-
sulfanylidene)methyl]sulfanyl}‐1,2,3,4-tetrahydronaphthalen‐1‐one 91t 
 By means of the general procedure, 49 mg (78% yield) of 92t (yellow solid) 
and 2 mg (10% yield) of 92t’ (yellow oil) were obtained after purification by 
chromatography (preparative plate eluting with Hex:AcOEt 9:1). 
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2-(tert-Butylsulfanylcarbothioyl)-2-hydroxy-1,2,3,4-tetrahydronaphthalen-1-one 
92t 
1H NMR δ: 8.03 (1H, d, J8,7=7.8, H-8); 7.50 (1H, td, J6,5=J6,7=7.5, J6,8=1.0;  H-
6); 7.34 (1H, td, J7,6=J7,8=7.5,  H-7); 7.23 (1H, d, J5,6=7.7, H-5); 4.95 (1H, s, OH); 
3.15-3.03 (2H, m, H-4); 2.86 (1H, dt, 2J=13.6, J3,4=4.8, H-3); 2.30 (1H, ddd, 2J=13.6, 
J3,4=8.6, J3,4=6.2, H-3); 1.60 (9H, s, tBu). 13C NMR δ: 238.3 (C=S); 196.6 (C-1); 143.7 
(C-4a); 133.8 (C-6); 131.9 (C-8a); 128.8 (C-5); 127.8 (C-8); 126.9 (C-7); 86.3 (C-2); 
52.4 (Cq tBu); 36.8 (C-3); 28.2 (3xCH3 tBu); 26.2 (C-4). FTIR (Neat): 3446 (O-H st); 
1686 (C=O st); 1290; 1081 (C=S st); 748 (Ar C-H o.o.p. bend). M.p.= 75-77°C. Anal. 
Calcd for C15H18O2S2: C 61.19; H 6.16; S 21.78. Found: C 60.90; H 6.41; S 21.60. 
2-(tert-Butylsulfanylcarbothioyl)naphthalen-1-ol 92t’ 
1H NMR δ: 14.16 (1H, s, OH); 8.51 (1H, d, J8,7=8.4, H-8); 8.13 (1H, td, 
J3,4=9.2, H-3); 7.71 (1H, d, J5,6=8.1, H-5); 7.60 (1H, td, J6,7=J6,5=7.5, J=1.1, H-6); 7.51 
(1H, td, J7,6=J7,8=7.7, J=1.0, H-7); 7.19 (1H, d, J4,3=9.2, H-4); 1.75 (9H, s, tBu). 13C 
NMR δ: 225.4 (C=S); 159.4 (C-1); 136.4 (C-4a); 129.8 (C-6); 127.3 (C-5); 126.6 (C-
8a); 126.0 (C-7); 125.2 (C-8); 122.7 (C-3); 121.5 (C-2); 117.8 (C-4); 53.0 (Cq tBu); 
28.9 (3xCH3 tBu). FTIR (Neat): 1623, 1562 (C=C st); 1187, 1145 (C-O st, C=S st); 
962, 801, 748 (Ar C-H o.o.p. bend). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C15H17OS2 277.0715; Found 277.0715. 
Basic rearrangement of 2-(benzoylsulfanyl)-1,2,3,4-tetrahydronaphthalen-1-one 
91u 
 By means of the general procedure, 97 mg (95% yield) of 2-benzoyl-3,4-
dihydronaphthalen-1-ol 92u94 were obtained as yellow oil after purification by 
chromatography (preparative plate eluting with Hex:AcOEt 9:1). 
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Basic rearrangement of 1‐oxo‐1,2,3,4‐tetrahydronaphthalen‐2‐yl 
benzenecarbodithioate 91v 
The general procedure was followed except that after 30 min of reaction 
methyl iodide (1.5 eq.) was added at 0°C and the reaction mixture was allowed 
to stir at the same temperature for additional 30 min. The reaction mixture was 
treated as in the general procedure and after purification by chromatography 
(preparative plate eluting with 1:2 Hex:DCM), 66mg (70% yield) of 92v were 
obtained as yellow solid. 
2-[(Methylsulfanyl)(phenyl)methylidene]-1,2,3,4-tetrahydronaphthalen-1-one 92v 
1H NMR δ: 8.15 (1H, d, J8,7=7.6, H-8); 7.48-7.32 (5H, m, 5, 7, Ar(m,p) Ph); 
7.19-7.15 (3H, m, H-6, Ar(o) Bz); 2.82 (2H, t, J4,3=6.5, H-4); 2.51 (2H, t, J3,4=6.5, H-
3); 1.75 (3H, s, Me). 13C NMR δ: 187.0 (C-1); 156.2 (C-SMe); 142.6 (C-8a); 137.5 
(Ar Cq Ph); 134.5 (C-4a); 132.5 (C-7); 128.9 (Ar(o) Ph); 128.0, 127.9, 127.8 (C-6, C-
8, Ar(m,p) Ph); 127.6 (C-2); 126.9 (C-5); 30.0 (C-3); 29.4 (C-4); 16.8 (Me). FTIR 
(Neat): 1638, 1596, 1522, 1484 (C=O st, C=C st); 1303; 1240; 1218; 981, 888, 769, 
743, 731, 701 (Ar C-H o.o.p. bend). M.p.=138°C. Anal. Calcd for C18H16OS: C 77.11; 
H 5.75; S 11.43. Found: C 77.20; H 5.98; S 11.40. 
Basic rearrangement of 1‐oxo‐1,2,3,4‐tetrahydronaphthalen‐2‐yl pentanedithioate 
91w 
By means of the same procedure as for 91v, 60 mg (66% yield) of 92w 
were obtained as yellow oil after purification by chromatography (preparative 
plate eluting with 1:1 Hex:DCM). 
2-[1-(Methylsulfanyl)pentylidene]-1,2,3,4-tetrahydronaphthalen-1-one 92w 
1H NMR δ: 8.08 (0.5H, dd, J8,7=7.8, J8,6=1.1, H-8); 8.05 (0.5H, dd, J8,7=7.9, 
J8,6=1.2, H-8); 7.40 (1H, td, J6,5=J6,7=7.4, J6,8=1.3, H-6); 7.31 (0.5H, td, J7,6=J7,8=7.5, 
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J7,5=0.8, H-7); 7.30 (0.5H, td, J7,6=J7,8=7.5, J7,5=1.0, H-7); 7.19 (1H, d, J5,6=7.5, H-5); 
2.98-2.84 (5H, m, H-3, H-4, H-2’); 2.63 (1H, t, 3J=8.0, H-2’); 2.39 (1.5H, s, Me); 2.35 
(1.5H, s, Me); 1.64-143 (4H, m, H-3’, H-4’); 0.979 (1.5H, t, 3J=7.1, H-5’); 0.976 
(1.5H, t, 3J=7.3, H-5’). 13C NMR δ: 186.5, 185.8 (C-1); 157.8, 157.7 (C-1’); 142.8, 
142.2 (C-8a); 135.1, 134.7 (C-4a); 132.3, 132.1 (C-6); 128.1, 126.0 (C-2); 128.0, 
127.9 (C-8); 127.8, 127.5 (C-5); 126.8, 126.7 (C-7); 32.0, 31.7 (C-3’); 31.2, 31.1  (C-
2’); 29.7, 29.2, 29.0, 28.4 (C-3, C-4); 22.9, 22.7 (C-4’); 15.5, 14.0 (Me); 13.91, 13.89 
(C-5’). FTIR (Neat): 1639, 1597, 1525 (C=O st, C=C st); 1296; 1224; 742 (Ar C-H 
o.o.p. bend). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C16H21OS 261.1308; Found 
261.1306. 
Basic rearrangement of O,O‐diethyl [(1‐oxo‐1,2,3,4‐tetrahydronaphthalen‐2‐
yl)sulfanyl]phosphonothioate 91x 
 By means of the general procedure, 57 mg (95% yield) of 92x were 
obtained as yellow oil (preparative plate eluting with Hex:AcOEt 9:1). 
Ethyl 2-sulfanyl-3,4-dihydronaphthalen-1-yl ethoxy(sulfanylidene)phosphonite 92x 
1H NMR δ: 7.62 (1H, d, J8,7=7.6, H-8); 7.21-7.08 (3H, m, H-5, H-6, H-7); 
4.28-4.18 (4H, m, 2xCH2 Et); 3.62 (1H, s, SH); 2.85 (2H, t, J4,3=7.8, H-4); 2.57-2.52 
(2H, m, H-3); 1.40 (6H, td, 3J=7.1, 4JH,P=0.8, 2xCH3 Et). 13C NMR δ: 140.0 (d, 2JC,P=9, 
C-1); 134.7 (d, 4JC,P=1, C-4a) 131.3 (d, 3JC,P=2, C-8a); 126.99, 126.95, 126.3 (C-5, C-
6, C-7); 121.6 (C-8); 118.9 (d, 3JC,P=8, C-2); 65.3 (d, 2JC,P=5, CH2 Et); 31.4 (d, 4JC,P=2, 
C-3); 28.1 (C-4); 15.9 (d, 3JC,P=8, CH3 Et). 31P NMR δ: 63.8. FTIR (Neat): 1021, 969, 
824 (P-O-C st). HRMS (ESI-TOF) m/z: [M - H]+ Calcd for C14H18O3PS2 329.0429; 
Found 329.0430. 
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2‐[(2‐Oxocyclooctyl)sulfanyl]cyclooctan‐1‐one 93 
To a stirred solution of 2-chloroketone 83c (160 mg, 1mmol) in dry 
acetonitrile (4mL) under argon atmosphere was added potassium ethyl xanthate 
(1.2 eq., 200mg) and the reaction mixture was refluxed for 24h. Afterwards water 
was added (10 mL) and extracted with DCM (3X5mL). The combined organic 
layers were dried with MgSO4 and evaporated to dryness. After purification by 
chromatography (preparative TLC eluted with Hex:AcOEt 8:2) 75 mg (53%) of 
product as a mixture of two diastereomers (d.r.=6:4). 
1H NMR δ: 3.38 (0.4H, dd, J2’,3’=11.2, J2’,3’=3.7, H-2’); 3.20 (0.6H, dd, 
J2,3=11.4, J2,3=4.3, H-2); 2.75 (0.6H, td, 2J=J8,7=12.5, J8,7=3.8, H-8); 2.62 (0.4H, ddd, 
2J=13.0, J8’,7’=10.4, J8’,7’=5.0, H-8’); 2.39 (0.6H, ddd, 2J=12.7, J8,7=5.7, J8,7=3.7, H-8); 
2.33 (0.4H, ddd, 2J=13.1, J8’,7’=6.4, J8’,7’=4.1, H-8’); 2.1-1.1 (10H, m, 5xCH2 13C NMR 
δ: 211.4 (212.7) (C-1); 52.2 (53.3) (C-1); 38.2 (38.7) (C-8); 29.4, 27.9, 26.9, 26.2, 
24.49 (30.1, 27.6, 26.34, 26.31, 24.45) (5xCH2). FTIR (Neat): 1686 (C=O st). MS 
(ESI-IT) m/z: 283 [M + H]+.
  
Bibliography 
 
 
 
  
Bibliography 
  
 
Bibliography 
 
213 
 
1. Ball, P. Nature (London, U. K.) 2015, 528, 327. 
2. Seebach, D.; Sutter, M. A.; Weber, R. H.; Zueger, M. F. Org. Synth. 1985, 63, 1. 
3. Martin, V. S.; Woodard, S. S.; Katsuki, T.; Yamada, Y.; Ikeda, M.; Sharpless, K. B. 
J. Am. Chem. Soc. 1981, 103, 6237. 
4. (a) Jiang, J.; Liu, H.; Lu, C.-D.; Xu, Y.-J. J. Org. Chem. 2017, 82, 811; (b) Pieczonka, 
A. M.; Misztal, E.; Rachwalski, M.; Lesniak, S. Arkivoc 2017, 223; (c) Liu, Y.; Li, Z.; 
Yuan, G.; Xia, Q.; Yuan, C.; Cui, Y. Inorg. Chem. 2016, 55, 12500; (d) Laserna, V.; 
Martin, E.; Escudero-Adán, E. C.; Kleij, A. W. Adv. Synth. Catal. 2016, 358, 3832; 
(e) Luo, H.; Chen, K.; Jiang, H.; Zhu, S. Org. Lett. 2016, 18, 5208; (f) Jiang, H.; Lang, 
K.; Lu, H.; Wojtas, L.; Zhang, X. P. Angew. Chem., Int. Ed. 2016, 55, 11604. 
5. (a) Mal, A.; Sayyad, M.; Wani, I. A.; Ghorai, M. K. J. Org. Chem. 2017, 82, 4; (b) 
Shahi, C. K.; Bhattacharyya, A.; Nanaji, Y.; Ghorai, M. K. J. Org. Chem. 2017, 82, 
37; (c) Shiomi, N.; Yamamoto, K.; Nagasaki, K.; Hatanaka, T.; Funahashi, Y.; 
Nakamura, S. Org. Lett. 2017, 19, 74; (d) Sengoden, M.; Bhowmick, A.; 
Punniyamurthy, T. Org. Lett. 2017, 19, 158; (e) Zhang, X.; Li, S.-S.; Wang, L.; Xu, 
L.; Xiao, J.; Liu, Z.-J. Tetrahedron 2016, 72, 8073; (f) Li, D.; Yang, D.; Wang, L.; Liu, 
X.; Jiang, X.; Wang, R. Chem. - Eur. J. 2016, 22, 17141; (g) Sengoden, M.; Irie, R.; 
Punniyamurthy, T. J. Org. Chem. 2016, 81, 11508; (h) Yin, J.; Hyland, D. C. J. T. 
Asian J. Org. Chem. 2016, 5, 1368; (i) Weseliński, Ł. J.; Grillo, M. J.; Tanasova, M. 
Tetrahedron Lett. 2016, 57, 4477; (j) Wan, S.-H.; Lin, Y.-C.; Liu, L.-K.; Liu, Y.-H. 
Chem. - Asian J. 2016, 11, 2889. 
6. Kaga, A.; Tnay, Y. L.; Chiba, S. Org. Lett. 2016, 18, 3506. 
7. Nakazaki, A.; Nakane, Y.; Ishikawa, Y.; Yotsu-Yamashita, M.; Nishikawa, T. Org. 
Biomol. Chem. 2016, 14, 5304. 
8. Chang, Y.-J.; Hsuan, Y.-C.; Lai, A. C.-Y.; Han, Y.-C.; Hou, D.-R. Org. Lett. 2016, 18, 
808. 
Bibliography 
 
214 
 
9. Ripa, L. E.; Lawitz, K.; Lepistoe, M. J.; Hemmerling, M.; Edman, K.; Llinas, A. 
WO2016046260A1, 2016 
10. (a) Gabriel, S. Ber. Dtsch. Chem. Ges. 1888, 21, 1049; (b) Cromwell, N. H.; 
Babson, R. D.; Harris, C. E. J. Am. Chem. Soc. 1943, 65, 312. 
11. Barros, M. T.; Maycock, C. D.; Ventura, M. R. Tetrahedron Lett. 2002, 43, 4329. 
12. Silva, S.; Rodrigues, P.; Bento, I.; Maycock, C. D. J. Org. Chem. 2015, 80, 3067. 
13. Barros, M. T.; Matias, P. M.; Maycock, C. D.; Ventura, M. R. Org. Lett. 2003, 5, 
4321. 
14. Maycock, C. D.; Rodrigues, P.; Ventura, M. R. J. Org. Chem. 2014, 79, 1929. 
15. Morgan, B. S.; Hoenner, D.; Evans, P.; Roberts, S. M. Tetrahedron: Asymmetry 
2004, 15, 2807. 
16. (a) Audia, J. E.; Boisvert, L.; Patten, A. D.; Villalobos, A.; Danishefsky, S. J. J. 
Org. Chem. 1989, 54, 3738; (b) Barros, M. T.; Maycock, C. D.; Ventura, M. R. J. 
Chem. Soc., Perkin Trans. 1 2001, 166. 
17. (a) Ren, K.; Zhao, M.; Hu, B.; Lu, B.; Xie, X.; Ratovelomanana-Vidal, V.; Zhang, 
Z. J. Org. Chem. 2015, 80, 12572; (b) Dickmeiss, G.; De Sio, V.; Udmark, J.; 
Poulsen, T. B.; Marcos, V.; Jørgensen, K. A. Angew. Chem., Int. Ed. 2009, 48, 6650; 
(c) Bayón, P.; Marjanet, G.; Toribio, G.; Alibés, R.; de March, P.; Figueredo, M.; 
Font, J. J. Org. Chem. 2008, 73, 3486; (d) Nising, C. F.; Ohnemüller, U. K.; Bräse, 
S. Synthesis 2006, 2006, 2643; (e) Fudickar, W.; Vorndran, K.; Linker, T. 
Tetrahedron 2006, 62, 10639; (f) Staben, S. T.; Linghu, X.; Toste, F. D. J. Am. Chem. 
Soc. 2006, 128, 12658; (g) Demir, A. S.; Sesenoglu, O. Org. Lett. 2002, 4, 2021; (h) 
de March, P.; Escoda, M.; Figueredo, M.; Font, J.; Garcıá-Garcıá, E.; Rodrıǵuez, S. 
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